FLUOROUS SYNTHESIS OF A TRI-β-PEPTIDE LIBRARY AND EIGHT STEREOISOMERS OF MACROLACTONE SCH725674 by Wang, Xiao
 FLUOROUS SYNTHESIS OF A TRI-?-PEPTIDE LIBRARY AND 
EIGHT STEREOISOMERS OF MACROLACTONE SCH725674 
 
 
 
 
 
 
 
 
by 
Xiao Wang 
BS, Nanjing University, 2003 
 
 
 
 
 
 
 
 
 
 
Submitted to the Graduate Faculty of 
Arts and Sciences in partial fulfillment  
of the requirements for the degree of 
Doctor of Philosophy 
 
 
 
 
 
 
 
 
 
University of Pittsburgh 
2009 
  ii 
UNIVERSITY OF PITTSBURGH 
SCHOOL OF ARTS AND SCIENCES 
 
 
 
 
 
 
 
 
This dissertation was presented 
 
by 
 
 
Xiao Wang 
 
 
 
It was defended on 
Feb 17, 2009 
and approved by 
Professor Billy W. Day 
Professor Paul E. Floreancig 
Professor Scott G. Nelson 
Dissertation Advisor: Professor Dennis P. Curran 
 
 
  iii 
Copyright © by Xiao Wang 
2009 
  iv
 
Chapter 1 of this dissertation describes a new strategy to make ?-peptide libraries. A 27-
membered tri-?-peptide library was prepared. ?-Azido acids as building blocks were tagged with 
fluorous PMB group. Two reduction-amide coupling cycles were done. Intermediates were 
separated by Fluorous Solid Phase Extraction (FSPE). The reductive deprotection gave the final 
27 tri-?-peptide, which were purified by reverse phase HPLC. Purity of the library was checked 
by LC-MS. Mass spectroscopy data of 25 products matched with calculation.   
Chapter 2 describes the Fluorous Mixture Synthesis (FMS) of eight stereoisomers of 14-
membered macrolactone Sch725674. The configurations of Sch725674 were completely 
unknown when discovered. A single diastereomer of Sch725674 was prepared first by traditional 
solution phase synthesis. In the FMS, stereoisomeric starting materials were tagged with 
different fluorous TIPS groups. The tagged quasidiastereomers were mixed and the mixture 
underwent a series of steps to make the fluorous tagged macrolactones, which were separated by 
fluorous HPLC followed by individual deprotections to provide the eight final products. The 
NMR data of the eight synthetic macrolactones were compared with those of Sch725674. The 
absolute configuration of Sch725674 was confirmed as (4R,5S,7R,13R).   
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CHAPTER 1.  THE PARALLEL SYNTHESIS OF  
A TRI-β-PEPTIDE LIBRARY BY FLUOROUS TAGGING 
 
1.1  INTRODUCTION  
 
1.1.1  β-Amino acids and β-peptides.  
 
Peptides constructed from α-amino acids play an important role in numerous biological and 
physiological processes in living organisms. Since the first synthesis of a dipeptide by Emil 
Fischer in 1901, tremendous progress has been made in peptide science, and large proteins can 
be synthesized nowadays.1 α-Amino acids are carboxylic acids that bear amino groups at the α 
carbons. The 20 naturally occurring α-amino acids serve as the basic structural units of natural 
proteins. β-Amino acids have their amino groups bonded to β-carbons.1 Peptides that consist of 
β-amino acids are called β-peptides. Several typical structures of β-amino acids and β-peptides 
are shown in Figure 1.1.  
β -Amino acids
NH2
COOH
A tri-β -peptide
H2N
O
N
H
O
N
H
O
O
NH2 O
OH
HO
 
 
Figure 1.1.  Typical structures of β-amino acids (top) and β-peptides (bottom) 
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 Because β-peptides do not appear in nature, they are often evaluated as a potential source of 
drugs to evade antibiotic resistance.2 They are also interesting scaffolds for building catalysts. 
From a structural viewpoint, β-peptides have predictable folding patterns and exhibit many kinds 
of secondary structures. These features have promoted the intensive study of the structures of 
β-peptide foldamers to better understand protein structures.3  
 
1.1.2  β-Peptides synthesis.  
 
Most syntheses of β-peptides are patterned after the traditional approach to make 
α-peptides.4 The key building blocks are N-protected β-amino acids 2, which are joined with 1 to 
form β-peptides 3 by an iterative sequence of N-deprotection and amide coupling (Scheme 1.1). 
Some of the most important ways5 to synthesize β-amino acids are the homologation of α-amino 
acids,6 preparation from aspartic acid and asparagines, Michael addition of amines to acrylates,7,8 
and the nucleophilic addition to imine equivalents.9  
 
R
N
H
O R2
NHPG
R1
1) removal of PG
2) coupling with
HO
O R4
NHPG
R3
R
N
H
O R2
R1
N
H
O R4
NHPG
R3
1
2
3
R1, R2 = β-amino acid side chains;
PG = protecting groups such as Boc, Foc
 
 
Scheme 1.1. The protected amino acid approach to β-peptides 
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α-Peptides have also been made from α-azido acids.11 But the azide approach is not used 
very often because: 1) α-amino acids are much more readily available than α-azido acids; 2) 
α-azido acids are prone to epimerization. The azido acid approach is much more useful for 
β-peptide synthesis because: 1) the small size makes the azido group more atom economic 
compared to protected amines; 2) β-azido acids do not have the epimerization problem. Nelson 
and coworkers recently developed the β-azido acid approach to make β-peptides. It involves an 
iterative sequence of reduction of the azide (4 or 6) to the amine followed by coupling of the 
amine with the next β-azido acid (7) (Scheme 1.2).10 
 
R
N
H
O R2
N3
R1
1) azide reduction
2) coupling with
HO
O R4
N3
R3
R
N
H
O R2
R1
N
H
O R4
N3
R3
4
7
6
R1, R2 = β-azido acid side chains
 
 
Scheme 1.2. The azido acid approach to β-peptides  
 
The azido group of a β-azido acid can be readily reduced by the well-known Staudinger 
reaction.12 The azide reacts with triphenylphosphine to give an aza-ylide, which is subsequently 
hydrolyzed to give the primary amine (Scheme 1.3). Heat sometimes is required for conducting 
the Staudinger reaction, especially in the hydrolysis step.  
 3
 R NH2R N PPh3
H2O
R N3
PPh3
+ Ph3PO
Azide Aza-ylide Amine  
 
Scheme 1.3.  The Staudinger reaction  
 
In Nelson’s β-peptide synthesis, β-azido acids are prepared from β-lactones via a 
ring-opening process (Scheme 1.4).10,13  β-Lactone 8 reacts with NaN3 to give β-azido acid 9. 
The regioselectivity of the nucleophilic attack of β-lactones can be explained by the Hard-Soft 
Acid-Base theory.14,15 Soft nuleophiles (such as azides) prefer to attack the soft, sp3-hybridized 
β-carbon, while hard nucleophiles (such as amines) prefer to attack the hard, sp2-hybridized 
carbonyl carbon. β-Azido acid 9 then undergoes methylation, two reduction-coupling cycles and 
hydrogenation to give tri-β-peptide 10.10  
 
O
O
R2R1
NaN3
HO
O R2
N3
R1
8 9
1) methylation
2) reduction-
coupling (twice)
MeO
O R2
N
H
R1
O R4
N
H
R3
O R6
NH2
R5
103) hydrogenation  
 
Scheme 1.4.  The Nelson’s approach to tri-β-peptide 
 
β-Lactones can be synthesized by the cycloaddition reactions of aldehydes and acid 
chlorides such as the Wynberg reaction.16,17 In 2004, Nelson and coworkers developed an 
asymmetric cinchona alkaloid-catalyzed acid chloride-aldehyde cyclocondensation (AAC) 
reaction.18 An example of the Nelson reaction is described in Scheme 1.5. Acid chloride 11 reacts 
with aldehyde 12 in the presence of the Lewis acid (LiClO4) and the protected cinchona alkaloid 
 4
9-trimethylsilylquinine (“TMSq”, 5a) or 9-trimethylsilylquinidine (“TMSQ”, 5b) to give 
β-lactone 13b or 13h, respectively. Unlike the Wynberg reaction, which is limited to 
electron-deficient aldehydes, the Nelson reaction can be used for many other aldehydes.  
 
N
MeO
N
H
H
O
H
Me3Si
TMSQ, 5b
N
H
N
O
Me3Si
MeO
TMSq, 5a
O
O
Ph
LiClO4, iPr2NEt
5a or 5b, −78°C
O
Cl
+
H
O
Ph
O
O
Ph
13b, >99% ee
(by 5a)
13h, >99% ee
(by 5b)
11 12
or
 
 
Scheme 1.5.  An example of Nelson’s cinchona alkaloid-catalyzed AAC reaction 
 
The combination of the Nelson’s AAC reaction and the azide ring-opening of the resulting 
β-lactones provides a powerful way to make β-azido acids for the β-peptide synthesis.  
 
1.1.3  Light fluorous tagging strategy for peptide synthesis.  
 
Solid-phase synthesis (SPS) is the most frequently used method to make peptides, and it is 
highlighted by the simple purification by filtration.23 Substrates are bonded to a solid phase and 
reactions can be done by adding reactants in the liquid phase in large excess. However, there are 
several advantages of the solution-phase synthesis. First, compared to SPS, much less reagents in 
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the liquid phase are needed. Second, compared to SPS, the yields of solution-phase reactions are 
generally higher because of the reaction homogeneity. And monitoring the reaction process and 
characterizing the product by NMR, LC and MS are much easier for solution-phase synthesis 
than for SPS.  
Recently, small libraries have been made by solution-phase synthesis with light fluorous 
technologies.24,25 Light fluorous molecules are organic molecules that bear small perfluoroalkyl 
tags such as C6F13 and C8F17.19-21 Light fluorous tags are chemically inert and the tagged 
compounds can react with other organic substrates under the same conditions as their 
nonfluorous relatives. The fluorous tags can be removed under the similar deprotection 
conditions to their nonfluorous relatives. The advantage of the fluorous approach is that fluorous 
compounds can be easily and rapidly separated from organic reaction products by fluorous 
solid-phase extraction (FSPE). The fluorous silica gel is used as sorbent in FSPE, and it is 
synthesized by functionalizing normal phase silica gel with a silane containing a perfluorocarbon 
chain. The fluorous affinity interaction between the fluorous silica gel and fluorous-tagged 
compounds separates them from nonfluorous compounds.21 
FSPE is easy to conduct. A washed and pre-conditioned FSPE cartridge is loaded with the 
reaction mixture of the fluorous-tagged compound and other nonfluorous compounds. The 
cartridge is washed with a fluorophobic solvent like MeCN, MeOH, DMF and DCM, usually in 
combination with water, to obtain a fraction containing nonfluorous compounds. The cartridge is 
subsequently washed with a fluorophilic solvent like THF, MeCN or MeOH to obtain the 
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fraction containing the fluorous compounds.21 A picture of FSPE is shown in Figure 1.2.  
 
 
Left tube: beginning of fluorophobic wash with 80:20 MeOH:H2O 
Center tube: end of fluorophobic wash (blue: organic dye) 
Right tube: end of fluorophilic wash with 100% MeOH (orange: fluorous-tagged dye) 
                    (Picture from www.fluorous.com)  
 
Figure 1.2.  An illustration of FSPE 
 
Reactions of fluorous tagged α-amino acids with separation by FSPE were previously 
reported by our group.22 We set out to develop a route for the synthesis of β-peptides by 
combining Nelson’s azido acid approach with separation of intermediates and products by FSPE. 
The proposed synthesis is shown in Scheme 1.6. After the tagging of β-azido acid 14 with a 
fluorous protecting group (FPG), the resulting β-azido ester 20 undergoes the reduction by the 
Staudinger reaction to give amine 21, which is coupled with a same or different β-azido acid 14 
to give azido dipeptide 22. Peptide 22 is subjected to the second reduction-coupling cycle to give 
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azido tripeptide 24. At last, the reduction of the azido group to the amino group and the removal 
of the fluorous tag furnish tri-β-peptide 25. A small tri-β-peptide library can be synthesized by 
performing these reactions in parallel. By using three different β-azido acids as building blocks 
in each stage, a 27-membered library of tri-β-peptides can be made.  
 
O
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R1
O
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O
N3
R1 R3
R2 R4
PGO
Staudinger reaction
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coupling
coupling (cycle 1)
Staudinger reaction
HO
O R4
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F
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O
NH2
R1
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F
O
N
H
O
NH2
R1 R3
R2 R4
PGO
F
coupling (cycle 2)
HO
O R6
N3
R5
O
N
H
O
N
HR1 R3
R2 R4
PGO
F
O R6
N3
R5
O
N
H
O
N
HR1 R3
R2 R4
HO
O R6
NH2
R5
1) reduction
β-azido acid, 14
(made by Nelson's AAC reaction)
β-azido ester, 20
β-amino ester, 21 β-azido dipeptide, 22
β-amino dipeptide, 23 β-azido tripeptide, 24
tri-β-peptide, 25
14
14
2) detagging
(cycle 1)
(cycle 2)
 
 
Scheme 1.6.  The proposed synthesis of a tri-β-peptide library 
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1.2. RESULTS AND DISCUSSION  
 
1.2.1  The synthesis of β-lactones.  
 
To make the 27-membered tri-β-peptide library, three β-azido acids derived from β-lactones 
are required as the building blocks. The choice of building blocks was primarily based on: 1) the 
yield and the enantiopurity of the β-lactone from the AAC reaction; 2) the feasibility of the 
azide-mediated ring-opening reaction of the β-lactone. The structures of the seven β-lactones 
(13a-13g) that were synthesized and evaluated are shown in Figure 1.3.  
 
O
O
O
O
CH2OBn
O
O
O
O
O
O
CH2CH2Ph
O
O
Ph
O
O
13a 13b 13d
13e 13f
13c
13g  
 
Figure 1.3.  The β-lactones prepared by Nelson’s AAC reactions 
 
The needed organocatalysts 9-trimethylsilylquinine (“TMSq”, 5a) and 
9-trimethylsilylquinidine (“TMSQ”, 5b) were synthesized by the addition of 
chlorotrimethylsilane to quinine and quinidine at ambient temperature.29 The HCl produced in 
the reaction was neutralized by the alkaloid, so no extra base was added. The crude products 
were purified by flash chromatography to give 5a and 5b in 93% and 98% yields, respectively 
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(Scheme 1.7).  
 
NH
N
O
Me3Si
MeO
TMSq, 5a, 93%
NH
N
HO
MeO
TMSCl
DCM, rt, 24 h
N
MeO
N
H
H
OH
H TMSCl
DCM, rt, 2 h
N
MeO
N
H
H
O
H
Me3Si
TMSQ, 5b, 98%
quinine
quinidine  
 
Scheme 1.7.  The synthesis of the cinchona alkaloid catalysts 5a and 5b 
 
β-Lactones 13a-13d and 13f were previously synthesized by Nelson and coworkers,18 while 
13e and 13g had not been prepared by the AAC reaction. In a typical reaction, propionyl chloride 
(2.0 equiv) reacted with hydrocinnamaldehyde (1.0 equiv) in the presence of 
N,N-diisopropylethylamine (2.5 equiv), LiClO4 (0.75 equiv) and TMSq (5a, 0.1 equiv) in DCM 
at –78 °C in 16 h to afford β-lactone 13a in 54% yield as a single cis isomer and 94% ee after 
flash chromatography (Scheme 1.8; Table 1.1, entry 1).18 The ee was determined by chiral HPLC 
analysis.  
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O
O
CH2CH2Ph
O
Cl
+ H
O
Ph
LiClO4, iPr2NEt, TMSq
DCM, −78°C, 16 h
13a, 54% yield, 94% eepropionyl chloride hydrocinnamaldehyde
(2R) (3S)
 
 
Scheme 1.8.  The synthesis of β-lactone 13a 
 
Six other β-lactones were similarly synthesized and purified by flash chromatography 
(Table 1.1).18 The AAC reaction of propionyl chloride and benzaldehyde gave 13b in 97% yield 
(>99% ee) (entry 2). The volatile 13c was made from the reaction of propionyl chloride and 
isovaleraldehyde (entry 3), and it was directly subjected to the azide ring-opening reaction 
without the complete removal of solvent. For this reason, the yield of 13c is not reported in Table 
1. Acetyl chloride readily reacted with pivalaldehyde to give 13d in 91% yield and 96% ee (entry 
4). β-Lactone 13e was made from propionyl chloride and methacrolein in 32% yield (entry 5). 
β-Lactone 13f was prepared in only 30% yield and 84% ee (entry 6). The reaction of propionyl 
chloride and isobutyraldehyde was expected to give 13g, but no product formation was observed, 
and the aldehyde never disappeared on TLC analysis (entry 7). When describing configurations 
of the β-lactones, we used the numbering system for carboxylic acids rather than that for lactones, 
because the β-lactones would be converted to β-azido acids.  
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Table 1.1.  The synthesis of β-lactones 13a-13g 
 
1
2 3
O
4O
R2
LiClO4, iPr2NEt, catalyst,
DCM, −78°C, 13-16 h
O
Cl
+
H
O
R2
R1
R1
Acid chlorides β-Lactones 13a-13gAldehydes  
 
Entry Product Configuration R1 R2 Catalyst
Equiv of 
LiClO4
Yield 
% 
ee % 
1 13a (2R,3S) Me CH2CH2Ph TMSq 0.75 54 94 a
2 13b (2R,3S) Me Ph TMSq 2.0 97 >99 a
3 13c (2S,3R) Me iBu TMSQ 2.0 — c 99 b
4 13d (2S,3R) H tBu TMSQ 3.0 91 96 b
5 13e (2R,3S) Me C(CH3)=CH2 TMSq 2.0 32 — d
6 13f (2S,3R) H CH2OBn TMSQ 0.30 30 84 a
7 13g (2R,3S) Me iPr TMSq 2.0 — e — e
a. Determined by chiral HPLC analysis;  b. Determined by chiral GLC analysis; 
c. Not measured due to volatility;  d. Not measured;  e. No product was detected.  
 
Since β-lactones 13a-13d were obtained with good ee, they were selected for the azide 
ring-opening reactions. The yields of 13e and 13f were low, and the attack of sodium azide to 
13e might proceed through the SN2΄ fashion, thus they were not advanced. In a representative 
experiment, sodium azide reacted with lactone 13a in DMF at 50 °C in 5 h to give β-azido acid 
14a in quantitative yield after purification by flash chromatography (Table 1.2, entry 1). 
Likewise, the reaction of 13b with sodium azide gave 14b in 100% yield (entry 2), while azido 
acid 14c was prepared from crude lactone 13c in a two-step yield of 65% calculated from the 
AAC reaction (entry 3). In contrast to these successful reactions, no product was formed for the 
reaction of 13d over 96 h (entry 4). It was possible that the bulky β-tert-Bu group of 13d 
retarded the SN2 ring-opening process. Based on these results, we decided to use β-azido acids 
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14a-14c as the three building blocks for the library synthesis.  
 
Table 1.2.  The azide ring-opening reactions  
 
Azido acids 14a-14dLactones 13a-13d
HO
O Ph
N3HO
O
N3
Ph
HO
O
N3
14a 14b 14c
HO
O
N3
14d
O
O
R1 R2
HO
O R2
N3
R1
NaN3, DMF
50°C
 
 
Entry β-Lactone 
β-Azido 
Acid 
Configuration R1 R2
Reaction 
Time (h) 
Yield 
% 
1 13a 14a (2R,3R) Me CH2CH2Ph 5 100 
2 13b 14b (2R,3R) Me Ph 4 100 
3 13c 14c (2S,3S) Me iBu 5  65 a
4 13d 14d (3S) H tBu 96  — b
a. 2-step yield from isovaleraldehyde;  b. SM recovered.  
 
In summary, β-lactones 13a-13f were synthesized by the alkaloid-catalyzed ketene-aldehyde 
cycloadditions. Lactones 13a-13c were successfully converted to β-azido acids 14a-14c as the 
building blocks for the parallel synthesis. In the next step, the carboxylate groups of 14a-14c 
would be protected with a fluorous tag.  
 
1.2.2  The synthesis of single fluorous β-azido esters.  
 
We evaluated protection of the carboxy group of β-azido acids as either the fluorous Boc or 
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the fluorous Cbz group. Accordingly, two commercially available fluorous tagging reagents were 
selected: 2-methyl-4-perfluorodecyl-2-butanol (Ft-BuOH, 15)30a and 4-[3-(perfluorooctyl)propyl- 
1-oxy]benzyl alcohol (FPMBOH, 16)30b (Figure 1.4).  
 
OHC8F17
C8F17
O
OH
Ft-BuOH, 15 FPMB-OH, 16  
 
Figure 1.4.  The structures of Ft-BuOH and FPMBOH  
 
We first tried the tagging reactions of β-azido acid 14a with alcohol 15. Direct coupling of 
acid 14a and 15 in the presence of EDCI and DMAP in DCM did not provide the desired β-azido 
ester 17 (Table 1.3, entry 1). The coupling reaction of 14a and 15 with DCC at 40 ºC in 
trifluorotoluene gave no product (entry 2).30a And no reaction occurred when 
4-(pyrrolidin-1-yl)pyridine (PPY), a more reactive catalyst than DMAP, was used (entry 3).28,31 
The low reactivity of 15 was probably due to the steric hindrance at its tertiary carbon. Next, 
treating 14a with (COCl)2 and DMF gave the corresponding acid chloride 18. Addition of 
alcohol 15 to the DCM solution of 18 in the presence of pyridine and DMAP did not give any 
product (entry 4). And no product was formed when the lithium salt of 15 was mixed with 18 in 
THF (entry 5).   
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Table 1.3.  Conditions of coupling reactions of β-azido acid 14a with 15 
 
OHC8F17
+
HO
Ph
O
N3
Ph
O
N3OC8F17
conditions
14a 15 17  
 
Entry Conditions Yield% 
1 EDCI, DMAP, DCM, rt, 48 h 0 
2 DCC, DMAP, trifluorotoluene, 40 ºC, 22 h 0 
3 EDCI, PPY, DCM, 120 ºC (μW), 0.5 h 0 
4 
1) 14a, (COCl)2, DCM, DMF (to give 18) 
2) 15, pyridine, DMAP, DCM, rt, 24 h 
0 
5 
1) nBuLi, 15, THF, 0 °C 
2) 14a, THF, 0 °C, 12 h 
0 
 
To esterify 14a by the alkene method, alcohol 15 was dehydrated with BF3?Et2O to give a 
mixture of two alkenes 19a and 19b in 22% and 1% yield after flash chromatography (Scheme 
1.9). However, no reaction took place when 19a/b was treated with β-azido acid 14a in the 
presence of a catalytic amount of trifluoroacetic acid (TFA) or sulfuric acid.  
 
C8F17 C8F17HO C8F17
BF3·Et2O
0°C
+
19a, 22% 19b, 1%15
HO
Ph
O
N3
Ph
O
N3OC8F17
17, not formed
14a
H2SO4 or TFA
DCM, rt  
 
Scheme 1.9.  Esterification of β-azido acid 14a with alkenes 19a/b 
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In contrast to the problems with installing the FtBu group to 14a, the tagging reaction of 14a 
with FPMBOH 16 was straightforward. FPMBOH (16, 1.2 equiv) was coupled with β-azido acid 
14a (1.0 equiv) in the presence of EDCI and DMAP in DCM to give azido ester 20a in 84% yield 
after extractive workup to remove the reagents and purification by flash chromatography 
(Scheme 1.10). EDCI was chosen because both EDCI and its derived urea are relatively polar 
and eluted very quickly under the first pass conditions of FSPE.27  
To reduce its azido group, 20a was microwaved at 120 ºC, 250 W in the presence of Ph3P 
(1.2 equiv) in THF, then H2O (20 equiv) was added and the mixture was microwaved again for 5 
min. Subjection of the cooled reaction mixture to FSPE provided amine 21a in 95% yield.  
Similarly, the amide coupling reaction of amine 21a (1.0 equiv) and β-azido acid 14a (1.2 
equiv) in the presence of EDCI and DMAP followed by FSPE provided azido-dipeptide 22aa in 
79% yield. The code “22aa” designates the azido-β-dipeptide (starts with number “22”) that 
consists β-azido acid 14a as building blocks. The second reduction-coupling cycle was initiated 
by reducing azido-dipeptide 22aa to amine 23aa (84% yield after FSPE). Amine 23aa was then 
coupled with 14a to give azido-tripeptide 24aaa in 68% yield after FSPE and flash 
chromatography. The structures of azido-dipeptide 22aa and azido-tripeptide 24aaa were 
confirmed by 1H, 13C, COSY and HMQC NMR experiments. These reactions indicated that 
β-azido acid 14a was a qualified building block for the synthesis of the tri-β-peptide library.  
 
 16
1) Ph3P, THF, μw 10min
3) FSPE
2) H2O (20 equiv), μw 5min
EDCI, DMAP, DCM, rt
20a, 84%
DCM, rt
21a, 95% 22aa, 79%
HO
Ph
O
N3
FPMBO
Ph
O
N3
FPMBO
Ph
O
NH2
FPMBO
Ph
O
N
H
Ph
O
N3
14a
FPMBOH
14a, EDCI, DMAP
23aa, 84% 24aaa, 68%
FPMBO
Ph
O
N
H
Ph
O
NH2 FPMBO
Ph
O
N
H
Ph
O
N
H
Ph
O
N3
DCM, rt
14a, EDCI, DMAP
1) Ph3P, THF, μw 10min
3) FSPE
2) H2O (20 equiv), μw 5min
 
 
Scheme 1.10.  Synthesis of azido-tripeptide 24aaa 
 
β-Azido acid 14b was also esterified with FPMBOH 16 in the presence of EDCI and DMAP 
in DCM to give azido-ester 20b in 98% yield after flash chromatography (Scheme 1.11). 
Azido-ester 20b was subjected to Staudinger reaction to give amine 21b in 77% yield after FSPE. 
Amide coupling reaction of 21b and 14b in the presence of EDCI and DMAP gave 
azido-dipeptide 22bb in 79% yield after flash chromatography. These reactions qualified β-azido 
acid 2b as a building block, so the corresponding azido-tripeptide was not synthesized. We 
expected 14c to have similar reactivity to 14a/14b, thus no tagging-reduction-coupling reactions 
were done for 14c.  
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DMAP, EDCI, DCM, rt
20b, 98%
21b, 77% 22bb, 89%
O
N3
Ph
FPMBOHO
O Ph
N3
1) Ph3P, THF, μw 10min
3) FSPE
O
NH2
Ph
FPMBO
O
N
H
O
N3
Ph Ph
FPMBO
DCM, rt
14b
FPMBOH
2) H2O (20 equiv), μw 5min
14b, DMAP, EDCI
 
 
Scheme 1.11.  Synthesis of azido-dipeptide 22bb 
 
All Staudinger reactions described above were followed by 31P NMR analysis (δ (THF-d8) 
for Ph3P: –5 ppm; for Ph3P=NR: 2 ppm; for Ph3PO: 27 ppm). The formation of the resonance of 
Ph3PO and the disappearance of the resonance of Ph3P=NR indicated the completion of the 
reaction. Comparing 31P NMR spectra and TLC results, we found that TLC was also convenient 
to follow the transformation of the azide to the amines. After the addition of water and the 
microwave irradiation, a very polar new spot on TLC indicated the formation of the amine, while 
the concomitant Ph3PO could always be detected by 31P NMR analysis.  
 
1.2.3  Fluorous HPLC analysis of the azido-peptides.  
 
Before starting the library synthesis, we needed more data to know how well FSPE can 
separate the fluorous tagged peptides from organic impurities. Since the fluorous HPLC column 
is packed with fluorous silica gel, which is also used in the FSPE cartridge, we measured the 
retention times of the already made azido-peptides 20a, 20b, 22aa, 22bb and 24aaa on the 
fluorous HPLC column (Figure 1.5). Under the conditions described in Figure 5, 20a, 20b, 22aa, 
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22bb and 24aaa were all strongly retained on the fluorous HPLC column with retention times 
around 25 min. Because non-fluorous compounds elute at the solvent front under these 
conditions, the results suggested that FSPE would be an efficient and rapid separation technique 
for separating 
F
PMB tagged compounds from any non-fluorous impurities in a library setting.  
 
O
N
H
O
N
H
FPMBO
Ph Ph
O
N3
Ph
O
N
H
O
N3FPMBO
Ph Ph
O
N
H
O
N3
Ph Ph
FPMBO
O
N3
Ph
FPMBO
O
N3FPMBO
Ph
20a, 27.6 min
22aa, 24.5 min 24aaa, 25.9 min
20b, 27.5 min 22bb, 25.3 min
 
 
Conditions:  FluoroFlash
TM
 PF-C8 HPLC column (4.6 ? 150 mm), 1 mL/min,  
  gradient elution, 80:20 to 100:0 MeCN:H2O in 30 min 
 
Figure 1.5.  Retention times of azido-peptides on the fluorous HPLC column 
 
In spadework for the parallel synthesis, the 
F
PMB group was used successfully to tag the 
C-terminus of several ?-peptides. Several amide coupling reactions and Staudinger reactions 
were accomplished with good yields. The retention times of several ?-azido peptides on the 
fluorous HPLC column were measured to confirm the feasibility of FSPE separation. With this 
knowledge gained, we commenced the library synthesis.  
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1.2.4  Parallel synthesis: the first reduction-coupling cycle.  
 
The synthesis of the library started with the fluorous tagging reactions of 14a-14c. ?-Azido 
acids 14a, 14b and 14c (0.6 mmol of each) were esterified with 16 in the presence of EDCI and 
DMAP to give azido-esters 20a, 20b and 20c in 80%, 87% and 53% yields, respectively 
(Scheme 1.12). The reactions were monitored by TLC and the products were purified by 
standard flash chromatography. With all six precursors: azido acids 14a-14c and FPMB esters 
20a-20c in hand, we started the parallel synthesis. The three azido-esters 20a-20c were treated 
with Ph3P (1.2 equiv) in THF under microwave (120 ºC, 250 W) for 5 min, followed by the 
addition of H2O (20 equiv) and irradiation by microwave again for 10 min (Scheme 1.12). At this 
time, each Staudinger reaction was complete by regular TLC analysis. Amines 21a-21c were 
isolated by FSPE and carried on directly to the coupling reactions without characterization.  
O
N3FPMBO
Ph
O
N3HO
Ph
14a (0.6 mmol) 20a, 80%
20b, 87%
O
N3
Ph
FPMBO
O
N3
Ph
HO
14b (0.6 mmol)
O
N3FPMBO
20c, 53%
O
N3HO
a. FPMBOH, EDCI, DMAP, DCM, rt, 30 min
14c (0.6 mmol)
a O
NH2FPMBO
Ph
21a
O
NH2
Ph
FPMBO
21b
O
NH2FPMBO
21c
b
b. 1) PPh3, THF, μw 5 min; 2) H2O (20 equiv), μw 10 min; 3) FSPE  
Scheme 1.12.  Synthesis of amines 21a-21c 
Each one of amines 21a-21c (approximately 0.5 mmol) was split into three equal portions 
and each portion was coupled with three β-azido acids 14a-14c in the presence of EDCI and 
DMAP in DCM. These nine reactions were done in parallel and all were complete in 30 min 
according to TLC analysis. Purification of the crude products by FSPE gave the nine 
azido-dipeptides 22aa-22cc in two-step yields of 55-86% (Scheme 1.13). The structures and 
purities of the products were confirmed by 1H, 13C NMR and LC-MS analysis.34b  
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O O
N
H
N3
Ph
FPMBO
O O
N
H
N3
FPMBO
O
22ca, 79% (2 steps) 22cb, 86% (2 steps) 22cc, 83% (2 steps)
EDCI, DMAP
DCM, rt, 30 min
21a-21c
+
14a-14c 22aa-22cc
(9 azido-dipeptides)(3 amines) (3 azido acids)
 
 
Scheme 1.13.  Synthesis and structures of azido-dipeptides 22aa-22cc 
 
1.2.5  The second reduction-coupling cycle.  
 
To begin the second reduction-coupling cycle, the nine azido-dipeptides 22aa-22cc 
(approximately 0.15 mmol for each one) were treated in parallel with Ph3P (1.2 equiv) in THF 
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under microwave (120 ºC, 250 W) for 5 min, followed by the addition of H2O (20 equiv) and 
irradiation by microwave again for 10 min (Scheme 1.14). All nine reactions were complete 
according to TLC analysis. The nine amines 23aa-23cc were isolated by FSPE with 80-100% 
yields.  
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(9 amines)
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(9 azido-dipeptides) 2) H2O (20 equiv), μw 10 min
3) FSPE
 
 
Scheme 1.14.  The reductions of azido-esters 22aa-22cc 
 
Each of the nine amines 23aa-22cc was divided into three equal portions and each portion 
was coupled with the three β-azido acids 14a-14c in the presence of EDCI and DMAP to give 27 
azido-tripeptides 24aaa-24ccc in 33-100% yields after FSPE (Scheme 1.15). Reactions were 
done in parallel and all were complete in 30 min according to TLC analysis.  
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Scheme 1.15.  Synthesis of the 27 azido-tripeptides 24aaa-24ccc 
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 The azido-tripeptides 24aaa-24ccc were characterized by LC-MS analysis on the 
FluoroFlashTM PF-C8 HPLC column under the conditions described in Table 1.4. Since we had 
many samples to test, a more rapid condition starting with 90:10 MeCN:H2O was used thus the 
retention times of the 27 products (all about 10 min) were much shorter than that of 24aaa from 
the single peptide synthesis (25.9 min, see Figure 1.5). The LC chromatograms of 24aaa-24ccc 
showed that the average purity of the samples is greater than 90%, and the MS data (with APCI 
detector) of the products matched well with the calculated molecular weights (Table 1.4).34a,b  
 
Table 1.4.  LC-MS data of the 27 azido-tripeptides 
 
Peptide 
Calculated 
Mass 
Measured 
Mass 
Peptide 
Calculated 
Mass 
Measured 
Mass 
24aaa 1177.4 [M+] 1178.2 [M + H]+ 24bbc 1073.3 [M+] 1074.2 [M + H]+
24aab 1149.4 [M+] 1150.0 [M + H]+ 24bca 1101.4 [M+] 1102.2 [M + H]+
24aac 1129.4 [M+] 1130.2 [M + H]+ 24bcb 1073.3 [M+] 1074.2 [M + H]+
24aba 1149.4 [M+] 1150.2 [M + H]+ 24bcc 1053.4 [M+] 1054.2 [M + H]+
24abb 1121.3 [M+] 1122.0 [M + H]+ 24caa 1129.4 [M+] 1130.2 [M + H]+
24abc 1101.4 [M+] 1102.2 [M + H]+ 24cab 1101.4 [M+] 1102.2 [M + H]+
24aca 1129.4 [M+] 1130.2 [M + H]+ 24cac 1081.4 [M+] 1082.2 [M + H]+
24acb 1101.4 [M+] 1102.2 [M + H]+ 24cba 1101.4 [M+] 1102.2 [M + H]+
24acc 1081.4 [M+] 1082.2 [M + H]+ 24cbb 1073.3 [M+] 1074.2 [M + H]+
24baa 1149.4 [M+] 1150.0 [M + H]+ 24cbc 1053.4 [M+] 1054.2 [M + H]+
24bab 1121.3 [M+] 1122.2 [M + H]+ 24cca 1081.4 [M+] 1082.2 [M + H]+
24bac 1101.4 [M+] 1102.2 [M + H]+ 24ccb 1053.4 [M+] 1054.2 [M + H]+
24bba 1121.3 [M+] 1122.2 [M + H]+ 24ccc 1033.4 [M+] 1034.2 [M + H]+
24bbb 1093.3 [M+] 1094.2 [M + H]+    
 
Conditions:  FluoroFlashTM PF-C8 HPLC column (4.6 × 150 mm), 1 mL/min,  
      gradient elution, 90:10 to 100:0 MeCN:H2O in 15 min, APCI detector 
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Five of the azido-tripeptides (24aaa, 24bbb, 24cba, 24ccb and 24ccc) were selected by 
molecular weight (including highest, median, and lowest) for 1H and 13C NMR analysis to 
provide additional support for structure and purity. The fluorous HPLC trace, MS and 1H NMR 
spectra of a typical azido-tripeptide 24cba are shown in Figure 1.6.34a,b The first three HPLC 
chromatograms show the UV absorbances at 254, 210 and 230 nm, while the last one shows the 
total ion count (TIC). Azido-tripeptide 24cba had a retention time of 9.6 min, and was visible at 
210 and 230 nm, but not 254 nm. The MS spectrum of the major peak at 9.6 min showed a strong 
signal of 1102.2 [M + H]+, which matched with the calculated mass of 24cba (1101.4 [M+]) 
within 0.2 mass units. In the 1H NMR spectrum of 24cba, two amide proton resonances were 
found (δ 8.24, 5.85 ppm), indicating the formation of the azido-tripeptide.  
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Figure 1.6.  The fluorous HPLC traces (top left), MS spectrum (peak at 9.6 min, top right)  
and 1H NMR spectrum (bottom, 500MHz, CDCl3) of azido-tripeptide 24cba  
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1.2.6  The detagging reactions.  
 
The final step of the library synthesis involves the deprotection of the FPMB group and the 
simultaneous reduction of the azido group. The hydrogenations of 24aaa-24ccc with Pd(OH)2/C 
(12–37 w%) in tBuOH in a parallel synthesizer went smoothly to give tri-β-peptides 25aaa-25ccc 
(Scheme 1.16). Other frequently used solvents for hydrogenation such as MeOH or EtOH led to 
partial esterification by the solvent at the C-terminus. Peptides 25aaa-25ccc were separated from 
the FPMB residue by plate-to-plate FSPE to give crude final products in yields listed in Table 6.33  
We further purified 22 of the 27 peptides (since 5 of them were pure) individually by 
preparative reverse phase HPLC with gradient conditions (see Experimental section), then all 
purified peptides were analyzed by LCMS (Table 1.5). Almost all peptides had retention times at 
about 2.5 min (near the solvent front) since they were probably zwitterionic. Under the 
conditions described under Table 1.5, 25 peptides ionized well and showed the expected masses, 
and no impurities were detected in their LCMS spectra. Five peptides among these 25 (25aba, 
25bab, 25bba, 25bbb and 25cba) were selected arbitrarily to conduct 1H NMR experiments 
(D2O/CD3CN) to confirm structure and purity. The NMR spectrum of 25cba is typical and is 
shown is Figure 1.7.  
Two expected products, 25bca and 25ccb were not found according to LCMS analysis. 
However, the two isolated products were pure and their proposed structures are shown in 
Scheme 1.16. Product 26bca exhibited the peak for [M – H2O + 2Na]+, so we tentatively 
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assigned the structure as a dehydrated cyclic peptide. Product 27ccb exhibited the peak for [M – 
15 + Na]+, suggesting that this product resulted from reductive deamination (hydrogenolysis) of 
the terminal benzylic amino group. A much longer retention time (5 min) also supported the 
proposed structure of 25ccb since the polarity of the deaminated product is less than the desired 
zwitterionic product. These side reactions seemed to be sequence specific, since they were not 
observed for any other members of the library.  
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Pd(OH)2/C (12-37 w%)
tBuOH, rt, 24h
25aaa-25ccc24aaa-24ccc
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25cba 25cbb 25cbc
25cca 27ccb 25ccc  
 
Scheme 1.16.  Synthesis of the 27 tri-β-peptides 25aaa-25ccc 
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Table 1.5.  LC-MS data of the 27 tri-β-peptides 
 
Peptide 
Yield 
(%) a
Recovery 
(%) b
Retention 
Time (min)
Calculated 
Mass 
Measured  
Mass 
25aaa 92 — c 2.4 585.4 [M+] 586.3 [M + H]+
25aab 89 — c 2.5 557.3 [M+] 558.3 [M + H]+
25aac 80 76 2.3 537.4 [M+] 538.3 [M + H]+
25aba 84 94 2.2 557.3 [M+] 558.3 [M + H]+
25abb 71 — c 2.6 529.3 [M+] 530.2 [M + H]+
25abc 64 45 2.3 509.3 [M+] 510.3 [M + H]+
25aca 61 80 2.3 537.4 [M+] 538.3 [M + H]+
25acb 72 67 2.2 509.3 [M+] 510.2 [M + H]+
25acc 68 — c 2.3 489.4 [M+] 490.4 [M + H]+
25baa 80 84 2.4 557.3 [M+] 558.3 [M + H]+
25bab 70 94 2.4 529.3 [M+] 530.2 [M + H]+
25bac 97 93 2.1 509.3 [M+] 510.2 [M + H]+
25bba 51 99 2.2 529.3 [M+] 530.2 [M + H]+
25bbb 60 — c 2.7 501.3 [M+] 502.2 [M + H]+
25bbc 88 86 2.1 481.3 [M+] 482.2 [M + H]+
26bca 82 64 ― d 509.3 [M+] 537.3 [M – H2O + 2Na]+ e
25bcb 76 53 1.9 481.3 [M+] 482.3 [M + H]+
25bcc 79 87 2.0 461.3 [M+] 462.3 [M + H]+
25caa 87 91 2.0 537.4 [M+] 538.3 [M + H]+
25cab 71 75 2.3 509.3 [M+] 510.4 [M + H]+
25cac 55 78 2.2 489.4 [M+] 490.3 [M + H]+
25cba 69 71 2.3 509.3 [M+] 510.2 [M + H]+
25cbb 88 90 2.2 481.3 [M+] 482.2 [M + H]+
25cbc 88 57 2.2 461.3 [M+] 462.3 [M + H]+
25cca 82 40 2.1 489.4 [M+] 490.4 [M + H]+
27ccb 97 83 5.0 461.3 [M+]  469.2 [M – 15 + Na]+ e
25ccc 78 88 2.1 441.4 [M+] 442.4 [M + H]+
Conditions: XTerra® MS-C18 HPLC column (4.6 × 100 mm), 0.4 mL/min, gradient elution,  
70:30 to 100:0 MeCN:H2O (w/ 0.1% TFA) in 15 min, ESI detector.  
 
a. After FSPE;  b. After HPLC purification;  c. The product after FSPE was pure by HPLC analysis and was 
not further purified;  d. Only MS analysis was done due to low solubility of the sample;  e. Undesired 
product (“M” is the molecular weight of the desired product).  
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Figure 1.7.  The 1H NMR spectrum of tri-β-peptide 25cba (500MHz, CDCl3) 
 
1.3  CONCLUSIONS 
 
In conclusion, we developed a convenient way to make β-peptide libraries. Starting from 
light fluorous tagged β-azido acids, followed by two reduction-amide coupling cycle and the 
reductive deprotection, we did the solution phase parallel synthesis of a 27-membered 
tri-β-peptide library with rapid separation by FSPE. Peptides were tested for purities by fluorous 
or reverse phase HPLC. Mass spectroscopy data of the products matched with calculation. The 
results suggest that the azido acid approach to make β-peptides deserves serious consideration as 
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an alternative to the traditional amino acid approach. The results further show the usefulness of 
fluorous solid phase extraction as a rapid and effective purification method of light fluorous 
molecules. By applying the same methodology, we expect that larger and more complex libraries 
of β-peptide can be made.  
 
 
1.4  EXPERIMENTAL 
 
1.4.1  General Information. 
 
All reaction solvents were freshly purified either by distillation or by passing through an 
activated alumina column. THF, CH2Cl2, Et2O were dried by activated alumina according to 
Pangborn, A.; Giardello, M. A.; Grubbs, R. H.; Rosen, R. K.; Timmer, F.; J. Organometallics, 
1996, 15, 1518.  
All reactions were followed by TLC. The Staudinger reactions were also followed by 
fluorous TLC. All Fluorous Solid Phase Extractions (FSPE) were done in a standard SPE 
manifold with FluoroFlashTM SPE Cartridges (5 g, 10 cc tube). The Staudinger reactions of 
20a-20c were done in a CEM Discover® LabMate™ microwave reactor one at a time. The 
Staudinger reactions of azido di-β-peptides 22aa-22cc were done in an Emrys™ Optimizer 
microwave reactor. Solvent from FSPE was removed in a ThermoSavant SC210A SpeedVac® 
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Plus. All hydrogenation reactions were done in a GreenHouse Classic Parallel Synthesizer.  
1
H and 
13
C NMR spectra were taken on a Bruker models Advance DPX 300 (300 MHz), 
Advance 300 (300 MHz) NMR spectrometer. Chemical shifts were reported in parts per million 
(ppm) downfield relative to TMS using the residue solvent proton resonance of CDCl3 (7.27 ppm) 
or central CDCl3 carbon peak (77.0 ppm) as internal standard. In reporting spectral data, the 
following abbreviations were used: s = singlet, d = doublet, t = triplet, q = quartet, quin = 
quintuplet, m = multiplet, dd = doublet doublet, td = doublet triplet, qd = doublet quartet, ddd = 
doublet doublet doublet.  
Azido di-?-peptides 22aa-22cc and azido tri-?-peptides 24aaa-24ccc were characterized by 
LC-MS in an Agilent HP 1100 series LC-MSD system with the FluoroFlash
TM
 PF-C8 HPLC 
column (5 μm, 10 Å, 4.6 ? 150 mm) and APCI detector, 1.0 mL/min, gradient elution (90:10 
MeCN:H2O to 100:0 in 15 min). Tri-?-peptides 25aaa-25ccc were characterized by LC-MS in an 
Agilent HP 1100 series LC-MSD with a XTerra
® 
MS C18 (3.5 μm, 4.6 ? 100 mm) HPLC column 
and ESI detector, 0.4 mL/min, gradient elution (70:30 MeCN:H2O (with 0.1% TFA) to 100:0 in 
15 min). Tri-?-peptides 25aaa-25ccc were purified in a HPLC instrument (Waters 600 Controller 
and Waters 2487 dual ? Absorbance Detector) with Waters SymmetryPrepTM C18 (7 μm, 7.8 ? 
150 mm) preparative HPLC column, 1.6 mL/min, gradient elution (MeCN:H2O = 20:80 (0-5 
min), 20:80 to 100:0 (5-25 min), 100:0 (25-35 min), 100:0 to 20:80 (35-40 min)).  
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1.4.2  General Experimental Procedures:  
 
General procedure 1: synthesis of ?-lactones.18  
CH2Cl2 (2.0 mL) was added to a solution of 9-trimethylsilylquinine 5a or 
9-trimethylsilylquinidine 5b (0.10 mmol) and LiClO4 (0.3-3.0 mmol) in diethyl ether (1.0 mL). 
The reaction mixture was cooled to –78 °C. N,N-Diisopropylethylamine (0.44 mL, 2.5 mmol) 
was added to the resulting mixture followed by the addition of the aldehyde (1.0 mmol). A 
solution of acid chloride (2.0 mmol) in CH2Cl2 (0.5 mL) was then added over 1 h via syringe 
pump. The mixture was stirred for 13-16 h and the reaction was quenched with Et2O (10 mL). 
The resulting mixture was partitioned between Et2O (30 mL) and saturated NH4Cl (15 mL). The 
organic layer was separated and washed with brine (10 mL), dried with Na2SO4, and 
concentrated in vacuo. The crude product was purified by flash chromatography.  
 
General procedure 2: SN2 addition of NaN3 to ?-lactones.10  
?-Lactone 13 (6.0 mmol) was added to a solution of NaN3 (12.0 mmol) in anhydrous DMF 
(35 mL, 0.3 M for lactone) via syringe at 50 °C. The resulting homogeneous solution was stirred 
for 4-5 h. The reaction mixture was cooled to ambient temperature, and saturated aqueous 
NaHCO3 (30 mL) was added. The resulting heterogeneous mixture was triturated with water 
until all the precipitated salts dissolved. The resulting mixture was washed with ethyl acetate (2 ? 
50 mL) and the aqueous layer was acidified with 1 M aqueous HCl to pH ? 1. The acidic 
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aqueous layer was extracted with ethyl acetate (3 ? 50 mL) and the combined organic portions 
were washed with water (2 ? 50 mL) and brine (2 ? 50 mL). The organic portion was dried with 
Na2SO4 and evaporated in vacuo to afford the ?-azido acid 14.  
 
General procedure 3: FPMB tagging reaction.30b  
To a solution of ?-azido acid 14 (0.2 mmol) in CH2Cl2 (10 mL) was added DMAP (12 mg, 
0.10 mmol). 
F
PMBOH (16, 140 mg, 0.240 mmol) was added to the solution followed by the 
addition of EDCI (46 mg, 0.24 mmol). After 30 min, the mixture was partitioned between Et2O 
(30 mL) and 1M aqueous HCl (15 mL). The organic layer was separated and washed with H2O 
(10 mL) and brine (10 mL), then dried with Na2SO4 and evaporated in vacuo to afford the crude 
F
PMB ester 20, which was purified by flash chromatography (4:1 Hex:EtOAc).  
 
General procedure 4: Staudinger reaction.12,26  
In a microwave tube, the azido-ester 20 or 22 (0.2 mmol) was dissolved in dry THF (0.5 
mL). A solution of triphenylphosphine (63 mg, 0.24 mmol) in dry THF (1 mL) was added to the 
microwave tube by syringe. The mixture was heated in the microwave reactor under stirring at 
120 ºC, 250 W, for 5 min. H2O (72 mg, 4.0 mmol) was added to the microwave tube via syringe. 
The resulting mixture was microwaved for 10 min, at 120 ºC, 250 W. The reaction progress can 
be monitored either by regular TLC or 
31
P NMR analysis (? (THF-d8) for Ph3P: –5 ppm; for 
Ph3P=NR: 2 ppm; for Ph3PO: 27 ppm). A very polar new spot on TLC indicates the formation of 
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the amine. In the 
31
P NMR spectrum of the reaction mixture, the formation of Ph3PO and the 
disappearance of Ph3P=NR indicate the completion of the reaction. The solvent was removed in 
vacuo when the reaction is complete. A new FSPE cartridge (5 g) was washed with THF (20 mL) 
under vacuum on a SPE manifold, and was preconditioned by passing through 70:30 MeCN:H2O 
(30 mL). The concentrated reaction mixture was dissolved in MeCN (1 mL) and loaded onto the 
cartridge by vacuum to ensure that the sample was completely adsorbed to the silica gel. The 
cartridge was washed with 70:30 MeCN:H2O (50 mL) to obtain the fraction containing organic 
compounds (Ph3PO and Ph3P), and washed with MeCN (30 mL) to obtain the fraction containing 
fluorous compounds (the amine). The fluorous fraction was dried with Na2SO4 and the solvent 
was evaporated in vacuo to afford amine 21 or 23.  
 
General procedure 5: amide coupling.  
DMAP (12 mg, 0.10 mmol) was added to a solution of amine 21 or 23 (0.2 mmol) in 
CH2Cl2 (2 mL). ?-Azido acid 14 (0.24 mmol) was added to the solution, followed by the addition 
of EDCI (46 mg, 0.24 mmol) and CH2Cl2 (1 mL). The mixture was stirred for 30 min before the 
solvent was removed in vacuo. A new FSPE cartridge (5 g) was washed with THF (20 mL) 
under vacuum on a SPE manifold, and was preconditioned by passing through 70:30 MeCN:H2O 
(30 mL). The concentrated reaction mixture was dissolved in MeCN (1 mL) and loaded onto the 
cartridge by vacuum to ensure that the sample was completely adsorbed to the silica gel. The 
cartridge was washed with 70:30 MeCN:H2O (50 mL) to obtain the fraction containing organic 
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compounds, and washed with MeCN (30 mL) to obtain the fraction containing the fluorous 
compound. The fluorous fraction was dried with Na2SO4 and the solvent was evaporated in 
vacuo to afford azido-peptide 22 or 24.  
 
General procedure 6: hydrogenation.  
In a GreenHouse Classic Parallel Synthesizer, the solution of each azido-tripeptide 24 (8 mg) 
in tert-butanol (2 mL) was loaded to each reaction tube. Pd(OH)2/C (2 mg, 25 w%) was added to 
each solution. The reactor was first vacuumed and then filled with hydrogen gas in a balloon, 
which was attached to the reactor during the reaction. With stirring on, all reactions were 
complete in 24 h according to TLC analysis. The solvent was removed in vacuo by the speed-vac. 
The reaction mixtures were directly loaded onto a preconditioned SPE cartridge plate, with each 
cartridge packed with FluoroFlash
TM 
silica gel (3 g).
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 The cartridges were eluted with 70:30 
MeCN:H2O (2 ? 5 mL). The solvent was removed in vacuo by speed-vac to afford ?-tripeptides 
25. The cartridges were washed with THF (3 ? 5 mL) to remove the FPMB residue before they 
were ready for reuse.  
 
1.4.3  Specific Experimental Procedures and Compound Data:  
(All NMR/MS spectra and HPLC traces can be found in the published paper. 
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NH
N
O
Me3Si
MeO  
9-Trimethylsilylquinine (“TMSq”, 5a): 29
Trimethylsilyl chloride (1.56 mL, 12.3 mmol) was added to a solution of quinine (4.00 g, 
12.3 mmol) in CH2Cl2 (40 mL). The reaction mixture was stirred at room temperature for 24 h 
and then partitioned between CH2Cl2 (40 mL) and saturated aqueous NaHCO3 (80 mL). The 
aqueous layer was extracted with CH2Cl2 (3 x 16 mL). The combined organic layer was dried 
with Na2SO4 and the solvent was removed in vacuo. Purification of the crude product by flash 
chromatography (93:7 CH2Cl2:MeOH) afforded 9-trimethylsilylquinine (4.49 g, 93%) as a white 
solid: 1H NMR (300 MHz, CDCl3) δ 13.15 (br, s, 1H), 8.71 (d, J = 4.5 Hz, 1H), 8.00 (d, J = 9.2 
Hz, 1H), 7.72 (d, J = 1.9 Hz, 1H), 7.46 (d, J = 4.5, 1H), 7.38 (dd, J = 9.2, 2.4 Hz, 1H), 6.74 (s, 
1H), 5.56 (ddd, J = 16.7, 10.3, 6.8 Hz, 1H), 5.03 (d, J = 15.1 Hz, 1H), 5.02 (d, J = 11.4 Hz, 1H), 
4.15 (s, 3H), 4.03 (m, 1H), 3.44 (t, J = 12.0 Hz, 2H), 3.27 (t, J = 9.0 Hz, 1H), 3.10 (m, 2H), 2.69 
(br, s, 1H), 2.22 (dd, J = 13.2, 7.7 Hz, 1H), 2.09 (m, 2H), 1.88 (m, 1H), 1.44 (td, J = 10.2, 1.8 Hz, 
1H), 0.13 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 157.7, 147.8, 147.5, 144.7, 142.2, 131.9, 126.5, 
121.4, 119.2 (br), 114.1, 101.2 (br), 61.2, 57.5, 55.7, 43.2 (br), 40.2, 28.1, 0.2.  
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9-Trimethylsilylquinidine (“TMSQ”, 5b):29
Trimethylsilyl chloride (0.79 mL, 6.16 mmol) was added to a solution of quinidine (2.00 g, 
6.16 mmol) in CH2Cl2 (20 mL). The reaction mixture was stirred at room temperature for 2 h and 
then partitioned between CH2Cl2 (20 mL) and saturated aqueous NaHCO3 (40 mL). The aqueous 
layer was extracted with CH2Cl2 (3 x 8 mL). The combined organic layer was dried with Na2SO4 
and the solvent was removed in vacuo. Purification of the crude product by flash 
chromatography (93:7 CH2Cl2:MeOH) afforded 9-trimethylsilylquinidine (2.39 g, 98%) as a 
white solid: 1H NMR (300 MHz, CDCl3) δ 13.10 (br, s, 1H), 8.71 (d, J = 4.4 Hz, 1H), 7.98 (d, J 
= 9.2 Hz, 1H), 7.70 (d, J = 2.9 Hz, 1H), 7.46 (d, J = 4.4, 1H), 7.37 (dd, J = 9.2, 2.9 Hz, 1H), 
6.91 (s, 1H), 5.98 (ddd, J = 17.1, 9.7, 7.1 Hz, 1H), 5.26 (d, J = 10.8 Hz, 1H), 5.22 (d, J = 17.6 
Hz, 1H), 4.12 (s, 3H), 3.95 (m, 1H), 3.38 (t, J = 11.5 Hz, 2H), 3.25 (t, J = 9.5 Hz, 1H), 3.13 (m, 
1H), 2.59 (q, J = 8.0 Hz, 1H), 2.49 (t, J = 11.3 Hz, 1H), 2.02 (br, s, 1H), 1.92 (m, 1H), 1.72 (m, 
1H), 1.14 (m, 1H), 0.15 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 159.8, 147.2, 145.0, 144.4, 136.8, 
132.1, 126.2, 123.7, 119.1, 118.2, 101.2, 68.6, 60.7, 58.23, 49.5, 48.0, 37.8, 28.0, 23.9, 18.3, 0.8.  
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O
O
CH2CH2Ph  
(3R,4S)-3-Methyl-4-phenethyloxetan-2-one (13a):18
General procedure 1 was followed by employing TMSq (5a, 4.80 g, 12.1 mmol), iPr2NEt 
(52.8 mL, 300 mmol), LiClO4 (9.54 g, 89.7 mmol) and hydrocinnamaldehyde (15.9 mL, 120 
mmol). Addition of a solution of propionyl chloride (21.0 mL, 240 mmol) in CH2Cl2 (30 mL) via 
syringe pump was done over 1 h. The reaction mixture was stirred for 16 h. Purification of the 
crude product by flash chromatography (9:1 Hex:EtOAc) gave the title compound (12.60 g, 54%) 
as a colorless oil: Analysis by chiral HPLC [Daicel Chiracel™ OD column, flow rate 1.0 mL/min, 
5% iPrOH, 95% hexane, tR: 8.8 min (3S,4R), 11.5 min (3R,4S)] showed an enantiomeric ratio of 
96.8/3.2 (3R,4R)/(3S,4S) (93.6% ee); 1H NMR (300 MHz, CDCl3) δ 7.35–7.20 (m, 5H), 4.56 
(ddd, J = 9.6, 6.2, 4.1 Hz, 1H), 3.78 (quin, J = 7.7 Hz, 1H), 2.88 (ddd, J = 12.4, 9.2, 5.2 Hz, 1H), 
2.73 (m, 1H), 2.08 (m, 1H), 1.97 (m, 1H), 1.28 (d, J = 7.8 Hz, 3H); 13C NMR (75 MHz, CDCl3) 
δ 172.3, 140.3, 128.5, 128.4, 126.3, 74.5, 47.1, 31.8, 31.4, 8.0.  
 
O
O
Ph  
(3R,4R)-3-Methyl-4-phenyloxetan-2-one (13b):18   
General procedure 1 was followed by employing TMSq (5a, 0.48 g, 1.21 mmol), iPr2NEt 
(5.30 mL, 30.0 mmol), LiClO4 (2.55 g, 24.0 mmol) and benzaldehyde (1.23 mL, 12.0 mmol). 
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Addition of a solution of propionyl chloride (2.10 mL, 24.0 mmol) in CH2Cl2 (3 mL) via syringe 
pump was done over 1 h. The reaction mixture was stirred for 16 h. Purification of the crude 
product by flash chromatography (8:1 Hex:EtOAc) gave the title compound (1.89 g, 97%) as a 
colorless oil: Analysis by chiral HPLC [Daicel Chiracel™ OD column, flow rate 1.0 mL/min, 
3% iPrOH, 97% hexane, tR: 9.4 min (3R,4R)] showed only one enantiomer (3R,4R) (>99% ee); 
1H NMR (300 MHz, CDCl3) δ 7.43–7.27 (m, 5H), 5.64 (d, J = 6.5 Hz, 1H), 4.05 (quin, J = 7.7 
Hz, 1H), 0.90 (d, J = 7.8 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 172.6, 135.0, 129.0, 128.9, 
126.1, 75.6, 50.5, 9.8.  
 
O
O
 
(3S,4R)-4-Isobutyl-3-methyloxetan-2-one (13c): 18
General procedure 1 was followed by employing TMSQ (5b, 0.48 g, 1.21 mmol), iPr2NEt (5.30 
mL, 30.0 mmol), LiClO4 (2.55 g, 24.0 mmol) and isovaleraldehyde (1.31 mL, 12.0 mmol). 
Addition of a solution of propionyl chloride (2.10 mL, 24.0 mmol) in CH2Cl2 (3 mL) via syringe 
pump was done over 1 h. The reaction mixture was stirred for 16 h. Purification of the crude 
product by flash chromatography (4:1 Hex:EtOAc) gave the title compound. A small amount of 
solvent remained in the sample and was not further removed because of the volatility of the title 
compound: Analysis by chiral GLC [Chiraldex™ G-TA column 20m × 0.25 mm, flow rate 0.6 
mL/min, method: 80 °C for 5.0 min, ramp @ 5.0 °C/min to 100 °C for 10.0 min, ramp @ 5.0 
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°C/min to 130 °C for 5.0 min, tR: 23.9 min (3R,4S) and 25.0 min (3S,4R)] showed an 
enantiomeric ratio of 99.7/0.3 (3S,4R)/(3R,4S) (99.4% ee); 1H NMR (300 MHz, CDCl3) δ 4.63 
(m, 1H), 3.72 (quin, J = 7.2 Hz, 1H), 1.77 (m, 1H), 1.63 (m, 1H), 1.47 (m, 1H), 1.23 (d, J = 6.8 
Hz, 3H), 0.95 (d, J = 6.5 Hz, 3H), 0.94 (d, J = 6.5 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 172.5, 
74.2, 47.3, 38.5, 25.3, 22.8, 22.0, 8.0.  
 
O
O
 
(S)-4-tert-Butyloxetan-2-one (13d):18
General procedure 1 was followed by employing TMSQ (5b, 0.48 g, 1.20 mmol), iPr2NEt 
(5.30 mL, 30.0 mmol), LiClO4 (3.83 g, 36.0 mmol) and pivalaldehyde (1.31 mL, 12.0 mmol). 
Addition of the solution of acetyl chloride (1.71 mL, 24.0 mmol) in CH2Cl2 (3 mL) via syringe 
pump was done over 1 h. The reaction mixture was stirred for 16 h. Purification of the crude 
product by flash chromatography (8:1 Hex:EtOAc) gave the title compound (1.40 g, 91%) as a 
colorless oil: Analysis by chiral GLC [Chiraldex™ G-TA column 20 m × 0.25 mm, flow rate 0.6 
mL/min, method: 80 °C for 5.0 min, ramp @ 5.0 °C/min to 100 °C for 10.0 min, ramp @ 5.0 
°C/min to 130 °C for 5.0 min, ramp @ 15.0 °C/min to 150 °C for 5.0 min, tR: 17.8 min (4R) and 
19.0 min (4S)] showed an enantiomeric ratio of 98/2 (4S)/(4R) (96% ee); 1H NMR (300 MHz, 
CDCl3) δ 4.20 (dd, J = 5.8, 4.8 Hz, 1H), 3.24 (dd, J = 6.0 Hz, 16.5 Hz, 1H), 3.09 (dd, J = 4.5 Hz, 
16.5 Hz, 1H), 0.94 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 168.5, 78.1, 38.4, 33.0, 24.2.  
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(3R,4R)-3-Methyl-4-(prop-1-en-2-yl)oxetan-2-one (13e):  
General procedure 1 was followed by employing TMSq (5a, 0.20 g, 0.50 mmol), iPr2NEt 
(2.30 mL, 12.6 mmol), LiClO4 (1.07 g, 10.1 mmol) and methacrolein (0.42 mL, 5.0 mmol). 
Addition of the solution of propionyl chloride (0.89 mL, 10.1 mmol) in CH2Cl2 (2 mL) via 
syringe pump was done over 1 h. The reaction mixture was stirred for 13 h. Purification of the 
crude product by flash chromatography (7:1 Hex:EtOAc) gave the title compound (198 mg, 32%) 
as a yellow oil: 1H NMR (300 MHz, CDCl3) δ 5.12 (m, 2H), 4.89 (d, J = 6.5 Hz, 1H), 3.81 (quin, 
J = 7.4 Hz, 1H), 1.70 (s, 3H), 1.18 (d, J = 7.7 Hz, 2H); 13C NMR (75 MHz, CDCl3) δ 171.8, 
138.2, 113.3, 75.9, 47.0, 18.9, 8.5.  
 
O
O
CH2OBn  
(R)-4-(Benzyloxymethyl)oxetan-2-one (13f):18   
General procedure 1 was followed by employing TMSq (5a, 0.24 g, 0.60 mmol), iPr2NEt 
(2.70 mL, 15.0 mmol), LiClO4 (0.19 mg, 1.8 mmol) and benzyloxyacetaldehyde (0.84 mL, 6.0 
mmol). Addition of the solution of acetyl chloride (0.86 mL, 12.0 mmol) in CH2Cl2 (3 mL) via 
syringe pump was done over 1 h. The reaction mixture was stirred for 16 h. Purification of the 
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crude product by flash chromatography (4:1 Hex:EtOAc) gave the title compound (351 mg, 30%) 
as a colorless oil: Analysis by chiral HPLC [Daicel Chiracel™ OD column, flow rate 0.9 
mL/min, 15% iPrOH, 85% hexane, tR 13.9 min (R) and 24.8 min (S)] showed an enantiomeric 
ratio of 92/8 (R)/(S) (84% ee); 1H NMR (300 MHz, CDCl3) δ 7.45–7.40 (m, 5H), 4.68 (m ,1H), 
4.66 (d, J = 1.9 Hz, 2H), 3.86 (dd, J = 11.7, 2.8 Hz, 1H), 3.73 (dd, J = 11.7, 4.5 Hz, 1H), 3.46 (d, 
J = 3.9 Hz, 1H), 3.44 (d, J = 3.0 Hz, 1H); 13C NMR (75 MHz, CDCl3) δ 168.1, 137.8, 128.6, 
128.0, 127.8, 73.7, 69.7, 69.4, 39.7.  
 
HO
O
N3
Ph
 
(2R,3R)-3-Azido-2-methyl-5-phenylpentanoic acid (14a): 
General procedure 2 was followed by employing β-lactone 13a (0.54 g, 2.8 mmol), NaN3 
(0.37 g, 5.7 mmol) and DMF (19 mL). The reaction mixture was stirred for 5 h. β-Azido acid 
14a (0.66 g, 100%) was isolated as a colorless oil: 1H NMR (300 MHz, CDCl3) δ 11.48 (br, s, 
1H), 7.36–7.22 (m, 5H), 3.60 (td, J = 7.0, 3.3 Hz, 1H), 2.87 (ddd, J = 14.1, 9.5, 5.0 Hz, 1H), 
2.72 (m, 1H), 2.70 (quin, J = 7.2 Hz, 1H), 1.96 (m, 1H), 1.85 (m, 1H), 1.25 (d, J = 7.0 Hz, 3H); 
13C NMR (75 MHz, CDCl3) δ 179.9, 141.2, 129.3, 129.0, 126.7, 64.1, 44.5, 33.5, 32.8, 13.9.  
 
HO
O Ph
N3
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(2R,3S)-3-Azido-2-methyl-3-phenylpropanoic acid (14b):  
General procedure 2 was followed by employing β-lactone 13b (1.00 g, 6.17 mmol), NaN3 
(0.80 g, 12 mmol) and DMF (35 mL). The reaction mixture was stirred for 4 h. β-Azido acid 14b 
(1.27 g, 100%) was isolated as a colorless oil: 1H NMR (300 MHz, CDCl3) δ 11.54 (br, s, 1H), 
7.44–7.27 (m, 5H), 4.67 (d, J = 10.4 Hz, 1H), 2.81 (td, J = 10.4, 7.1 Hz, 1H), 0.98 (d, J = 7.1 Hz, 
3H); 13C NMR (75 MHz, CDCl3) δ 180.8, 151.5, 136.4, 129.0, 127.7, 68.1, 45.7, 14.6.  
 
HO
O
N3
 
(2S,3S)-3-Azido-2,5-dimethylhexanoic acid (14c): 
General procedure 2 was followed by employing β-lactone 13c (from the AAC reaction), 
NaN3 (1.56 g, 24.0 mmol) and DMF (50 mL). The reaction mixture was stirred for 5 h. β-Azido 
acid 14c (1.44 g, 65% in two steps) was isolated as a yellow oil: 1H NMR (300 MHz, CDCl3) δ 
10.94 (br, s, 1H), 3.63 (ddd, J = 10.4, 7.1, 3.2 Hz, 1H), 2.65 (quin, J = 7.1 Hz, 1H), 1.82 (m, 1H), 
1.51 (td, J = 10.4, 3.9 Hz, 1H), 1.28 (td, J = 9.7, 3.2 Hz, 1H), 1.23 (d, J = 7.1 Hz, 3H), 0.97 (d, J 
= 6.7 Hz, 3H), 0.96 (d, J = 6.5 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 180.2, 62.3, 44.5, 40.0, 
25.0, 23.4, 21.3, 13.3.  
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(2R,3R)-4-[3-(Perfluorooctyl)propyl-1-oxy]benzyl-3-azido-2-methyl-5-phenylpentanoate 
(20a): 
General procedure 3 was followed by employing β-azido acid 14a (140 mg, 0.600 mmol), 
DMAP (37 mg, 0.30 mmol), FPMBOH (16, 421 mg, 0.720 mmol) and EDCI (115 mg, 0.600 
mmol). Purification of the crude product by flash chromatography (4:1 Hex:EtOAc) gave the 
title compound (385 mg, 80%) as a colorless oil: 1H NMR (300 MHz, CDCl3) δ 7.33–7.22 (m, 
5H), 7.17 (d, J = 6.8 Hz, 2H), 6.89 (d, J = 8.7 Hz, 2H), 5.10 (d, J = 4.8 Hz, 2H), 4.05 (t, J = 5.9 
Hz, 2H), 3.60 (ddd, J = 9.7, 6.3, 3.9 Hz, 1H), 2.83 (ddd, J = 14.5, 8.7, 5.8 Hz, 1H), 2.69 (quin, J 
= 7.1 Hz, 1H), 2.68 (m, 1H), 2.30 (m, 2H), 2.12 (m, 2H), 1.86 (m, 1H), 1.78 (m, 1H), 1.19 (d, J 
= 7.1 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 174.1, 159.2, 141.3, 130.7, 129.0, 128.9, 128.7, 
126.7, 115.0, 66.9, 66.8, 64.3, 44.7, 33.5, 32.7, 28.7, 28.4, 28.1, 21.0, 13.9.  
 
O
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(2R,3S)-4-[3-(Perfluorooctyl)propyl-1-oxy]benzyl-3-azido-2-methyl-3-phenylpropanoate 
(20b): 
General procedure 3 was followed by employing β-azido acid 14b (123 mg, 0.600 mmol), 
DMAP (37 mg, 0.30 mmol), FPMBOH (16, 421 mg, 0.720 mmol) and EDCI (115 mg, 0.600 
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mmol). Purification of the crude product by flash chromatography (4:1 Hex:EtOAc) gave the 
title compound (405 mg, 87%) as a colorless oil: 1H NMR (300 MHz, CDCl3) δ 7.43–7.34 (m, 
5H), 7.29 (d, J = 8.6 Hz, 2H), 6.92 (d, J = 8.6 Hz, 2H), 5.18 (s, 2H), 4.66 (d, J = 10.4 Hz, 1H), 
4.06 (t, J = 5.8 Hz, 2H), 2.82 (qd, J = 10.4, 7.1 Hz, 1H), 2.31 (m, 2H), 2.13 (m, 2H), 0.94 (d, J = 
7.1 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 174.1, 158.7, 136.7, 130.1, 128.9, 128.8, 128.4, 127.7, 
114.6, 68.5, 66.5, 66.4, 45.8, 28.3, 28.0, 27.7, 20.6, 14.6.  
 
 
O
N3FPMBO
 
(2S,3S)-4-[3-(Perfluorooctyl)propyl-1-oxy]benzyl 3-azido-2,5-dimethylhexanoate (20c): 
General procedure 3 was followed by employing β-azido acid 14c (111 mg, 0.600 mmol), 
DMAP (37 mg, 0.30 mmol), FPMBOH (16, 421 mg, 0.720 mmol) and EDCI (115 mg, 0.600 
mmol). Purification of the crude product by flash chromatography (4:1 Hex:EtOAc) gave the 
title compound (241 mg, 53%) as a colorless oil: 1H NMR (300 MHz, CDCl3) δ 7.29 (d, J =7.0 
Hz, 2H), 6.88 (d, J = 8.7 Hz, 2H), 5.09 (q, J = 12.1 Hz, 2H), 4.05 (t, J = 5.8 Hz, 2H), 3.61 (ddd, 
J = 10.5, 7.2, 3.1 Hz, 1H), 2.65 (quin, J = 7.1 Hz, 1H), 2.31 (m, 2H), 2.12 (m, 2H), 1.79 (m, 1H), 
1.43 (m, 1H), 1.27 (m, 1H), 1.18 (d, J = 7.1 Hz, 3H), 0.94 (d, J = 6.7 Hz, 3H), 0.90 (d, J = 6.6 
Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 173.7, 158.8, 130.2, 128.5, 114.6, 66.5, 66.3, 62.6, 44.6, 
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40.1, 28.3, 28.0, 27.7, 25.0, 23.4, 21.3, 20.7, 13.3.  
 
O
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(2R,3R)-4-[3-(Perfluorooctyl)propyl-1-oxy]benzyl-3-amino-2-methyl-5-phenyl-pentanoate 
(21a): 
General procedure 4 was followed by employing β-azido ester 20a (385 mg, 0.482 mmol), 
triphenylphosphine (179 mg, 0.682 mmol) and H2O (189 mg, 10.5 mmol). Purification by FSPE 
gave the title compound as a yellow oil.  
 
O
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(2R,3S)-4-[3-(Perfluorooctyl)propyl-1-oxy]benzyl-3-amino-2-methyl-3-phenylpropanoate 
(21b): 
General procedure 4 was followed by employing β-azido ester 20b (405 mg, 0.524 mmol), 
triphenylphosphine (179 mg, 0.682 mmol) and H2O (189 mg, 10.5 mmol). Purification by FSPE 
gave the title compound as a yellow oil.  
 
O
NH2FPMBO
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(2S,3S)-4-[3-(Perfluorooctyl)propyl-1-oxy]benzyl 3-amino-2,5-dimethylhexanoate (21c): 
General procedure 4 was followed by employing β-azido ester 20c (241 mg, 0.320 mmol), 
triphenylphosphine (179 mg, 0.682 mmol) and H2O (189 mg, 10.5 mmol). Purification by FSPE 
gave the title compound as a yellow oil.  
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(2R,3R)-4-[3-(Perfluorooctyl)propyl-1-oxy]benzyl 3-((2R,3R)-3-azido-2-methyl-5-phenyl- 
pentanamido)-2-methyl-5-phenylpentanoate (22aa): 
General procedure 5 was followed by employing amine 21a (1/3 of its total weight, and the 
yield of amine was assumed to be 100%), DMAP (11 mg, 0.087 mmol), β-azido acid 14a (49 mg, 
0.21 mmol) and EDCI (40 mg, 0.21 mmol). Purification by FSPE gave the title compound (111 
mg, 70% in two steps) as a white solid: 1H NMR (300 MHz, CDCl3) δ 7.22–7.09 (m, 10H), 6.95 
(d, J = 7.4 Hz, 2H), 6.78 (d, J = 8.2 Hz, 2H), 6.45 (d, J = 9.6 Hz, 1H), 5.02 (d, J = 11.9 Hz, 1H), 
4.96 (d, J = 11.9 Hz, 1H), 4.10 (m, 1H), 3.91 (t, J = 5.8 Hz, 2H), 3.51 (td, J = 8.7, 3.5 Hz, 1H), 
2.75 (ddd, J = 13.3, 9.6, 4.6 Hz, 1H), 2.69–2.64 (m, 2H), 2.51 (t, J = 8.1 Hz, 2H), 2.26 (quin, J 
= 7.1 Hz, 1H), 2.24 (m, 2H), 2.00 (m, 2H), 1.86 (m, 1H), 1.66 (m, 3H), 1.16 (d, J = 7.2 Hz, 3H), 
1.08 (d, J = 7.0 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 174.5, 172.4, 157.8, 140.5, 140.0, 129.2, 
127.6, 127.4, 125.2, 124.9, 117.5, 113.6, 65.4, 65.2, 63.6, 49.9, 45.4, 41.5, 35.1, 32.7, 31.7, 31.2, 
28.7, 27.4, 27.0, 26.7, 19.6, 14.0, 13.9; LC-MS (APCI) m/z [M + H]+ 989.2, tR = 8.4 min.  
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(2R,3R)-4-[3-(Perfluorooctyl)propyl-1-oxy]benzyl 3-((2R,3S)-3-azido-2-methyl-3-phenylpro- 
panamido)-2-methyl-5-phenylpentanoate (22ab): 
General procedure 5 was followed by employing amine 21a (1/3 of its total weight, and the 
yield of amine was assumed to be 100%), DMAP (11 mg, 0.087 mmol), β-azido acid 14b (43 mg, 
0.21 mmol) and EDCI (40 mg, 0.21 mmol). Purification by FSPE gave the title compound (91 
mg, 59% in two steps) as a white solid: 1H NMR (300 MHz, CDCl3) δ 7.31–7.07 (m, 10H), 7.01 
(d, J = 6.9 Hz, 2H), 6.79 (d, J = 8.6 Hz, 2H), 6.52 (d, J = 9.6 Hz, 1H), 5.03 (d, J = 12.0 Hz, 1H), 
4.98 (d, J = 12.0 Hz, 1H), 4.60 (d, J = 10.3 Hz, 1H), 4.15 (m, 1H), 3.92 (t, J = 5.8 Hz, 2H), 2.71 
(qd, J = 7.2, 3.5 Hz, 1H), 2.52 (t, J = 8.0 Hz, 2H), 2.38 (qd, J = 10.3, 6.9 Hz, 1H), 2.22 (m, 2H), 
2.01 (m, 2H), 1.66 (m, 2H), 1.23 (d, J = 7.2 Hz, 3H), 0.82 (d, J = 6.9 Hz, 3H); 13C NMR (75 
MHz, CDCl3) δ 175.7, 173.8, 157.5, 141.5, 137.3, 130.1, 128.7, 128.4, 127.8, 118.5, 114.6, 68.7, 
66.4, 66.2, 51.0, 47.8, 42.5, 36.1, 32.6, 29.7, 28.3, 28.0, 27.7, 20.6, 19.6, 15.5, 15.0; LC-MS 
(APCI) m/z [M + H]+ 961.2, tR = 8.4 min.  
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(2R,3R)-4-[3-(Perfluorooctyl)propyl-1-oxy]benzyl-3-((2S,3S)-3-azido-2,5-dimethylhexan- 
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amido)-2-methyl-5-phenylpentanoate (22ac): 
General procedure 5 was followed by employing amine 21a (1/3 of its total weight, and the 
yield of amine was assumed to be 100%), DMAP (11 mg, 0.087 mmol), β-azido acid 14c (39 mg, 
0.21 mmol) and EDCI (40 mg, 0.21 mmol). Purification by FSPE gave the title compound (91 
mg, 60% in two steps) as a white solid: 1H NMR (300 MHz, CDCl3) δ 7.21–7.06 (m, 5H), 7.03 
(d, J = 6.9 Hz, 2H), 6.78 (d, J = 8.6 Hz, 2H), 6.35 (d, J = 9.6 Hz, 1H), 5.02 (d, J = 11.9 Hz, 1H), 
4.96 (d, J = 12.0 Hz, 1H), 4.11 (m, 1H), 3.94 (t, J = 5.8 Hz, 2H), 3.56 (td, J = 8.6, 4.7 Hz, 1H), 
2.65 (qd, J = 7.1, 3.8 Hz, 1H), 2.56 (m, 2H), 2.22 (quin, J = 7.1 Hz, 1H), 2.21 (m, 2H), 2.03 (m, 
2H), 1.76 (m, 1H), 1.74 (m, 1H), 1.66 (m, 2H), 1.33 (td, J = 9.6, 5.1 Hz, 1H), 1.12 (d, J = 4.6 Hz, 
3H), 1.10 (d, J = 4.4 Hz, 3H), 0.88 (d, J = 6.6 Hz, 3H), 0.86 (d, J = 6.5 Hz, 3H); 13C NMR (75 
MHz, CDCl3) δ 175.4, 173.6, 158.8, 141.5, 130.1, 128.3, 125.8, 118.5, 114.6, 66.4, 66.2, 63.4, 
50.8, 46.8, 42.7, 40.9, 36.0, 32.6, 32.4, 28.3, 28.0, 27.7, 25.1, 23.4, 22.4, 21.4, 20.6, 15.1, 15.0; 
LC-MS (APCI) m/z [M + H]+ 941.2, tR = 9.7 min.  
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(2R,3S)-4-[3-(Perfluorooctyl)propyl-1-oxy]benzyl 3-((2R,3R)-3-azido-2-methyl-5-phenyl- 
pentanamido)-2-methyl-3-phenylpropanoate (22ba): 
General procedure 5 was followed by employing amine 21b (1/3 of its total weight, and the 
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yield of amine was assumed to be 100%), DMAP (11 mg, 0.087 mmol), β-azido acid 14a (49 mg, 
0.21 mmol) and EDCI (40 mg, 0.21 mmol). Purification by FSPE gave the title compound (92 
mg, 55% in two steps) as a colorless oil: 1H NMR (300 MHz, CDCl3) δ 7.32–7.19 (m, 11H), 7.12 
(d, J = 8.4 Hz, 2H), 6.85 (d, J = 8.5 Hz, 2H), 5.25 (dd, J = 8.9, 4.9 Hz, 1H), 4.97 (br, s, 2H), 
4.04 (t, J = 5.8 Hz, 2H), 3.64 (td, J = 7.8, 3.4 Hz, 1H), 3.06 (qd, J = 6.9, 5.2 Hz, 1H), 2.83 (ddd, 
J = 14.0, 9.6, 4.7 Hz, 1H), 2.73 (ddd, J = 15.3, 13.0, 6.1 Hz, 1H), 2.48 (quin, J = 7.1 Hz, 1H), 
2.33 (m, 2H), 2.12 (m, 2H), 1.93 (m, 1H), 1.79 (m, 1H), 1.33 (d, J = 7.1 Hz, 3H), 1.20 (d, J = 
7.0 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 175.2, 173.0, 158.7, 140.9, 140.5, 129.9, 128.5, 128.0, 
127.3, 126.2, 118.5, 114.5, 66.4, 66.2, 64.7, 54.8, 46.2, 44.7, 33.6, 32.2, 29.7, 29.3, 28.3, 28.0, 
27.7, 20.6, 15.4, 14.8; LC-MS (APCI) m/z [M + H]+ 961.2, tR = 8.5 min.  
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(2R,3S)-4-[3-(Perfluorooctyl)propyl-1-oxy]benzyl 3-((2R,3S)-3-azido-2-methyl-3-phenyl- 
propanamido)-2-methyl-3-phenylpropanoate (22bb): 
General procedure 5 was followed by employing amine 21b (1/3 of its total weight, and the 
yield of amine was assumed to be 100%), DMAP (11 mg, 0.087 mmol), β-azido acid 14b (43 mg, 
0.21 mmol) and EDCI (40 mg, 0.21 mmol). Purification by FSPE gave the title compound (135 
mg, 83% in two steps) as a colorless oil: 1H NMR (300 MHz, CDCl3) δ 7.29–7.13 (m, 11H), 7.02 
(d, J = 8.4 Hz, 2H), 6.74 (d, J = 8.4 Hz, 2H), 5.21 (dd, J = 8.9, 4.7 Hz, 1H), 4.88 (br, s, 2H), 
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4.60 (d, J = 10.0 Hz, 1H), 3.92 (t, J = 5.8 Hz, 2H), 2.99 (qd, J = 6.8, 5.1 Hz, 1H), 2.50 (qd, J = 
9.6, 6.8 Hz, 1H), 2.19 (m, 2H), 2.01 (m, 2H), 1.29 (d, J = 7.1 Hz, 3H), 0.80 (d, J = 6.9 Hz, 3H); 
13C NMR (75 MHz, CDCl3) δ 175.3, 173.4, 158.7, 140.5, 137.3, 129.9, 128.9, 128.6, 128.1, 
127.7, 127.3, 126.2, 118.5, 114.5, 68.6, 66.4, 66.2, 54.8, 47.5, 44.6, 29.2, 28.2, 28.0, 27.7, 20.6, 
15.5, 15.1, 14.1; LC-MS (APCI) m/z [M + H]+ 933.2, tR = 8.3 min.  
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(2R,3S)-4-[3-(Perfluorooctyl)propyl-1-oxy]benzyl-3-((2S,3S)-3-azido-2,5-dimethylhexan- 
amido)-2-methyl-3-phenylpropanoate (22bc): 
General procedure 5 was followed by employing amine 21b (1/3 of its total weight, and the 
yield of amine was assumed to be 100%), DMAP (11 mg, 0.087 mmol), β-azido acid 14c (39 mg, 
0.21 mmol) and EDCI (40 mg, 0.21 mmol). Purification by FSPE gave the title compound (120 
mg, 75% in two steps) as a colorless oil: 1H NMR (300 MHz, CDCl3) δ 7.22–7.11 (m, 6H), 6.99 
(d, J = 8.6 Hz, 2H), 6.74 (d, J = 8.6 Hz, 2H), 5.12 (dd, J = 8.9, 5.2 Hz, 1H), 4.89 (d, J = 12.1 Hz, 
1H), 4.84 (d, J = 12.0 Hz, 1H), 3.94 (t, J = 5.8 Hz, 2H), 3.52 (td, J = 8.5, 4.0 Hz, 1H), 2.96 (qd, 
J = 7.0, 5.4 Hz, 1H), 2.30 (quin, J = 7.0 Hz, 1H), 2.23 (m, 2H), 2.02 (m, 2H), 1.79 (m, 1H), 1.74 
(m, 1H), 1.31 (td, J = 10.4, 4.5 Hz, 1H), 1.19 (d, J = 7.1 Hz, 3H), 1.12 (d, J = 7.0 Hz, 3H), 0.86 
(d, J = 7.2 Hz, 3H), 0.84 (d, J = 6.8 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 175.1, 173.2, 158.7, 
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140.3, 129.9, 128.5, 128.0, 127.3, 126.2, 118.4, 114.5, 66.3, 66.2, 63.4, 54.9, 46.6, 44.6, 40.9, 
28.4, 28.2, 27.9, 25.0, 23.4, 22.4, 21.4, 20.6, 15.6, 14.8; LC-MS (APCI) m/z [M + H]+ 913.2, tR = 
9.8 min.  
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(2S,3S)-4-[3-(Perfluorooctyl)propyl-1-oxy]benzyl-3-((2R,3R)-3-azido-2-methyl-5-phenyl- 
pentanamido)-2,5-dimethylhexanoate (22ca): 
General procedure 5 was followed by employing amine 21c (1/3 of its total weight, and the 
yield of amine was assumed to be 100%), DMAP (11 mg, 0.087 mmol), β-azido acid 14a (49 mg, 
0.21 mmol) and EDCI (40 mg, 0.21 mmol). Purification by FSPE gave the title compound (79 
mg, 79% in two steps) as a white solid: 1H NMR (300 MHz, CDCl3) δ 7.22–7.13 (m, 5H), 7.11 
(d, J = 7.4 Hz, 2H), 6.80 (d, J = 8.5 Hz, 2H), 6.16 (d, J = 9.6 Hz, 1H), 5.02 (d, J = 11.9 Hz, 1H), 
4.96 (d, J = 12.0 Hz, 1H), 4.20 (m, 1H), 3.95 (t, 2H), 3.51 (td, J = 8.5, 3.3 Hz, 1H), 2.75 (ddd, J 
= 13.7, 9.7, 5.1 Hz, 1H), 2.68–2.56 (m, 2H), 2.24 (quin, J = 7.3 Hz, 1H), 2.22 (m, 2H), 2.01 (m, 
2H), 1.91 (m, 1H), 1.68 (m, 1H), 1.52 (m, 1H), 1.28 (m, 1H), 1.18 (m, 1H), 1.10 (d, J = 7.4 Hz, 
2H), 1.07 (d, J = 7.3 Hz, 2H), 0.81 (d, J = 6.3 Hz, 3H), 0.80 (d, J = 6.5 Hz, 3H); 13C NMR (75 
MHz, CDCl3) δ 175.5, 173.2, 158.8, 141.0, 130.1, 128.6, 128.4, 126.1, 118.5, 114.6, 66.4, 66.1, 
64.6, 49.1, 46.2, 43.2, 43.0, 33.6, 32.2, 28.3, 28.0, 27.7, 25.0, 23.0, 22.0, 20.6, 15.0; LC-MS 
(APCI) m/z [M + H]+ 941.2, tR = 9.4 min.  
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(2S,3S)-4-[3-(Perfluorooctyl)propyl-1-oxy]benzyl-3-((2R,3S)-3-azido-2-methyl-3-phenylpro-
panamido)-2,5-dimethylhexanoate (22cb): 
General procedure 5 was followed by employing amine 21c (1/3 of its total weight, and the 
yield of amine was assumed to be 100%), DMAP (11 mg, 0.087 mmol), β-azido acid 14b (43 mg, 
0.21 mmol) and EDCI (40 mg, 0.21 mmol). Purification by FSPE gave the title compound (84 
mg, 86% in two steps) as a white solid: 1H NMR (300 MHz, CDCl3) δ 7.32–7.20 (m, 7H), 6.81 
(d, J = 8.5 Hz, 2H), 6.18 (d, J = 9.6 Hz, 1H), 5.03 (d, J = 12.0 Hz, 1H), 4.97 (d, J = 12.0 Hz, 
1H), 4.58 (d, J = 10.2 Hz, 1H), 4.19 (m, 1H), 3.95 (t, J = 5.8 Hz, 2H), 2.61 (qd, J = 7.1, 3.7 Hz, 
1H), 2.35 (qd, J = 10.1, 7.0 Hz, 1H), 2.22 (m, 2H), 2.01 (m, 2H), 1.63 (m, 1H), 1.34 (m, 1H), 
1.18 (m, 1H), 1.07 (d, J = 7.2 Hz, 3H), 0.85 (d, J = 6.2 Hz, 3H), 0.83 (d, J = 6.0 Hz, 3H), 0.81 
(d, J = 6.7 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 175.6, 173.5, 158.8, 137.5, 130.1, 128.8, 
128.6, 128.4, 127.7, 118.0, 114.6, 68.7, 66.4, 66.1, 49.3, 47.6, 43.3, 43.0, 29.3, 28.3, 28.0, 27.7, 
24.9, 23.0, 22.0, 20.6, 15.4, 14.9; LC-MS (APCI) m/z [M + H]+ 913.2, tR = 9.3 min.  
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(2S,3S)-4-[3-(Perfluorooctyl)propyl-1-oxy]benzyl-3-((2S,3S)-3-azido-2,5-dimethylhexan- 
amido)-2,5-dimethylhexanoate (22cc): 
General procedure 5 was followed by employing amine 21c (1/3 of its total weight, and the 
yield of amine was assumed to be 100%), DMAP (11 mg, 0.087 mmol), β-azido acid 14c (39 mg, 
0.21 mmol) and EDCI (40 mg, 0.21 mmol). Purification by FSPE gave the title compound (79 
mg, 83% in two steps) as a white solid: 1H NMR (300 MHz, CDCl3) δ 7.21 (d, J = 8.4 Hz, 2H), 
6.81 (d, J = 8.5 Hz, 2H), 6.25 (d, J = 9.5 Hz, 1H), 5.02 (d, J = 11.8 Hz, 1H), 4.98 (d, J = 12.0 
Hz, 1H), 4.15 (m, 1H), 3.96 (t, J = 5.8 Hz, 2H), 3.54 (td, J = 8.1, 4.5 Hz, 1H), 2.63 (qd, J = 6.9, 
3.6 Hz, 1H), 2.23 (m, 2H), 2,20 (quin, J = 7.3 Hz, 1H), 2.03 (m, 2H), 1.85 (m, 1H), 1.75 (m, 1H), 
1.46 (m, 1H), 1.30 (m, 2H), 1.18 (m, 1H), 1.15 (d, J = 7.2 Hz, 3H), 1.08 (d, J = 6.9 Hz, 3H), 
0.88 (d, J = 6.6 Hz, 3H), 0.87 (d, J = 6.4 Hz, 3H), 0.80 (d, J = 6.3 Hz, 3H), 0.79 (d, J = 6.5 Hz, 
3H); 13C NMR (75 MHz, CDCl3) δ 175.6, 173.4, 158.8, 130.1, 128.4, 118.5, 114.7, 66.5, 66.1, 
63.5, 49.1, 46.9, 43.2, 42.9, 40.9, 29.7, 28.3, 28.0, 27.7, 25.1, 23.4, 23.0, 22.0, 21.4, 20.6, 14.9, 
14.6; LC-MS (APCI) m/z [M + H]+ 893.2, tR = 11.5 min.  
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(2R,3R)-4-[3-(Perfluorooctyl)propyl-1-oxy]benzyl 3-((2R,3R)-3-amino-2-methyl-5-phenyl- 
pentanamido)-2-methyl-5-phenylpentanoate (23aa): 
General procedure 4 was followed by employing azido-dipeptide 22aa (102 mg, 0.103 
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mmol), triphenylphosphine (45 mg, 0.17 mmol) and H2O (52 mg, 2.9 mmol). Purification by 
FSPE gave the title compound (99 mg, 100%) as a white solid.  
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(2R,3R)-4-[3-(Perfluorooctyl)propyl-1-oxy]benzyl 3-((2R,3S)-3-amino-2-methyl-3-phenyl- 
propanamido)-2-methyl-5-phenylpentanoate (23ab): 
General procedure 4 was followed by employing azido-dipeptide 22ab (83 mg, 0.086 
mmol), triphenylphosphine (45 mg, 0.17 mmol) and H2O (52 mg, 2.9 mmol). Purification by 
FSPE gave the title compound (77 mg, 95%) as a white solid.  
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(2R,3R)-4-[3-(Perfluorooctyl)propyl-1-oxy]benzyl-3-((2S,3S)-3-amino-2,5-dimethylhexan- 
amido)-2-methyl-5-phenylpentanoate (23ac): 
General procedure 4 was followed by employing azido-dipeptide 22ac (83 mg, 0.088 mmol), 
triphenylphosphine (45 mg, 0.17 mmol) and H2O (52 mg, 2.9 mmol). Purification by FSPE gave 
the title compound (71 mg, 88%) as a white solid.  
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(2R,3S)-4-[3-(Perfluorooctyl)propyl-1-oxy]benzyl 3-((2R,3R)-3-amino-2-methyl-5-phenyl- 
pentanamido)-2-methyl-3-phenylpropanoate (23ba): 
General procedure 4 was followed by employing azido-dipeptide 22ba (84 mg, 0.087 
mmol), triphenylphosphine (45 mg, 0.17 mmol) and H2O (52 mg, 2.9 mmol). Purification by 
FSPE gave the title compound (65 mg, 80%) as a white solid.  
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(2R,3S)-4-[3-(Perfluorooctyl)propyl-1-oxy]benzyl 3-((2R,3S)-3-amino-2-methyl-3-phenyl- 
propanamido)-2-methyl-3-phenylpropanoate (23bb): 
General procedure 4 was followed by employing azido-dipeptide 22bb (123 mg, 0.132 
mmol), triphenylphosphine (45 mg, 0.17 mmol) and H2O (52 mg, 2.9 mmol). Purification by 
FSPE gave the title compound (99 mg, 83%) as a white solid.  
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(2R,3S)-4-[3-(Perfluorooctyl)propyl-1-oxy]benzyl-3-((2S,3S)-3-amino-2,5-dimethylhexan- 
amido)-2-methyl-3-phenylpropanoate (23bc): 
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General procedure 4 was followed by employing azido-dipeptide 22bc (108 mg, 0.118 
mmol), triphenylphosphine (45 mg, 0.17 mmol) and H2O (52 mg, 2.9 mmol). Purification by 
FSPE gave the title compound (82 mg, 78%) as a white solid.  
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(2S,3S)-4-[3-(Perfluorooctyl)propyl-1-oxy]benzyl-3-((2R,3R)-3-amino-2-methyl-5-phenylpe-
ntanamido)-2,5-dimethylhexanoate (23ca): 
General procedure 4 was followed by employing azido-dipeptide 22ca (71 mg, 0.075 mmol), 
triphenylphosphine (45 mg, 0.17 mmol) and H2O (52 mg, 2.9 mmol). Purification by FSPE gave 
the title compound (65 mg, 94%) as a white solid.  
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(2S,3S)-4-[3-(Perfluorooctyl)propyl-1-oxy]benzyl-3-((2R,3S)-3-amino-2-methyl-3-phenyl- 
propanamido)-2,5-dimethylhexanoate (23cb): 
General procedure 4 was followed by employing azido-dipeptide 22cb (76 mg, 0.083 
mmol), triphenylphosphine (45 mg, 0.17 mmol) and H2O (52 mg, 2.9 mmol). Purification by 
FSPE gave the title compound (72 mg, 97%) as a white solid.  
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(2S,3S)-4-[3-(Perfluorooctyl)propyl-1-oxy]benzyl-3-((2S,3S)-3-amino-2,5-dimethylhexan- 
amido)-2,5-dimethylhexanoate (23cc): 
General procedure 4 was followed by employing azido-dipeptide 22cc (71 mg, 0.080 mmol), 
triphenylphosphine (45 mg, 0.17 mmol) and H2O (52 mg, 2.9 mmol). Purification by FSPE gave 
the title compound (66 mg, 95%) as a white solid.  
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(2R,3R)-4-[3-(Perfluorooctyl)propyl-1-oxy]benzyl 3-((2R,3R)-3-((2R,3R)-3-azido-2-methyl- 
5-phenylpentanamido)-2-methyl-5-phenylpentanamido)-2-methyl-5-phenylpentanoate 
(24aaa): 
General procedure 5 was followed by employing amine 23aa (33 mg, 0.034 mmol), DMAP 
(3 mg, 0.02 mmol), β-azido acid 14a (13 mg, 0.058 mmol) and EDCI (11 mg, 0.058 mmol). 
Purification by FSPE gave the title compound (13 mg, 33%) as a white solid: 1H NMR (500 
MHz, CDCl3) δ 7.41 (d, J = 9.2 Hz, 1H), 7.29–7.14 (m, 15H), 7.08 (d, J = 7.3 Hz, 2H), 6.85 (d, 
J = 8.6 Hz, 2H), 6.49 (d, J = 9.7 Hz, 1H), 5.06 (d, J = 11.9 Hz, 1H), 5.01 (d, J = 11.9 Hz, 1H), 
4.12 (m, 2H), 4.00 (t, J = 5.9 Hz, 2H), 3.67 (td, J = 9.4, 3.0 Hz, 1H), 2.85 (ddd, J = 14.3, 10.5, 
4.9 Hz, 1H), 2.76–2.68 (m, 2H), 2.66 (dd, J = 10.5, 5.9 Hz, 2H), 2.58 (t, J = 8.2 Hz, 2H), 2.39 
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(quin, J = 7.4 Hz, 1H), 2.39 (qd, J = 10.7, 3.8 Hz, 1H), 2.31 (m, 2H), 2.10 (dtd, J = 9.8, 5.8, 5.8 
Hz, 2H), 1.98 (dddd, J = 17.3, 10.2, 6.8, 3.0 Hz, 1H), 1.85 (m, 1H), 1.78–1.66 (m, 4H), 1.28 (d, J 
= 7.0 Hz, 3H), 1.19 (d, J = 7.0 Hz, 3H), 1.16 (d, J = 7.2 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 
175.8, 175.5, 173.6, 158.8, 141.6, 141.1, 130.1, 128.5, 128.4, 128.3, 128.0, 126.1, 125.9, 114.6, 
110.8, 66.3, 64.5, 51.3, 50.9, 46.4, 43.5, 42.0, 36.6, 36.2, 33.5, 32.8, 32.6, 32.2, 27.9, 20.6, 16.3, 
15.4, 15.0; LC-MS (APCI) m/z [M + H]+ 1178.2, tR = 8.7 min.  
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(2R,3R)-4-[3-(Perfluorooctyl)propyl-1-oxy]benzyl 3-((2R,3R)-3-((2R,3S)-3-azido-2-methyl- 
3-phenylpropanamido)-2-methyl-5-phenylpentanamido)-2-methyl-5-phenylpentanoate 
(24aab): 
General procedure 5 was followed by employing amine 23aa (33 mg, 0.034 mmol), DMAP 
(3 mg, 0.02 mmol), β-azido acid 14b (12 mg, 0.058 mmol) and EDCI (11 mg, 0.058 mmol). 
Purification by FSPE gave the title compound (13 mg, 37%) as a white solid: LC-MS (APCI) 
m/z [M + H]+ 1150.0, tR = 8.6 min.  
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(2R,3R)-4-[3-(Perfluorooctyl)propyl-1-oxy]benzyl 3-((2R,3R)-3-((2S,3S)-3-azido-2,5- 
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dimethylhexanamido)-2-methyl-5-phenyl-pentanamido)-2-methyl-5-phenylpentanoate 
(24aac): 
General procedure 5 was followed by employing amine 23aa (33 mg, 0.034 mmol), DMAP 
(3 mg, 0.02 mmol), β-azido acid 14c (11 mg, 0.058 mmol) and EDCI (11 mg, 0.058 mmol). 
Purification by FSPE gave the title compound (21 mg, 55%) as a white solid: LC-MS (APCI) 
m/z [M + H]+ 1130.2, tR = 9.8 min.  
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(2R,3R)-4-[3-(Perfluorooctyl)propyl-1-oxy]benzyl 3-((2R,3S)-3-((2R,3R)-3-azido-2-methyl- 
5-phenylpentanamido)-2-methyl-3-phenylpropanamido)-2-methyl-5-phenylpentanoate 
(24aba): 
General procedure 5 was followed by employing amine 23ab (26 mg, 0.027 mmol), DMAP 
(3 mg, 0.02 mmol), β-azido acid 14a (13 mg, 0.058 mmol) and EDCI (11 mg, 0.058 mmol). 
Purification by FSPE gave the title compound (31 mg, 100%) as a white solid: LC-MS (APCI) 
m/z [M + H]+ 1150.2, tR = 8.6 min.  
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(2R,3R)-4-[3-(Perfluorooctyl)propyl-1-oxy]benzyl 3-((2R,3S)-3-((2R,3S)-3-azido-2-methyl-3- 
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phenylpropanamido)-2-methyl-3-phenylpropanamido)-2-methyl-5-phenylpentanoate 
(24abb): 
General procedure 5 was followed by employing amine 23ab (26 mg, 0.027 mmol), DMAP 
(3 mg, 0.02 mmol), β-azido acid 14b (12 mg, 0.058 mmol) and EDCI (11 mg, 0.058 mmol). 
Purification by FSPE gave the title compound (30 mg, 99%) as a white solid: LC-MS (APCI) 
m/z [M + H]+ 1122.0, tR = 8.5 min.  
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(2R,3R)-4-[3-(Perfluorooctyl)propyl-1-oxy]benzyl 3-((2R,3S)-3-((2S,3S)-3-azido-2,5- 
dimethylhexanamido)-2-methyl-3-phenylpropanamido)-2-methyl-5-phenylpentanoate 
(24abc): 
General procedure 5 was followed by employing amine 23ab (26 mg, 0.027 mmol), DMAP 
(3 mg, 0.02 mmol), β-azido acid 14c (11 mg, 0.058 mmol) and EDCI (11 mg, 0.058 mmol). 
Purification by FSPE gave the title compound (28 mg, 94%) as a white solid: LC-MS (APCI) 
m/z [M + H]+ 1102.2, tR = 10.0 min.  
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(2R,3R)-4-[3-(Perfluorooctyl)propyl-1-oxy]benzyl 3-((2S,3S)-3-((2R,3R)-3-azido-2-methyl- 
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5-phenylpentanamido)-2,5-dimethylhexanamido)-2-methyl-5-phenylpentanoate (24aca): 
General procedure 5 was followed by employing amine 23ac (24 mg, 0.026 mmol), DMAP 
(3 mg, 0.02 mmol), β-azido acid 14a (13 mg, 0.058 mmol) and EDCI (11 mg, 0.058 mmol). 
Purification by FSPE gave the title compound (17 mg, 58%) as a white solid: LC-MS (APCI) 
m/z [M + H]+ 1130.2, tR = 9.4 min. 
 
O
N
H
O
N
H
FPMBO
Ph
O
N3
Ph
 
(2R,3R)-4-[3-(Perfluorooctyl)propyl-1-oxy]benzyl 3-((2S,3S)-3-((2R,3S)-3-azido-2-methyl-3- 
phenylpropanamido)-2,5-dimethylhexanamido)-2-methyl-5-phenylpentanoate (24acb): 
General procedure 5 was followed by employing amine 23ac (24 mg, 0.026 mmol), DMAP 
(3 mg, 0.02 mmol), β-azido acid 14b (12 mg, 0.058 mmol) and EDCI (11 mg, 0.058 mmol). 
Purification by FSPE gave the title compound (21 mg, 74%) as a white solid: LC-MS (APCI) 
m/z [M + H]+ 1102.2, tR = 9.3 min.  
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(2R,3R)-4-[3-(Perfluorooctyl)propyl-1-oxy]benzyl 3-((2S,3S)-3-((2S,3S)-3-azido-2,5- 
dimethylhexanamido)-2,5-dimethylhexanamido)-2-methyl-5-phenylpentanoate (24acc): 
General procedure 5 was followed by employing amine 23ac (24 mg, 0.026 mmol), DMAP 
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(3 mg, 0.02 mmol), β-azido acid 14c (11 mg, 0.058 mmol) and EDCI (11 mg, 0.058 mmol). 
Purification by FSPE gave the title compound (12 mg, 41%) as a white solid: LC-MS (APCI) 
m/z [M + H]+ 1082.2, tR = 11.0 min. 
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(2R,3S)-4-[3-(Perfluorooctyl)propyl-1-oxy]benzyl 3-((2R,3R)-3-((2R,3R)-3-azido-2-methyl- 
5-phenylpentanamido)-2-methyl-5-phenylpentanamido)-2-methyl-3-phenylpropanoate 
(24baa): 
General procedure 5 was followed by employing amine 23ba (22 mg, 0.023 mmol), DMAP 
(3 mg, 0.02 mmol), β-azido acid 14a (13 mg, 0.058 mmol) and EDCI (11 mg, 0.058 mmol). 
Purification by FSPE gave the title compound (25 mg, 95%) as a white solid: LC-MS (APCI) 
m/z [M + H]+ 1150.0, tR = 8.6 min. 
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(2R,3S)-4-[3-(Perfluorooctyl)propyl-1-oxy]benzyl 3-((2R,3R)-3-((2R,3S)-3-azido-2-methyl- 
3-phenylpropanamido)-2-methyl-5-phenylpentanamido)-2-methyl-3-phenylpropanoate 
(24bab): 
General procedure 5 was followed by employing amine 23ba (22 mg, 0.023 mmol), DMAP 
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(3 mg, 0.02 mmol), β-azido acid 14b (12 mg, 0.058 mmol) and EDCI (11 mg, 0.058 mmol). 
Purification by FSPE gave the title compound (22 mg, 84%) as a white solid: LC-MS (APCI) 
m/z [M + H]+ 1122.2, tR = 8.6 min. 
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(2R,3S)-4-[3-(Perfluorooctyl)propyl-1-oxy]benzyl 3-((2R,3R)-3-((2S,3S)-3-azido-2,5- 
dimethylhexanamido)-2-methyl-5-phenylpentanamido)-2-methyl-3-phenylpropanoate 
(24bac): 
General procedure 5 was followed by employing amine 23ba (22 mg, 0.023 mmol), DMAP 
(3 mg, 0.02 mmol), β-azido acid 14c (11 mg, 0.058 mmol) and EDCI (11 mg, 0.058 mmol). 
Purification by FSPE gave the title compound (25 mg, 97%) as a white solid: LC-MS (APCI) 
m/z [M + H]+ 1102.2, tR = 9.9 min. 
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(2R,3S)-4-[3-(Perfluorooctyl)propyl-1-oxy]benzyl 3-((2R,3S)-3-((2R,3R)-3-azido-2-methyl- 
5-phenylpentanamido)-2-methyl-3-phenylpropanamido)-2-methyl-3-phenylpropanoate 
(24bba): 
General procedure 5 was followed by employing amine 23bb (33 mg, 0.036 mmol), DMAP 
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(3 mg, 0.02 mmol), β-azido acid 14a (13 mg, 0.058 mmol) and EDCI (11 mg, 0.058 mmol). 
Purification by FSPE gave the title compound (34 mg, 84%) as a white solid: LC-MS (APCI) 
m/z [M + H]+ 1122.2, tR = 8.5 min. 
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(2R,3S)-4-[3-(Perfluorooctyl)propyl-1-oxy]benzyl 3-((2R,3S)-3-((2R,3S)-3-azido-2-methyl-3- 
phenylpropanamido)-2-methyl-3-phenylpropanamido)-2-methyl-3-phenylpropanoate 
(24bbb): 
General procedure 5 was followed by employing amine 23bb (33 mg, 0.036 mmol), DMAP 
(3 mg, 0.02 mmol), β-azido acid 14b (12 mg, 0.058 mmol) and EDCI (11 mg, 0.058 mmol). 
Purification by FSPE gave the title compound (34 mg, 87%) as a white solid: 1H NMR (500 
MHz, CDCl3) δ 8.20 (d, J = 8.5 Hz, 1H), 7.39–7.08 (m, 15H), 7.05 (d, J = 8.6 Hz, 1H), 6.97 (d, 
J = 8.6 Hz, 2H), 6.79 (d, J = 8.6 Hz, 2H), 5.27 (dd, J = 8.5, 3.4 Hz, 1H), 4.91 (dd, J = 8.5, 4.1 
Hz, 1H), 4.82 (d, J = 12.1 Hz, 1H), 4.79 (d, J = 12.1 Hz, 1H), 4.71 (d, J = 10.3 Hz, 1H), 4.02 (t, 
J = 5.9 Hz, 2H), 2.83 (qd, J = 7.1, 3.6 Hz, 1H), 2.81 (qd, J = 7.4, 4.1 Hz, 1H), 2.62 (dq, J = 10.3, 
6.9 Hz, 1H), 2.31 (m, 2H), 2.11 (dtd, J = 9.8, 5.8, 5.8 Hz, 2H), 1.48 (d, J = 7.1 Hz, 3H), 0.89 (d, 
J = 7.0 Hz, 3H), 0.68 (d, J = 7.2 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 175.2, 175.0, 173.6, 
158.7, 141.2, 140.0, 137.4, 129.8, 128.8, 128.7, 128.6, 127.8, 127.5, 127.2, 126.0, 125.7, 114.4, 
 67
109.5, 68.5, 66.4, 66.2, 55.4, 54.8, 47.6, 46.3, 44.0, 27.9, 20.6, 16.5, 15.2, 15.1; LC-MS (APCI) 
m/z [M + H]+ 1094.2, tR = 8.4 min.  
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(2R,3S)-4-[3-(Perfluorooctyl)propyl-1-oxy]benzyl 3-((2R,3S)-3-((2S,3S)-3-azido-2,5- 
dimethylhexanamido)-2-methyl-3-phenylpropanamido)-2-methyl-3-phenylpropanoate 
(24bbc): 
General procedure 5 was followed by employing amine 23bb (33 mg, 0.036 mmol), DMAP 
(3 mg, 0.02 mmol), β-azido acid 14c (11 mg, 0.058 mmol) and EDCI (11 mg, 0.058 mmol). 
Purification by FSPE gave the title compound (29 mg, 75%) as a white solid: LC-MS (APCI) 
m/z [M + H]+ 1074.2, tR = 9.7 min.  
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(2R,3S)-4-[3-(Perfluorooctyl)propyl-1-oxy]benzyl 3-((2S,3S)-3-((2R,3S)-3-azido-2-methyl- 
5-phenylpentanamido)-2,5-dimethylhexanamido)-2-methyl-3-phenylpropanoate (24bca): 
General procedure 5 was followed by employing amine 23bc (27 mg, 0.031 mmol), DMAP 
(3 mg, 0.02 mmol), β-azido acid 14a (13 mg, 0.058 mmol) and EDCI (11 mg, 0.058 mmol). 
Purification by FSPE gave the title compound (10 mg, 30%) as a white solid: LC-MS (APCI) 
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m/z [M + H]+ 1102.2, tR = 9.1 min.  
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(2R,3S)-4-[3-(Perfluorooctyl)propyl-1-oxy]benzyl 3-((2S,3S)-3-((2R,3S)-3-azido-2-methyl-3- 
phenylpropanamido)-2,5-dimethylhexanamido)-2-methyl-3-phenylpropanoate (24bcb): 
General procedure 5 was followed by employing amine 23bc (27 mg, 0.031 mmol), DMAP 
(3 mg, 0.02 mmol), β-azido acid 14b (12 mg, 0.058 mmol) and EDCI (11 mg, 0.058 mmol). 
Purification by FSPE gave the title compound (15 mg, 46%) as a white solid: LC-MS (APCI) 
m/z [M + H]+ 1074.2, tR = 9.0 min.  
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(2R,3S)-4-[3-(Perfluorooctyl)propyl-1-oxy]benzyl 3-((2S,3S)-3-((2S,3S)-3-azido-2,5- 
dimethylhexanamido)-2,5-dimethylhexanamido)-2-methyl-3-phenylpropanoate (24bcc): 
General procedure 5 was followed by employing amine 23bc (27 mg, 0.031 mmol), DMAP 
(3 mg, 0.02 mmol), β-azido acid 14c (11 mg, 0.058 mmol) and EDCI (11 mg, 0.058 mmol). 
Purification by FSPE gave the title compound (13 mg, 41%) as a white solid: LC-MS (APCI) 
m/z [M + H]+ 1054.2, tR = 10.7 min.  
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(2S,3S)-4-[3-(Perfluorooctyl)propyl-1-oxy]benzyl 3-((2R,3R)-3-((2R,3R)-3-azido-2-methyl-5- 
phenylpentanamido)-2-methyl-5-phenylpentanamido)-2,5-dimethylhexanoate (24caa): 
General procedure 5 was followed by employing amine 23ca (22 mg, 0.024 mmol), DMAP 
(3 mg, 0.02 mmol), β-azido acid 14a (13 mg, 0.058 mmol) and EDCI (11 mg, 0.058 mmol). 
Purification by FSPE gave the title compound (11 mg, 42%) as a white solid: LC-MS (APCI) 
m/z [M + H]+ 1130.2, tR = 9.6 min.  
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(2S,3S)-4-[3-(Perfluorooctyl)propyl-1-oxy]benzyl 3-((2R,3R)-3-((2R,3S)-3-azido-2-methyl-3- 
phenylpropanamido)-2-methyl-5-phenylpentanamido)-2,5-dimethylhexanoate (24cab): 
General procedure 5 was followed by employing amine 23ca (22 mg, 0.024 mmol), DMAP 
(3 mg, 0.02 mmol), β-azido acid 14b (12 mg, 0.058 mmol) and EDCI (11 mg, 0.058 mmol). 
Purification by FSPE gave the title compound (14 mg, 53%) as a white solid: LC-MS (APCI) 
m/z [M + H]+ 1102.2, tR = 9.4 min.  
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(2S,3S)-4-[3-(Perfluorooctyl)propyl-1-oxy]benzyl 3-((2R,3R)-3-((2S,3S)-3-azido-2,5- 
dimethylhexanamido)-2-methyl-5-phenylpentanamido)-2,5-dimethylhexanoate (24cac): 
General procedure 5 was followed by employing amine 23ca (22 mg, 0.024 mmol), DMAP 
(3 mg, 0.02 mmol), β-azido acid 14c (11 mg, 0.058 mmol) and EDCI (11 mg, 0.058 mmol). 
Purification by FSPE gave the title compound (18 mg, 69%) as a white solid: LC-MS (APCI) 
m/z [M + H]+ 1082.2, tR = 11.0 min.  
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(2S,3S)-4-[3-(Perfluorooctyl)propyl-1-oxy]benzyl 3-((2R,3S)-3-((2R,3R)-3-azido-2-methyl-5- 
phenylpentanamido)-2-methyl-3-phenylpropanamido)-2,5-dimethylhexanoate (24cba): 
General procedure 5 was followed by employing amine 23cb (24 mg, 0.027 mmol), DMAP 
(3 mg, 0.02 mmol), β-azido acid 14a (13 mg, 0.058 mmol) and EDCI (11 mg, 0.058 mmol). 
Purification by FSPE gave the title compound (29 mg, 97%) as a white solid: 1H NMR (500 
MHz, CDCl3) δ 8.23 (d, J = 8.5 Hz, 1H), 7.30–7.17 (m, 12H), 6.87 (d, J = 8.7 Hz, 2H), 5.86 (d, 
J = 9.9 Hz, 1H), 5.16 (dd, J = 8.5, 3.3 Hz, 1H), 5.03 (d, J = 12.0 Hz, 1H), 4.99 (d, J = 12.0 Hz, 
1H), 4.04 (t, J = 5.9 Hz, 2H), 3.96 (m, 1H), 3.69 (td, J = 9.4, 3.2 Hz, 1H), 2.84 (ddd, J = 14.8, 
10.3, 4.9 Hz, 1H), 2.69 (ddd, J = 13.9, 10.2, 6.6 Hz, 1H), 2.60 (qd, J = 7.0, 3.5 Hz, 1H), 2.55 (qd, 
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J = 7.2, 3.6 Hz, 1H), 2.52 (quin, J = 7.9 Hz, 1H), 2.31 (m, 2H), 2.11 (dtd, J = 9.8, 5.8, 5.8 Hz, 
2H), 1.95 (dddd, J = 16.0, 8.8, 5.0, 2.5 Hz, 1H), 1.75 (m, 1H), 1.41 (d, J = 7.0 Hz, 3H), 1.20 (d, 
J = 7.0 Hz, 3H), 1.12 (d, J = 7.2 Hz, 3H), 0.94 (m, 1H), 0.87 (m, 2H), 0.68 (d, J = 5.9 Hz, 3H), 
0.61 (d, J = 6.3 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 175.3, 175.0, 173.2, 159.0, 130.0, 128.6, 
128.4, 127.1, 126.2, 114.9, 66.7, 66.1, 64.7, 55.7, 49.0, 46.5, 46.2, 43.2, 42.8, 33.5, 32.4, 28.2, 
24.3, 23.0, 21.8, 20.8, 16.9, 14.8, 14.6; LC-MS (APCI) m/z [M + H]+ 1102.2, tR = 9.6 min.  
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(2S,3S)-4-[3-(Perfluorooctyl)propyl-1-oxy]benzyl 3-((2R,3S)-3-((2R,3S)-3-azido-2-methyl-3- 
phenylpropanamido)-2-methyl-3-phenylpropanamido)-2,5-dimethylhexanoate (24cbb): 
General procedure 5 was followed by employing amine 23cb (24 mg, 0.027 mmol), DMAP 
(3 mg, 0.02 mmol), β-azido acid 14b (12 mg, 0.058 mmol) and EDCI (11 mg, 0.058 mmol). 
Purification by FSPE gave the title compound (27 mg, 92%) as a white solid: LC-MS (APCI) 
m/z [M + H]+ 1074.2, tR = 9.5 min.  
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(2S,3S)-4-[3-(Perfluorooctyl)propyl-1-oxy]benzyl 3-((2R,3S)-3-((2S,3S)-3-azido-2,5- 
dimethylhexanamido)-2-methyl-3-phenylpropanamido)-2,5-dimethylhexanoate (24cbc): 
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General procedure 5 was followed by employing amine 23cb (24 mg, 0.027 mmol), DMAP 
(3 mg, 0.02 mmol), β-azido acid 14c (11 mg, 0.058 mmol) and EDCI (11 mg, 0.058 mmol). 
Purification by FSPE gave the title compound (25 mg, 88%) as a white solid: LC-MS (APCI) 
m/z [M + H]+ 1054.2, tR = 11.1 min.  
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(2S,3S)-4-[3-(Perfluorooctyl)propyl-1-oxy]benzyl 3-((2S,3S)-3-((2R,3R)-3-azido-2-methyl-5- 
phenylpentanamido)-2,5-dimethylhexanamido)-2,5-dimethylhexanoate (24cca):  
General procedure 5 was followed by employing amine 23cc (22 mg, 0.025 mmol), DMAP 
(3 mg, 0.02 mmol), β-azido acid 14a (13 mg, 0.058 mmol) and EDCI (11 mg, 0.058 mmol). 
Purification by FSPE gave the title compound (10 mg, 37%) as a white solid: LC-MS (APCI) 
m/z [M + H]+ 1082.2, tR = 10.5 min.  
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(2S,3S)-4-[3-(Perfluorooctyl)propyl-1-oxy]benzyl 3-((2S,3S)-3-((2R,3S)-3-azido-2-methyl-3- 
phenylpropanamido)-2,5-dimethylhexanamido)-2,5-dimethylhexanoate (24ccb): 
General procedure 5 was followed by employing amine 23cc (22 mg, 0.025 mmol), DMAP 
(3 mg, 0.02 mmol), β-azido acid 14b (12 mg, 0.058 mmol) and EDCI (11 mg, 0.058 mmol). 
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Purification by FSPE gave the title compound (10 mg, 38%) as a white solid: 1H NMR (500 
MHz, CDCl3) δ 7.41–7.28 (m, 7H), 7.20 (d, J = 9.4 Hz, 1H), 6.89 (d, J = 8.7 Hz, 2H), 6.36 (d, J 
= 9.8 Hz, 1H), 5.12 (d, J = 11.9 Hz, 1H), 5.06 (d, J = 11.9 Hz, 1H), 4.68 (d, J = 10.5 Hz, 1H), 
4.21–4.10 (m, 2H), 4.05 (t, J = 5.9 Hz, 2H), 2.72 (qd, J = 7.2, 3.4 Hz, 1H), 2.51 (dq, J = 10.5, 
6.9 Hz, 1H), 2.37–2.25 (m, 3H), 2.11 (dtd, J = 10.0, 5.9, 5.9 Hz, 2H), 1.74 (m, 1H), 1.52 (m, 2H), 
1.33 (m, 2H), 1.26 (m, 1H), 1.22 (d, J = 7.2 Hz, 3H), 1.18 (d, J = 7.0 Hz, 3H), 0.97 (d, J = 6.5 
Hz, 3H), 0.92 (d, J = 6.6 Hz, 3H), 0.90 (d, J = 6.9 Hz, 3H), 0.87 (d, J = 6.6 Hz, 3H), 0.86 (d, J = 
6.5 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 175.6, 175.4, 173.5, 158.8, 137.7, 130.1, 128.8, 128.5, 
128.4, 127.8, 114.7, 68.8, 66.6, 66.3, 49.8, 49.3, 47.6, 44.2, 44.1, 43.3, 42.5, 29.7, 28.1, 25.1, 
22.9, 22.8, 22.4, 22.2, 20.7, 16.2, 15.6, 15.2; LC-MS (APCI) m/z [M + H]+ 1054.2, tR = 10.4 min.  
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(2S,3S)-4-[3-(Perfluorooctyl)propyl-1-oxy]benzyl 3-((2S,3S)-3-((2S,3S)-3-azido-2,5- 
dimethylhexanamido)-2,5-dimethylhexanamido)-2,5-dimethylhexanoate (24ccc): 
General procedure 5 was followed by employing amine 23cc (22 mg, 0.025 mmol), DMAP 
(3 mg, 0.02 mmol), β-azido acid 14c (11 mg, 0.058 mmol) and EDCI (11 mg, 0.058 mmol). 
Purification by FSPE gave the title compound (9 mg, 33%) as a white solid: 1H NMR (500 MHz, 
CDCl3) δ 7.28 (d, J = 8.5 Hz, 2H), 7.21 (d, J = 9.3 Hz, 1H), 6.89 (d, J = 8.5 Hz, 2H), 6.30 (d, J 
= 9.8 Hz, 1H), 5.10 (d, J = 12.0 Hz, 1H), 5.05 (d, J = 11.9 Hz, 1H), 4.17–4.10 (m, 2H), 4.04 (t, J 
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= 5.9 Hz, 2H), 3.66 (td, J = 9.2, 3.5 Hz, 1H), 2.69 (qd, J = 7.2, 3.4 Hz, 1H), 2.30 (m, 4H), 2.11 
(dtd, J = 9.6, 5.8, 5.8 Hz, 2H), 1.84 (m, 1H), 1.61–1.51 (m, 3H), 1.44 (ddd, J = 14.1, 9.0, 6.4 Hz, 
1H), 1.38–1.31 (m, 4H), 1.24 (d, J = 7.0 Hz, 3H), 1.20 (d, J = 7.2 Hz, 3H), 1.15 (d, J = 7.0 Hz, 
3H), 0.95 (d, J = 6.1 Hz, 3H), 0.93 (d, J = 6.6 Hz, 3H), 0.92 (d, J = 7.1 Hz, 3H), 0.88 (d, J = 6.7 
Hz, 3H), 0.86 (d, J = 6.3 Hz, 6H); 13C NMR (125 MHz, CDCl3) δ 175.9, 175.6, 173.6, 158.8, 
130.1, 128.2, 114.6, 109.6, 66.4, 66.2, 63.3, 49.5, 49.0, 46.9, 43.9, 43.7, 43.2, 42.3, 40.6, 27.9, 
25.1, 25.0, 23.7, 22.8, 22.4, 22.2, 21.3, 20.6, 16.0, 15.2, 15.0; LC-MS (APCI) m/z [M + H]+ 
1034.2, tR = 12.2 min.  
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(2R,3R)-3-((2R,3R)-3-((2R,3R)-3-Amino-2-methyl-5-phenylpentanamido)-2-methyl-5- 
phenylpentanamido)-2-methyl-5-phenylpentanoic acid (25aaa):  
General procedure 6 was followed by employing 24aaa (6.8 mg, 0.0058 mmol). 
Purification by FSPE gave the title compound (3.1 mg, 92%) as a white solid: LC-MS (ESI) m/z 
[M + H]+ 586.3, tR = 2.4 min.  
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(2R,3R)-3-((2R,3R)-3-((2R,3S)-3-Amino-2-methyl-3-phenylpropanamido)-2-methyl-5- 
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phenylpentanamido)-2-methyl-5-phenylpentanoic acid (25aab):  
General procedure 6 was followed by employing 24aab (7.4 mg, 0.0064 mmol). 
Purification by FSPE gave the title compound (3.2 mg, 89%) as a white solid: LC-MS (ESI) m/z 
[M + H]+ 558.3, tR = 2.5 min.  
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(2R,3R)-3-((2R,3R)-3-((2S,3S)-3-Amino-2,5-dimethylhexanamido)-2-methyl-5-phenyl- 
pentanamido)-2-methyl-5-phenylpentanoic acid (25aac):  
General procedure 6 was followed by employing 24aac (13.4 mg, 0.0119 mmol). 
Purification by FSPE gave the title compound (5.1 mg, 80%) as a white solid. A part of it (1.7 
mg) was further purified by preparative reverse phase HPLC to afford pure product (1.3 mg, 
76% recovery): LC-MS (ESI) m/z [M + H]+ 538.3, tR = 2.3 min.  
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(2R,3R)-3-((2R,3S)-3-((2R,3R)-3-Amino-2-methyl-5-phenylpentanamido)-2-methyl-3- 
phenylpropanamido)-2-methyl-5-phenylpentanoic acid (25aba):  
General procedure 6 was followed by employing 24aba (11.5 mg, 0.0100 mmol). 
Purification by FSPE gave the title compound (4.7 mg, 84%) as a white solid. A part of it (1.7 
 76
mg) was further purified by preparative reverse phase HPLC to afford pure product (1.6 mg, 
94% recovery): 1H NMR (500 MHz, 1:1 D2O:CD3CN, δ (CHD2CN) = 1.92 ppm) δ 7.37–7.09 (m, 
15H), 4.80 (d, J = 10.3 Hz, 1H), 3.87 (td, J = 10.1, 3.7 Hz, 1H), 3.08 (br, m, 1H), 2.79–2.65 (m, 
3H), 2.57 (m, 1H), 2.51 (m, 2H), 2.26 (quin, J = 7.2 Hz, 1H), 1.82 (m, 2H), 1.74 (m, 1H), 1.55 
(m, 1H), 0.92 (d, J = 6.8 Hz, 3H), 0.90 (d, J = 7.0 Hz, 3H), 0.87 (d, J = 6.9 Hz, 3H); LC-MS 
(ESI) m/z [M + H]+ 558.3, tR = 2.2 min.  
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(2R,3R)-3-((2R,3S)-3-((2R,3S)-3-Amino-2-methyl-3-phenylpropanamido)-2-methyl-3- 
phenylpropanamido)-2-methyl-5-phenylpentanoic acid (25abb):  
General procedure 6 was followed by employing 24abb (9.6 mg, 0.0086 mmol). 
Purification by FSPE gave the title compound (3.2 mg, 71%) as a white solid: LC-MS (ESI) m/z 
[M + H]+ 530.2, tR = 2.6 min.  
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(2R,3R)-3-((2R,3S)-3-((2S,3S)-3-Amino-2,5-dimethylhexanamido)-2-methyl-3-phenyl- 
propanamido)-2-methyl-5-phenylpentanoic acid (25abc):  
General procedure 6 was followed by employing 24abc (10.2 mg, 0.00926 mmol). 
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Purification by FSPE gave the title compound (3.0 mg, 64%) as a white solid. A part of it (1.1 
mg) was further purified by preparative reverse phase HPLC to afford pure product (0.5 mg, 
45% recovery): LC-MS (ESI) m/z [M + H]+ 510.3, tR = 2.3 min.  
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(2R,3R)-3-((2S,3S)-3-((2R,3R)-3-Amino-2-methyl-5-phenylpentanamido)-2,5-dimethyl- 
hexanamido)-2-methyl-5-phenylpentanoic acid (25aca):  
General procedure 6 was followed by employing 24aca (9.6 mg, 0.0085 mmol). Purification 
by FSPE gave the title compound (2.8 mg, 61%) as a white solid. A part of it (1.0 mg) was 
further purified by preparative reverse phase HPLC to afford pure product (0.8 mg, 80% 
recovery): LC-MS (ESI) m/z [M + H]+ 538.3, tR = 2.3 min.  
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(2R,3R)-3-((2S,3S)-3-((2R,3S)-3-Amino-2-methyl-3-phenylpropanamido)-2,5-dimethyl- 
hexanamido)-2-methyl-5-phenylpentanoic acid (25acb):  
General procedure 6 was followed by employing 24acb (9.3 mg, 0.0084 mmol). 
Purification by FSPE gave the title compound (3.1 mg, 72%) as a white solid. A part of it (0.9 
mg) was further purified by preparative reverse phase HPLC to afford pure product (0.6 mg, 
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67% recovery): LC-MS (ESI) m/z [M + H]+ 510.2, tR = 2.2 min.  
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(2R,3R)-3-((2S,3S)-3-((2S,3S)-3-Amino-2,5-dimethylhexanamido)-2,5-dimethylhexan- 
amido)-2-methyl-5-phenylpentanoic acid (25acc):  
General procedure 6 was followed by employing 24acc (6.5 mg, 0.0060 mmol). Purification 
by FSPE gave the title compound (2.0 mg, 68%) as a white solid: LC-MS (ESI) m/z [M + H]+ 
490.4, tR = 2.3 min.  
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(2R,3S)-3-((2R,3R)-3-((2R,3R)-3-Amino-2-methyl-5-phenylpentanamido)-2-methyl-5- 
phenylpentanamido)-2-methyl-3-phenylpropanoic acid (25baa):  
General procedure 5 was followed by employing 24baa (10.0 mg, 0.00870 mmol). 
Purification by FSPE gave the title compound (3.9 mg, 80%) as a white solid. A part of it (1.9 
mg) was further purified by preparative reverse phase HPLC to afford pure product (1.6 mg, 
84% recovery): LC-MS (ESI) m/z [M + H]+ 558.3, tR = 2.4 min.  
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(2R,3S)-3-((2R,3R)-3-((2R,3S)-3-Amino-2-methyl-3-phenylpropanamido)-2-methyl-5- 
phenylpentanamido)-2-methyl-3-phenylpropanoic acid (25bab):  
General procedure 6 was followed by employing 24bab (8.8 mg, 0.0078 mmol). 
Purification by FSPE gave the title compound (2.9 mg, 70%) as a white solid. A part of it (1.7 
mg) was further purified by preparative reverse phase HPLC to afford pure product (1.6 mg, 
94% recovery): 1H NMR (500 MHz, 1:1 D2O:CD3CN, δ (CHD2CN) = 1.92 ppm) δ 7.44–7.10 (m, 
15H), 4.68 (d, J = 8.0 Hz, 1H), 3.99 (ddd, J = 10.5, 7.5, 3.5 Hz, 1H), 3.92 (br, d, J = 9.3 Hz, 1H), 
2.56–2.51 (m, 3H), 2.47 (ddd, J = 16.7, 10.4, 6.0 Hz, 1H), 2.34 (m, 1H), 1.75 (m, 1H), 1.63 (m, 
1H), 0.96 (d, J = 7.0 Hz, 3H), 0.89 (d, J = 7.0 Hz, 3H), 0.82 (d, J = 7.0 Hz, 3H); LC-MS (ESI) 
m/z [M + H]+ 530.2, tR = 2.4 min.  
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(2R,3S)-3-((2R,3R)-3-((2S,3S)-3-Amino-2,5-dimethylhexanamido)-2-methyl-5-phenyl- 
pentanamido)-2-methyl-3-phenylpropanoic acid (25bac):  
General procedure 6 was followed by employing 24bac (9.8 mg, 0.0089 mmol). 
Purification by FSPE gave the title compound (4.4 mg, 97%) as a white solid. A part of it (1.5 
mg) was further purified by preparative reverse phase HPLC to afford pure product (1.4 mg, 
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93% recovery): LC-MS (ESI) m/z [M + H]+ 510.2, tR = 2.1 min.  
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(2R,3S)-3-((2R,3S)-3-((2R,3R)-3-Amino-2-methyl-5-phenylpentanamido)-2-methyl-3- 
phenylpropanamido)-2-methyl-3-phenylpropanoic acid (25bba):  
General procedure 6 was followed by employing 24bba (11.7 mg, 0.0104 mmol). 
Purification by FSPE gave the title compound (2.8 mg, 51%) as a white solid. A part of it (1.2 
mg) was further purified by preparative reverse phase HPLC to afford pure product (1.2 mg, 
>99% recovery): 1H NMR (500 MHz, 1:1 D2O:CD3CN, δ (CHD2CN) = 1.92 ppm) δ 7.56–7.15 
(m, 15H), 4.77 (d, J = 10.7 Hz, 3H), 4.75 (d, J = 9.0 Hz, 1H), 3.17 (m, 1H), 2.85–2.72 (m, 2H), 
2.66 (m, 2H), 2.55 (dq, J = 10.2, 7.0 Hz, 1H), 1.81 (m, 1H), 0.89 (d, J = 7.0 Hz, 3H), 0.76 (d, J 
= 6.9 Hz, 3H), 0.63 (d, J = 6.9 Hz, 3H); LC-MS (ESI) m/z [M + H]+ 530.2, tR = 2.2 min.  
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(2R,3S)-3-((2R,3S)-3-((2R,3S)-3-Amino-2-methyl-3-phenylpropanamido)-2-methyl-3- 
phenylpropanamido)-2-methyl-3-phenylpropanoic acid (25bbb):  
General procedure 6 was followed by employing 24bbb (8.7 mg, 0.0080 mmol). 
Purification by FSPE gave the title compound (2.4 mg, 60%) as a white solid: 1H NMR (500 
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MHz, 1:1 D2O:CD3CN, δ (HOD) = 4.67 ppm) δ 7.95–7.48 (m, 15H), 5.24 (d, J = 10.9 Hz, 1H), 
5.20 (d, J = 10.9 Hz, 1H), 3.66 (dq, J = 10.1, 6.7 Hz, 1H), 3.07 (dq, J = 11.5, 7.4 Hz, 1H), 3.04 
(dq, J = 11.1, 7.3 Hz, 1H), 1.15 (d, J = 7.0 Hz, 3H), 1.04 (d, J = 7.2 Hz, 3H), 1.01 (d, J = 7.1 Hz, 
3H); LC-MS (ESI) m/z [M + H]+ 502.2, tR = 2.7 min.  
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(2R,3S)-3-((2R,3S)-3-((2S,3S)-3-Amino-2,5-dimethylhexanamido)-2-methyl-3-phenyl- 
propanamido)-2-methyl-3-phenylpropanoic acid (25bbc):  
General procedure 6 was followed by employing 24bbc (12.1 mg, 0.0113 mmol). 
Purification by FSPE gave the title compound (4.8 mg, 88%) as a white solid. A part of it (2.1 
mg) was further purified by preparative reverse phase HPLC to afford pure product (1.8 mg, 
86% recovery): LC-MS (ESI) m/z [M + H]+ 482.2, tR = 2.1 min.  
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(3S,4S,7R,8R,11R,12S)-4-Isobutyl-3,7,11-trimethyl-8-phenethyl-12-phenyl-1,5,9-triazacyclo-
dodecane-2,6,10-trione (26bca):  
General procedure 6 was followed by employing 24bca (7.1 mg, 0.0064 mmol). 
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Purification by FSPE gave the title compound (2.7 mg, 82%) as a white solid. A part of it (1.4 
mg) was further purified by preparative reverse phase HPLC to afford pure product (0.9 mg, 
64% recovery): MS (ESI) m/z [M – H2O + 2Na]+ 537.3 (“M” is the mass of the desired product).  
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(2R,3S)-3-((2S,3S)-3-((2R,3S)-3-Amino-2-methyl-3-phenylpropanamido)-2,5-dimethyl- 
hexanamido)-2-methyl-3-phenylpropanoic acid (25bcb):  
General procedure 6 was followed by employing 24bcb (10.6 mg, 0.00987 mmol). 
Purification by FSPE gave the title compound (3.6 mg, 76%) as a white solid. A part of it (1.9 
mg) was further purified by preparative reverse phase HPLC to afford pure product (1.0 mg, 
53% recovery): LC-MS (ESI) m/z [M + H]+ 482.3, tR = 1.9 min.  
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(2R,3S)-3-((2S,3S)-3-((2S,3S)-3-Amino-2,5-dimethylhexanamido)-2,5-dimethylhexan- 
amido)-2-methyl-3-phenylpropanoic acid (25bcc):  
General procedure 6 was followed by employing 24bcc (9.2 mg, 0.0087 mmol). Purification 
by FSPE gave the title compound (3.2 mg, 79%) as a white solid. A part of it (1.5 mg) was 
further purified by preparative reverse phase HPLC to afford pure product (1.3 mg, 87% 
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recovery): LC-MS (ESI) m/z [M + H]+ 462.3, tR = 2.0 min.  
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(2S,3S)-3-((2R,3R)-3-((2R,3R)-3-Amino-2-methyl-5-phenylpentanamido)-2-methyl-5- 
phenylpentanamido)-2,5-dimethylhexanoic acid (25caa):  
General procedure 6 was followed by employing 24caa (6.5 mg, 0.0058 mmol). Purification 
by FSPE gave the title compound (2.7 mg, 87%) as a white solid. A part of it (1.1 mg) was 
further purified by preparative reverse phase HPLC to afford pure product (1.0 mg, 91% 
recovery): LC-MS (ESI) m/z [M + H]+ 538.3, tR = 2.0 min.  
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(2S,3S)-3-((2R,3R)-3-((2R,3S)-3-Amino-2-methyl-3-phenylpropanamido)-2-methyl-5- 
phenylpentanamido)-2,5-dimethylhexanoic acid (25cab):  
General procedure 6 was followed by employing 24cab (7.0 mg, 0.0064 mmol). 
Purification by FSPE gave the title compound (2.3 mg, 71%) as a white solid. A part of it (0.8 
mg) was further purified by preparative reverse phase HPLC to afford pure product (0.6 mg, 
75% recovery): LC-MS (ESI) m/z [M + H]+ 510.4, tR = 2.3 min.  
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(2S,3S)-3-((2R,3R)-3-((2S,3S)-3-Amino-2,5-dimethylhexanamido)-2-methyl-5-phenyl- 
pentanamido)-2,5-dimethylhexanoic acid (25cac):  
General procedure 6 was followed by employing 24cac (12.8 mg, 0.0118 mmol). 
Purification by FSPE gave the title compound (3.2 mg, 55%) as a white solid. A part of it (0.9 
mg) was further purified by preparative reverse phase HPLC to afford pure product (0.7 mg, 
78% recovery): LC-MS (ESI) m/z [M + H]+ 490.3, tR = 2.2 min.  
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(2S,3S)-3-((2R,3S)-3-((2R,3R)-3-Amino-2-methyl-5-phenylpentanamido)-2-methyl-3- 
phenylpropanamido)-2,5-dimethylhexanoic acid (25cba):  
General procedure 6 was followed by employing 24cba (16.7 mg, 0.0152 mmol). 
Purification by FSPE gave the title compound (5.3 mg, 69%) as a white solid. A part of it (2.4 
mg) was further purified by preparative reverse phase HPLC to afford pure product (1.7 mg, 
71% recovery): 1H NMR (500 MHz, 1:1 D2O:CD3CN, δ (HOD) = 4.67 ppm) δ 7.86–7.69 (m, 
10H), 5.40 (d, J = 7.0 Hz, 1H), 4.25 (ddd, J = 9.6, 4.1, 4.1 Hz, 1H), 3.69 (br, m, 1H), 3.30 (quin, 
J = 7.1 Hz, 1H), 3.28–3.17 (m, 2H), 3.14 (ddd, J = 16.9, 9.6, 6.8 Hz, 1H), 2.84 (qd, J = 7.0, 5.5 
Hz, 1H), 2.33 (m, 2H), 1.62 (d, J = 7.5 Hz, 3H), 1.57 (d, J = 7.0 Hz, 3H), 1.45 (d, J = 7.0 Hz, 
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3H), 1.21 (d, J = 4.6 Hz, 3H), 1.20 (d, J = 4.7 Hz, 3H); LC-MS (ESI) m/z [M + H]+ 510.2, tR = 
2.3 min.  
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(2S,3S)-3-((2R,3S)-3-((2R,3S)-3-Amino-2-methyl-3-phenylpropanamido)-2-methyl-3- 
phenylpropanamido)-2,5-dimethylhexanoic acid (25cbb):  
General procedure 6 was followed by employing 24cbb (10.6 mg, 0.00987 mmol). 
Purification by FSPE gave the title compound (4.2 mg, 88%) as a white solid. A part of it (2.0 
mg) was further purified by preparative reverse phase HPLC to afford pure product (1.8 mg, 
90% recovery): LC-MS (ESI) m/z [M + H]+ 482.2, tR = 2.2 min.  
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(2S,3S)-3-((2R,3S)-3-((2S,3S)-3-Amino-2,5-dimethylhexanamido)-2-methyl-3-phenyl- 
propanamido)-2,5-dimethylhexanoic acid (25cbc):  
General procedure 6 was followed by employing 24cbc (9.6 mg, 0.0091 mmol). Purification 
by FSPE gave the title compound (3.7 mg, 88%) as a white solid. A part of it (1.4 mg) was 
further purified by preparative reverse phase HPLC to afford pure product (0.8 mg, 57% 
recovery): LC-MS (ESI) m/z [M + H]+ 462.3, tR = 2.2 min.  
 86
 O
N
H
N
H
HO
O
NH2
Ph
O
 
(2S,3S)-3-((2S,3S)-3-((2R,3R)-3-Amino-2-methyl-5-phenylpentanamido)-2,5-dimethyl- 
hexanamido)-2,5-dimethylhexanoic acid (25cca):  
General procedure 6 was followed by employing 24cca (6.7 mg, 0.0062 mmol). Purification 
by FSPE gave the title compound (2.5 mg, 82%) as a white solid. A part of it (1.0 mg) was 
further purified by preparative reverse phase HPLC to afford pure product (0.4 mg, 40% 
recovery): LC-MS (ESI) m/z [M + H]+ 490.4, tR = 2.1 min.  
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(2S,3S)-3-((2S,3S)-2,5-Dimethyl-3-((R)-2-methyl-3-phenylpropanamido)hexanamido)-2,5- 
dimethylhexanoic acid (27ccb):  
General procedure 6 was followed by employing 24ccb (7.3 mg, 0.0069 mmol). Purification 
by FSPE gave the title compound (3.1 mg, 97%) as a white solid. A part of it (1.2 mg) was 
further purified by preparative reverse phase HPLC to afford pure product (1.0 mg, 83% 
recovery): LC-MS (ESI) m/z [M – 15 + Na]+ 469.2 (“M” is the mass of the desired product), tR = 
5.0 min.  
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(2S,3S)-3-((2S,3S)-3-((2S,3S)-3-Amino-2,5-dimethylhexanamido)-2,5-dimethylhexanamido)-
2,5-dimethylhexanoic acid (25ccc):  
General procedure 6 was followed by employing 24ccc (5.4 mg, 0.0052 mmol). Purification 
by FSPE gave the title compound (1.8 mg, 78%) as a white solid. A part of it (0.8 mg) was 
further purified by preparative reverse phase HPLC to afford pure product (0.7 mg, 88% 
recovery): LC-MS (ESI) m/z [M + H]+ 442.4, tR = 2.1 min.  
 
 
1.5  REFERENCES 
 
1.  Fischer, E.; Fourneau, E. Ber. Dtsch. Chem. Ges. 1901, 34, 2868.  
2.  a) Seebach, D.; Matthews, J. L. Chem. Commun. 1997, 21, 2015; b) Borman, S. C&EN 1997, 
75, 32; c) Gura, T. Science 2001, 291, 2068; d) Werder, M.; Hauser, H.; Abele, S.; Seebach, 
D. Helv. Chim. Acta 1999, 82, 1774; e) Hauser, H.; Dyer, J. H.; Nandy, A.; Vega, M. A.; 
Werder, M.; Bieliauskaite, E.; Weber, F. E.; Compassi, S.; Gemperli, A.; Boffelli, D.; 
Werhl, E.; Schulthess, G.; Phillips, M. Biochemistry 1998, 377, 17843.  
3.  a) Cheng, R. P.; Gellman, S. H.; DeGrado, W. F. Chem. Rev. 2001, 101, 3219; b) Seebach, 
D.; Overhand, M. K.; Kühnle, F. N. M.; Martinoni, B.; Oberer, L.; Hommel, U.; Widmer, H. 
 88
Helv. Chim. Acta 1996, 79, 913; c) Dado, G. P.; Gellman, S. H. J. Am. Chem. Soc. 1994, 
116, 1054; d) Pomerantz, W. C.; Grygiel, T. L. R.; Lai, J. R.; Gellman, S. H. Org. Lett. 
2008, 10, 1799.  
4.  a) Murray, J. K.; Gellman, S. H. Org. Lett. 2005, 7, 1517; b) Murray, J. K.; Farooqi, B.; 
Sadowsky, J. D.; Scalf, M.; Freund, W. A.; Smith, L. M.; Chen, J.; Gellman, S. H. J. Am. 
Chem. Soc. 2005, 127, 13271; c) Kimmerlin, T.; Seebach, D. J. Pept. Res. 2005, 65, 229; d) 
Seebach, D.; Kimmerlin, T.; Sebesta, R.; Campo, M. A.; Beck, A. K. Tetrahedron 2004, 60, 
7455; e) Watts, P.; Wiles, C.; Haswell, S. J.; Pombo-Villar, E. Tetrahedron 2002, 58, 5427.  
5.  a) Cole, D. C. Tetrahedron 1994, 50, 9517; b) Cole, D. C. Tetrahedron 1994, 50, 9517; c) 
Enders, D.; Wahl, H.; Bettray, W. Angew. Chem. Int. Ed. 1995, 34, 455; d) Farras, J.; 
Ginesta, X.; Sutton, P. W.; Taltavull, J.; Egeler, F.; Romea, P.; Urpi, F.; Vilarrasa, J. 
Tetrahedron 2001, 57, 7665; e) Enantioselective Synthesis of β-Amino Acids; Juaristi, E.; 
Wiley–VCH: New York, 1997.  
6.  Guibourdenche, C.; Podlech, J.; Seebach, D. Liebigs Ann. 1996, 7, 1121.  
7.  Negrete, G. R.; Konopelski, J. P. Tetrahedron: Asymmetry 1991, 2, 105.  
8.  Chu, K. S.; Negrete, G. R.; Konopelski, J. P.; Lakner, F. J.; Woo, N. T.; Olmstead, M. M. J. 
Am. Chem. Soc. 1992, 114, 1800.  
9.  Evans, D. A.; Uripi, F.; Somers, T. C.; Clark, J. S.; Bilodeau, M. T. J. Am. Chem. Soc. 1990, 
112, 8215.  
10.  Nelson, S. G.; Spencer, K. L.; Cheung W. S.; Mamie, S. J. Tetrahedron 2002, 58, 7081.  
 89
11.  a) Garcia, J.; Urpi, F.; Vilarrasa, J. Tetrahedron Lett. 1984, 25, 4841; b) Meldal, M.; Juliano, 
M. A.; Jansson, A. M. Tetrahedron Lett. 1997, 38, 2531.  
12.  a) Staudinger, H.; Meyer, J. Helv. Chim. Acta 1919, 2, 635; b) Leffler, J. E.; Temple, R. D.; 
J. Am. Chem. Soc. 1967, 89, 5235; c) Venturini, A.; Gonzalez, Jr. J. Org. Chem. 2002, 67, 
9089; d) Chen, J.; Forsyth, C. J. Org. Lett. 2003, 5, 1281; e) Gololobov, Y. G. Tetrahedron 
1981, 37, 437.  
13.  a) Yang, H. W.; Romo, D. Tetrehedron 1999, 55, 6403; b) Yang, H. W.; Romo, D. J. Org. 
Chem. 1999, 64, 7657.  
14.  a) Pearson, R. G. J. Am. Chem. Soc. 1963, 85, 3533; b) Pearson, R. G. Science 1966, 151, 
172; c) Pearson, R. G. J. Chem. Ed. 1987, 64, 561; d) Pearson, R. G. J. Am. Chem. Soc. 1988, 
110, 7684.  
15.  Ho, T. Tetrahedron 1985, 41, 1.  
16.  Wynberg, H.; Staring, E. G. J. J. Am. Chem. Soc. 1982, 104, 166. 
17.  Wynberg, H.; Staring, E. G. J. J. Org. Chem. 1985, 50, 1977. 
18.  Zhu, C.; Shen, X.; Nelson, S. G. J. Am. Chem. Soc. 2004, 126, 5352. 
19.  Curran, D. P. in Handbook of Fluorous Chemistry; Gladysz, J. A., Horvath, I., Curran, D. 
P., Eds.; Wiley-VCH: Wienheim, 2004.  
20.  Curran, D. P.; Luo, Z. J. Am. Chem. Soc. 1999, 121, 9069.  
21.  a) Curran, D. P. Synlett 2001, 9, 1488; b) Zhang, W. Tetrahedron 2003, 59, 4475; c) Zhang, 
W.; Curran, D. P. Tetrahedron 2006, 62, 11837; d) Curran, D. P. Aldrichimica Acta 2006, 
 90
39, 3.  
22.  Curran, D. P.; Amatore, M.; Guthrie, D.; Campbell, M.; Go, E.; Luo, Z. J. Org. Chem. 
2003, 68, 4643.  
23.  a) Merrifield, R. B. J. Am. Chem. Soc. 1963, 85, 2149; b) Letsinger, R. L.; Mahadevan, V. J. 
Am. Chem. Soc. 1965, 87, 3526; c) Hayatsu, H.; Khorana, H. G. J. Am. Chem. Soc. 1966, 88, 
3182; d) Gutte, B.; Merrifield, R. B. J. Am. Chem. Soc. 1969, 91, 501; e) Schuerch, C.; 
Frechet, J. M. J. Am. Chem. Soc. 1971, 93, 492; f) Atherton, E.; Sheppard, R. C. Solid 
Phase Peptide Synthesis: A Pratical Approach; IRL press at Oxford University Press: 
Oxford, UK, 1989; g) Thompson, L. A.; Ellman, J. A.; Chem. Rev. 1996, 96, 555; h) Murray, 
J. K.; Farooqi, B.; Sadowsky, J. D.; Scalf, M.; Freund, W. A.; Smith, L. M.; Chen, J.; 
Gellman, S. H. J. Am. Chem. Soc. 2005, 127, 13271.  
24.  a) Nagashima, T.; Zhang, W. J. Comb. Chem..2004, 6, 942; b) Zhang, W.; Lu, Y.; Chen, C. 
H.-T.; Curran, D. P.; Geib, S. Eur. J. Org. Chem. 2006, 2055.  
25.  Zhang, W. Chem. Rev. 2004, 104, 2531.  
26.  Curran, D. P.; Wang, X.; Zhang, Q. J. Org. Chem. 2005, 70, 3716. 
27.  Chacun-Lefevre, L.; Joseph, B.; Merour, J. Y. Tetrahedron 2000, 56, 4491.  
28.  Lawrence, N. J.; Bushell, S. M. Tetrahedron Lett. 2001, 42, 7671.  
29.  Calter, M. A. J. Org. Chem. 1996, 61, 8006.  
30.  a) Pardo, J.; Cobas, A.; Guitian, E.; Castedo, L. Org. Lett. 2001, 3, 3711; b) Curran, D. P.; 
Furukawa, T. Org. Lett. 2002, 4, 2233.  
 91
31.  Nikolakakis, A; Haidara, K.; Sauriol, F.; Mamer, O.; Zamir, L. O. Bioorg. Med. Chem. 
2003, 11, 1551.  
32.  Posner, G.; Shulman-Roskes, E. M.; Oh, C. H.; Carry, J. C.; Green, J. V.; Clark, A. B.; Dai, 
H. Y.; Anjeh, T. E. N. Tetrahedron Lett. 1991, 32, 6489.  
33.  a) Zhang, W.; Lu, Y.; Nagashima, T. J. Comb. Chem. 2005, 7, 893; b) Zhang, W.; Lu, Y. J. 
Comb. Chem. 2006, 8, 890; c) Zhang, W.; Lu, Y. J. Comb. Chem. 2007, 9, 836. 
34.  a) Wang, X.; Nelson, S. G.; Curran, D. P. Tetrahedron 2007, 63, 6141; b) All HPLC traces, 
NMR and MS spectra can be found online in the supplementary data of the published paper: 
http://dx.doi.org/doi:10.1016/j.tet.2007.03.034.  
 
 
 
 
 
 92
CHAPTER 2. FLUOROUS MIXTURE SYNTHESIS OF  
EIGHT STEREOISOMERS OF MACROLACTONE SCH725674  
 
2.1  INTRODUCTION 
 
2.1.1  Fluorous Mixture Synthesis.  
 
In the traditional total synthesis of a natural product, the ultimate goal is to obtain the target 
molecule in enantiomerically pure form. The synthesis of stereoisomers is only necessary when: 
1) the isomer is also a natural product (such as epoxyquinol A and B1); 2) the configurations of 
the natural product are not fully assigned (such as aurilol2); 3) the original structure assignment 
is not correct (such as homononactinic acid and azaspiracid-13). To solve problems 2 and 3, 
people usually synthesize the stereoisomer one at a time. If the first is not proved be the natural 
product, then another one will be prepared, and so on. This is adventurous since it is not adequate 
to prove the proposed structure simply because the spectroscopic data match with those of the 
natural product. The disproval of other stereoisomers has to be demonstrated at the same time. 
Thus, systematic synthesis of the stereoisomers of the natural product becomes necessary.  
Compared to the traditional total synthesis, modern combinatorial techniques can generate a 
large number of isomers in a short time. Among these techniques, solution-phase parallel 
synthesis deals with individual pure compounds and most reactions are carried out separately for 
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different isomers.4 However, parallel synthesis involves a large amount of work and may not be 
suitable to generate a large library of isomers. Solution-phase mixture synthesis is more 
attractive with regard to reduced number of steps.5-7 However, it has several drawbacks: 1) it 
usually does not target the isolation of the individual target molecules but uses deconvolution 
methods to identify only the most active compounds;8 2) the time saved during the mixture 
synthesis is often spent in finding the hit structure. The separation of final products in the 
mixture synthesis can be accomplished by a strategy based on separation tags. Thus, the 
technique of fluorous mixture synthesis (FMS) was developed. 9-16
FMS is a solution-phase synthetic technique to prepare multiple isomers in a single series of 
reactions. While single intermediates and final product are obtained in a traditional organic 
synthesis, FMS allows us to conduct reactions on mixtures of quasiisomers (isomeric compounds 
with different tags). FMS has five stages: tagging, mixing, mixture syntheses, demixing and 
detagging (Scheme 2.1). To start, the required isomeric subtrates (S1-Sn) are prepared, and the 
configuration of each isomer is encoded by a unique, highly fluorinated tag (fluorous tag, F1-Fn) 
which has a unique number of florines. Fluorous tags have been used to encode enantiomers (to 
give quasienantiomers), diastereomers (to give quasidiastereomers), and analogues. During the 
mixture synthesis stage, the quasiisomers (S1F1-SnFn) are mixed to get the starting mixture (M1). 
The bulk of the synthesis is then carried out on the mixture, so only one synthesis is performed. 
When an additional stereocenter is introduced, the splitting of the mixture is required for the 
stereoselective reaction and adding different new tags. When this is done, remixing occurs (not 
 94
shown in Scheme 2.1). At the end of the synthesis, demixing of the end mixture (M3) by 
chromatography over fluorous silica gel separates the quasiisomers (P1F1-PnFn) in the order of 
increasing fluorine content. In the detagging stage, removal of the fluorous tags from each 
individual pure compound furnishes the final stereoisomeric products (P1-Pn).  
 
 
S = Substrate; F = Fluorous tag; M1 = Starting mixture; M2 = Intermediate mixture;  
M3 = End mixture; P = Product 
 
Scheme 2.1. The conceptual basis of Fluorous Mixture Synthesis  
 
FMS has the advantages of both the solution-phase parallel synthesis (homogeneous 
reactions) and the solid-phase mixture synthesis (reduced amount of work). The early work 
validated the principles and features of FMS, such as the synthesis of the stereoisomer libraries 
of murisolin,11 passifloricin12 and dictyostatin,13 and the analogs of mappicine.14 After that, we 
started to use FMS to solve structure problems. For the natural products whose three-dimensional 
structure is not fully assigned, a set of stereoisomers is synthesized unambiguously and the 
spectroscopic data of the synthetic samples are compared with those of the natural sample to 
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determine the configurations. With this purpose, we successfully performed the stereoisomer 
synthesis and the structure elucidation of (+)-cytostatin15 and lagunapyrone B,16 whose relative 
configurations were only partially assigned. We now seek to solve even more challenging 
problems with natural products for which no configurations were assigned.  
 
2.1.2  Macrolactones.  
 
Many natural products are macrolactones, such as erythromycins,17 epothilone18 and 
spongistatins.19 The definition of a macrolactone is sometimes expanded to a macrocyclic 
lactone with the ring size often greater than 12-membered and with many substituents 
asymmetrically placed on the periphery of the ring.20,21 From a chemical viewpoint, a 
macrolactone can be viewed as the intramolecular esterification product of a hydroxy acid 
(Scheme 2.2). A macrolactone can also have more than one ester linkage.  
O
R O
O
R OH
OH
A macrolactone A hydroxy acid  
Scheme 2.2. The general structure of a macrolactone 
 
Macrolactones are often of immense pharmacological importance. Since the discovery of 
the first clinically useful macrolactone erythromycin (also can be classified as “macrolactone” 
since it is a macrolactone glycoside antibiotics) in the 1950’s, macrolactone antibiotics have been 
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used as therapeutic agents to treat infections in humans and animals for over 50 years. Four 
biologically active macrolactones with ring sizes of 12 (methymycin,22 1a), 14 (rosamicin,23 1b), 
16 (erythromycin A,17 1c) and 18 ((+)-aspicilin,24 1d) are shown in Figure 2.1.  
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Figure 2.1. Representative biologically active macrolactones with different ring sizes 
 
2.1.3  Sch725674. 
 
Sch725674 (2) is a natural product isolated by Schering-Plough Research Institute from 
Aspergillus sp. culture in 2005.25 Approximately 1.5 mg of the pure compound was isolated. 
Sch725674 displays antifungal activity against Saccharomyces (PM503) and Candida albicans 
(C43) with MICs (Minimum Inhibitory Concentration) 8 and 32 mg/mL. Sch725674 was 
identified as a 14-membered macrolactone based on the analysis of its MS, 1D and 2D NMR 
spectra (Figure 2.2).  
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Figure 2.2. The 2D structure of Sch725674  
 
The molecular formula of Sch725674 was established as C18H32O5, which was consistent 
with a positive ESI-MS measurement (m/z 329, [M + H]+). In the 1H and 13C NMR spectra, 29 
proton and 18 carbon signals were found. Based on the APT, HSQC and TOCSY experiments, 
multiplicity and the proton-attached carbon resonances were assigned and a cyclic structure 
through an ester linkage was proposed. The 18 carbon signals were assigned as one methyl (C18), 
one carbonyl (C1), two olefinic methine (Δ2,3), four oxygenated-methine (C4, C5, C7, and C13), 
ten aliphatic methylene carbons. The resonance of H2 (δ 6.07, dd, J = 15.8, 1.6 Hz) indicated 
that C2 was adjacent to the carbonyl. The coupling constant (J = 15.8 Hz) between H2 and H3 
established the trans configuration of the Δ2,3 olefin.  
No configuration of any stereogenic center of Sch725674 was assigned, and no synthesis of 
any isomer has been reported to date. The ultimate goal of this project is to synthesize a set of 
stereoisomers of Sch725674 by FMS to confirm the constitution (2D structure) and to determine 
the configuration (3D structure) of the natural product. The relative configurations will be 
assigned by comparing the spectra of a set of diastereomers with those of Sch725674.  
We can tentatively and partially assign the most likely absolute configuration for 2 based on 
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literature guidelines. The structures of several known 14-membered macrolactones are shown in 
Figure 2.3. All such 14-membered macrolactones for which the absolute configurations have 
been determined have the (13R) configuration (such as 1c, 1e-h).26 Also, all known 
14-membered macrolactones that have the 4,7 or 4,5,7 polyoxygenation pattern have the (7R) 
configuration (such as 1e-f, 1h). Based on these guidelines, we postulate that both C13 and C7 of 
Sch725674 are very likely to have (R) configurations.  
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Figure 2.3. Some known 14-membered macrolactones 
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2.2  RESULTS AND DISCUSSION 
 
2.2.1  The retrosynthesis of a single isomer of Sch725674.  
 
Prior to the FMS of eight isomers of Sch725674, a total synthesis of one isomer was 
performed. The first aim for this synthesis was to make sure that every step could work for FMS. 
The second aim was to know if the 2D structure of Sch725674 had been assigned correctly in the 
original paper. The structure of the selected isomer 2d (numbered as “d” because it is the fourth 
isomer made in the later FMS) is shown in Figure 2.4. The C13 configuration of the isomer was 
set as (R) based on the ”13R rule”, while other configurations were selected on the fly as the 
synthesis progressed.  
O
C5H11
O
OH
OH
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(13R)
(4R)
(5R)
(7S)
 
Figure 2.4. The structure of the selected isomer 
 
The retrosynthesis of the single isomer 2d is shown in Scheme 2.3. Macrolactone 2d can be 
prepared from protected lactone triol 3 by the reduction of Δ9,10 alkene followed by 
debenzylation and desilylation. Breaking of the C9-C10 bond by a RCM transform followed by 
the cleavage of the Δ2,3 alkene by a Wadsworth-Emmons transformation provides aldehyde 4 and 
phosphonate ester 5-(R).  
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Scheme 2.3. The retrosynthetic analysis of macrolactone 2d 
 
As shown in Scheme 2.4, aldehyde 4 can be prepared from aldehyde 6 by allylation reaction, 
TIPS protection, TBS desilylation and oxidation. Further retrosynthesis of aldehyde 6 leads to 
olefin 7, which can be prepared by TBS and TIPS protection reactions of 8. Diol 8 can be 
constructed from D-glyceraldehyde acetonide 13 by allylation, benzylation and removal of the 
ketal. Aldehyde 13 can be made from the oxidative cleavage of diol 12.27-28  
Allylation
O
O
O
H
13, D-glyceraldehyde acetonide
4
1
2 3
OTIPS
4O 5 6
7
8
OBn OTIPS
Oxidation
1
2 3
OTIPS
4TBSO O
OBn
5
6
1
2 3
OTIPS
4TBSO
OBn
5
6
Tagging
Allylation
1
2 3
OH
4HO
OBn
Protection
5
6
7
8
O
OOH
OHO
O
12, 1,2:5,6-Di-O-isopropyli-
dene-D-mannitol  
Scheme 2.4. Retrosynthesis of aldehyde 4 
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 As shown in Scheme 2.5, ester 5-(R) can be prepared from alcohol 9-(R) by the 
esterification with phosphorylacetic acid, while alcohol 9-(R) can derive from epoxide 10-(S) by 
the ring opening reaction. Enantiopure 10-(S) can be resolved from the racemic epoxide rac-10 
by Jacobsen HKR resolution.29 
 
Esterification
Epoxide OpeningC5H11
O
P(OEt)2
OO
5-(R)
O
10-(S)
C5H11
OH
9-(R)
O
rac-10  
 
Scheme 2.5. Retrosynthesis of ester 5-(R) 
 
2.2.2  The synthesis of single isomer 2d.  
 
The synthesis of the single isomer 2d commenced with the construction of aldehyde 4. Diol 
12 was oxidatively cleaved with NaIO4 in the presence of NaHCO3 in DCM to afford 
D-glyceraldehyde acetonide 13 in quantitative yield (Scheme 2.6).27,28 The reason for choosing 
the D-isomer is that the starting material to make L-isomer is not readily available. Aldehyde 13 
was then treated with allylMgBr in diethyl ether to afford homoallylic alcohol 14 in 78% yield as 
a mixture of unseparable anti/syn isomers with a diastereomeric ratio of 1.4/1.0 based on 1H 
NMR analysis.30 We did the non-selective allylation of 13 at this point because both 14-anti and 
14-syn were ultimately needed in FMS.  
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12, 1,2:5,6-Di-O-isopropyli-
dene-D-mannitol  
 
Scheme 2.6. Preparation of homoallylic alcohol 14 
 
The benzylation products of 14-anti and 14-syn are separable on silica gel according to a 
literature report.30 Therefore, alcohol 14 was benzylated with BnBr in the presence of NaH and a 
catalytic amount of nBu4NI in refluxing THF to afford 15-anti (the (2R,3S) isomer) and 15-syn 
(the (2R,3R) isomer) with a diastereomeric ratio of 1.6/1.0 based on 1H NMR analysis of the 
crude product (Scheme 2.7).30-32 This matched well with the reported anti/syn ratio of 1.5/1.0.30 
Separation of the reaction mixture by flash chromatography provided 50% 15-anti and 33% 
15-syn (83% total yield). The configurations of 15-anti and 15-syn were assigned by comparing 
their 1H NMR spectra with literature data.30  
 
O
O
OH
1) BnBr, NaH, Bu4NI,
THF, reflux O
O
OBn
O
O
OBn
+
15-anti, 50% 15-syn, 33%14
(R)
(S)
(R) (R)
(R)
2) Flash chromatography
 
 
Scheme 2.7. Benzylation of homoallylic alcohol 14  
 
The acetonides of 15-anti and 15-syn were removed with 3.5 equiv of FeCl3?6H2O in DCM 
to give the two diols 8-anti and 8-syn in 97% and 100% yields.33 The primary hydroxy groups of 
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8-anti and 8-syn were selectively protected with TBSCl in the presence imidazole in DCM to 
give 17-anti and 17-syn in 74% and 62% yields (Scheme 2.8).  
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Scheme 2.8. Synthesis of alcohols 17-anti and 17-syn 
 
Comparison of the TLC data of 17-anti and 17-syn showed that these two diastereomers 
could also be separated by silica gel flash chromatography. Accordingly, on scale up, we decided 
to save two steps by synthesizing 17-anti and 17-syn together in only one reaction sequence. 
Starting from homoallylic alcohol 14, benzylation followed by acetonide deprotection and TBS 
protection gave alcohol 17 as a mixture of two diastereomers (1.6/1.0 mixture of anti and syn 
isomers based on 1H NMR analysis) in 33% yield over 3 steps. Approximately 23 g of alcohol 
17 was prepared. Separating 10.6 g of 17 by flash chromatography gave 2.5 g of pure 17-anti 
and 3.4 g of pure 17-syn (Scheme 2.9). The mixture fractions (4.8 g) were also saved for future 
separation.  
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Scheme 2.9. A more expedient synthesis of 17-anti and 17-syn 
 
On the surface, 17-syn and 17-anti are equally suitable for the single isomer synthesis 
because the relative configuration of 2 is unknown. Although 17-anti was the major product 
according to 1H NMR analysis of the crude product, 17-syn was selected for the single isomer 
synthesis because it was obtained in larger quantity in pure form after chromatography. Alcohol 
17-syn was treated with TIPSOTf and 2,6-lutidine in DCM to give 7 in 96% yield (Scheme 2.10). 
The ozonolysis of olefin 7 with Ph3P as the reducing agent afforded aldehyde 6 in 59% yield.34 
We also tried small-scale ozonolysis with Me2S as the reductant, but the spot suspected as the 
intermediate ozonide never disappeared on TLC.  
The construction of the C7 stereocenter in the target molecule requires a diastereoselective 
allylation of aldehyde 6. To generate both possible diastereomers, we first carried out a 
non-selective allylation of 6 with allylMgBr in Et2O. Separation of the reaction mixture by flash 
chromatography provided pure homoallylic alcohols 20a, 20b and the overlapped fractions in 
44%, 32% and 21% yields, respectively. The total yield of the allylation was 95%. The 
configurations of 20a and 20b were confirmed by the later asymmetric allylations as discussed 
below.  
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Scheme 2.10. Preparation of homoallylic alcohols 20a and 20b 
 
Several asymmetric allylations of aldehyde 6 were attempted. The Duthaler-Hafner 
allylation35 and the Soderquist allylation36 of 6 only gave the recovered starting material. The 
Brown allylation with (-)-Ipc2Ballyl in Et2O at –78 ºC afforded a mixture of 20a/b in 83% yield 
with a diastereomeric ratio of 93/7 (Scheme 2.11, entry 1).37 The C5 configuration of 20a was 
assigned as (S) based on Brown’s model, and the diastereoselectvity was determined by 
comparing the 1H NMR spectrum of 20a/b mixture with those of pure 20a and 20b from the 
non-selective reaction in Scheme 10. The allylation of 6 with (+)-Ipc2Ballyl gave 20a/b mixture 
in 65% yield with a diastereomeric ratio of 16/84 (entry 2). Needing only one pure homoallylic 
alcohol to complete the single isomer synthesis, we selected alcohol 20a (major product in entry 
1) since the yield and diastereoselectivity was higher than those of 20b (major product in entry 
2).  
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Scheme 2.11. Brown allylations of aldehyde 6 
 
To continue the synthesis, alcohol 20a (with 93/7 dr) was purified by flash chromatography 
to remove 20b. Pure 20a was silylated with TIPSOTf in the presence of 2,6-lutidine to give 21 in 
71% yield (Scheme 2.12). The TBS group of 21 was selectively removed with CH3COCl at –10 
°C in MeOH to give primary alcohol 22 in 87% yield.38 The reaction temperature was crucial to 
the yield and the selectivity. We found that no desilylation of 21 occurred below –10 °C 
according to TLC analysis, while the desired product 22 was formed at between –10 and –5 °C. 
However, when the temperature was raised above –5 °C, a new and more polar spot showed on 
TLC analysis. We suspected that this spot was a diol from the concomitant desilylation of the 
TIPS group at O5. Alcohol 22 was then subjected to PCC oxidation to afford aldehyde 4 in 79% 
yield. Although PCC is known to be acidic, aldehyde 4 was a single isomer confirmed by 1H 
NMR analysis, suggesting there was no epimerization at C2.  
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Scheme 2.12. Preparation of aldehyde 4 
 
The synthesis of HWE reaction fragments 5-(S) and 5-(R) is shown in Scheme 2.13. This 
work was done by Mr. Claude A. Ogoe. Jacobsen HKR resolution of 1,2-epoxy-5-hexene rac-10 
with (S,S)-Salen-Co complexes afforded epoxide 10-(S), which was treated with n-butyllithium 
in the presence of CuCN to afford the secondary alcohol 9-(R).29 Esterification of alcohol 9-(R) 
with 2-(diethoxyphosphoryl)acetic acid in the presence of EDCI and DMAP provided ester 5-(R) 
in a two-step yield of 47%. Ester 5-(S) was prepared with the same route from rac-10 with 
(R,R)-Salen-Co complexes in a two-step yield of 81%. Approximately 5 g of each ester was 
made.  
O (S,S)-Salen-Co
HOAc, THF
1,2-Epoxy-5-hexene rac-10
O nBuLi, CuCN
THF
OH
C5H11
C5H11
O
P(OEt)2
OO
HO
P(OEt)2
OO
EDCI, DMAP, DCM
5-(R)47% (2 steps)
10-(S) 9-(R)
C5H11
O
P(OEt)2
OO
5-(S), 81% (2 steps)
(with (R,R)-Salen-Co)  
 
Scheme 2.13. Synthesis of esters 5-(S) and 5-(R) 
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To determine the enantiopurities of 5-(R) and 5-(S) provided by Mr. Ogoe, the esters were 
hydrolyzed with K2CO3 in the water-methanol mixed solvent to afford alcohols 9-(R) and 9-(S) 
in 79% and 94% yields, respectively (Scheme 2.14). Alcohols 9-(R) and 9-(S) were esterified 
with (R)-3,3,3-trifluoro-2-methoxy-2-phenyl-propanoyl chloride (Mosher chloride) in the 
presence of pyridine and a catalytic amount of DMAP.39 When 9-(R) and 9-(S) were totally 
consumed according to TLC analysis, both reactions were worked up and analyzed by 19F NMR 
experiment. The diastereomeric ratios of Mosher esters 27-(R) and 27-(S) were 100/0 (major 
peak at –71.92 ppm) and 99/1 (major peak at –71.97 ppm) respectively. This means the presusors 
5-(R) and 5-(S) are enantiopure as needed for the Wadsworth-Emmons reactions with aldehyde 4. 
As previously stated, the 13R configuration had been seen in many 14-membered macrolactones. 
Accordingly, ester 5-(R) was selected for the single isomer synthesis.  
 
C5H11
O
P(OEt)2
OO 1) K2CO3, H2O, MeOH,
rt, 5h, 79% (9-(R))
2) (R)-Mosher Chloride,
Py, DMAP, DCM
27-(R), d.r = 100:05-(R)
C5H11
O O
MeO
PhF3C
27-(S), d.r = 99:1
(prepared from 5-(S))
C5H11
O O
MeO
PhF3C
(R) (R)
(S) (S)
(S)
 
 
Scheme 2.14. Determine the enantiopurities of 5-(S) and 5-(R) 
 
To prevent the possible base-induced epimerization of aldehyde 4 and the decomposition of 
ester 5-(R) in the Wadsworth-Emmons reaction, we used the mild Masamune-Roush 
conditions.40,41 Aldehyde 4 was coupled with ester 5-(R) in the presence of LiCl and DBU to 
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afford α,β-unsaturated ester 28 (152 mg) in 73% yield (Scheme 2.15, entry 1). DIPEA was also 
used in place of DBU but the yield of 28 was only 34% (entry 2).  
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Scheme 2.15. Masamune-Roush coupling of 4 and 5-(R)  
 
The ring-closing metathesis of 28 is the key reaction to construct the backbone of the 
14-membered macrolactone,42 and we surveyed different conditions on small-scale as 
summarized in Scheme 2.16. Treating 28 with Grubbs 2nd generation catalyst in DCM at both 
23 °C and 50 °C gave only 20% yields of the desired cyclized product 3 (entry 1 and 2).43 
However, the reaction of 28 with Grubbs 1st generation catalyst in DCM at 23 °C gave 3 in 75% 
yield (entry 3).44,45 No competing reaction such as the formation of the 7-membered rings via 
involvement of the conjugated alkene was observed. We also tried the Hoveyda-Grubbs catalyst 
but no reaction occurred.46 Repeating the RCM reaction of 28 in entry 3 on large scale afforded 3 
(112 mg) in 73% yield.  
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Scheme 2.16. Ring-closing metathesis of ester 28 
 
The E/Z rario of the newly formed double bond of 3 (from entry 3) was 6/1 according to 1H 
NMR analysis of product 28. The chemical shifts and coupling constants of H9 and H10 of 
3-(E)/(Z) are listed in Table 2.1. The E and Z isomers could not be separated by silica gel flash 
chromatography, but this was not a problem since the next step was the reduction of Δ9,10 alkene.  
 
Table 2.1. Comparison of 1H NMR resonances for H9 and H10 of 3-(E)/(Z) a
 
O
C5H11
O
OBn
OTIPS
OTIPS
3-(E)
O
C5H11
O
BnO
TIPSO
OTIPS
3-(Z)
9
10
9 10
 
Prodcut δ (H9, ppm) J (H9, Hz) δ (H10, ppm) J (H10, Hz) 
3-(E) 5.43 (ddd) 14.8, 7.9, 4.7 5.27 (ddd) 14.6, 8.3, 4.5 
3-(Z) 5.50 (ddd) 9.7, 6.5, 2.8 5.36 (m)b — 
a. NMR spectra were taken on a 500 MHz spectrometer with samples dissolved in CDCl3; 
b. Overlapped with other peaks.  
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Different conditions for reducing the Δ9,10 alkene of 3 were tried as summarized in Scheme 
2.17. Diimide reduction of 3 with hydrazine and CuSO4 led to the overly hydrogenated product 
30 in quantitative yield (entry 1).10c The hydrogenation of 3 with Pd/C (0.1 equiv) gave the 
over-reduced product 31 in which both double bonds were reduced and the benzyl group was 
hydrogenolyzed in 76% yield (entry 2). The hydrogenation of 3 with 1.05 equiv of Pd/BaSO4 
(Rosenmund catalyst) in EtOH gave the desired product 32 in 100% yield (entry 3).44
 
Conditions
Conditions Yield
Hydrazine, CuSO4, EtOH, 70 °C, 12h 30, 100%
H2, Pd/BaSO4 (1.05 equiv), EtOH, rt, 48h 32, 100%
H2, Pd/C (0.1 equiv), EtOH, rt, 20h 31, 76%
O
C5H11
O
OBn
OTIPS
OTIPS
O
C5H11
O
OBn
OTIPS
OTIPS
3-(E/Z) 3231
O
C5H11
O
OH
OTIPS
OTIPS
Entry
3
2
1
30
O
C5H11
O
OBn
OTIPS
OTIPS
 
 
Scheme 2.17. Reductions of lactone 3-(E)/(Z)  
 
Several conditions for the benzyl deprotection of 32 were tried as shown in Scheme 2.18. 
The debenzylation of 32 with BCl3 in DCM at −78 °C led to product mixture in which six 
different mass signals (ESI, M–) were detected: 437.1, 451.2, 465.3, 479.3, 493.3, 507.3 (entry 
1).44 This result indicated that the product was a mixture of triols bearing different boron residues. 
One proposed structure of 33 with a mass of 479.3 is shown in Scheme 18. Other analogs of 33 
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in the product mixture were different in the numbers of OH and OMe groups. We tried to remove 
the boron residues and free the OH groups by treating 33 with MeOH or NH3?H2O, but 2d was 
not detected. The oxidative debenzylation of 32 with DDQ in a mixed solvent of DCM and 
buffer (pH = 7) gave decomposition (entry 2).47 Finally, treating 32 with BF3?Et2O and EtSH in 
DCM at 32 °C removed the benzyl group and both TIPS groups to give target triol 2d (1.9 mg) in 
85% yield (entry 3).48 Triol 2d was purified by preparative reverse phase HPLC with gradient 
conditions eluting with CH3CN and H2O to give 1.3 mg (68%) of pure sample as a white solid.  
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Scheme 2.18. Deprotections of lactone 32  
 
Triol 2d was characterized by 1H NMR, 13C NMR, COSY and HMQC experiments. The 
NMR resonances (δ and J) of 2d were similar to those of the natural product but had slight 
differences (see Table 2.3 in section 2.2.4). However, all 1H-1H and 1H-13C correlations of 
Sch725674 could be found in the 2D NMR spectra of 2d. Thus we concluded that: 1) the 2D 
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structure of Sch725674 was assigned correctly; 2) 2d is a diastereomer of Sch725674.  
 
2.2.3  The tagging strategy for the FMS.  
 
With all the steps of the single isomer synthesis validated, we targeted the FMS of 
stereoisomers of Sch725674. We made a complete set of eight diastereomers 2a-2h (all with C4 
being (R)) and one of them (2a) proved to have the same relative configurations as the natural 
product (Figure 2.5).  
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Figure 2.5. The eight stereoisomers of Sch725674 prepared by FMS 
 
In the FMS, diisopropyl(perfluoroalkylethyl)silyl groups (FTIPS) are used as tags because 
they are stable under most reaction conditions and easily deprotected.12,16 The structures of two 
frequently used FTIPS groups are shown in Figure 2.6. In the numbering of the following text, 
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“M” is used to denote a mixture of fluorous tagged quasiisomers. The letter “F” followed by a 
number (0, 7 or 9) is an abbreviation of the FTIPS group with a certain fluorine content (when 
used in a coding scheme, the regular TIPS group is displayed as F0TIPS). A single component in 
the mixture is designated as the combination of a number and abbreviations of flourous tags. For 
example, “35[F9F7]” represents a quasiisomer in mixture M-35 that bears F9TIPS and F7TIPS 
groups. The total fluorine content of 35[F9F7] is 16, the sum of 9 and 7.  
 
Si
Rf
TIPSF9 (Rf = C4F9): diisopropyl(3,3,4,4,5,5,6,6,6-nonafluorohexyl)silyl
TIPSF7 (Rf = C3F7): diisopropyl(3,3,4,4,5,5,5-heptafluoropentyl)silyl
 
 
Figure 2.6. The structures of FTIPS groups 
 
The retrosynthesis and the tagging strategy of FMS are shown in Scheme 2.19. Take the 
synthesis of the four (13R) isomers 2a-2d as example. Instead of making the single lactone 3 (see 
Scheme 2.16 in section 2.2.1), we will prepare a mixture of four tagged quasidiastereomers M-35. 
The OH groups in M-35 provide convenient locations for fluorous tags. The configurations of C4 
and C13 are fixed as (R) so that four quasidiastereomers will be prepared. Different combinations 
of tags are used to encode different configurations of C5 and C7. We used F7TIPS (O4) and 
F0TIPS (O7) to encode (5S,7R), F9TIPS (O4) and F0TIPS (O7) to encode (5R,7R), F7TIPS (O4) 
and F7TIPS (O7) to encode (5S,7S), F9TIPS (O4) and F7TIPS (O7) to encode (5R,7S). Thus the 
total fluorine contents of the four quasidiastereomers of M-35 are 7, 9, 14 and 16. The OH at C3 
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is protected with Bn group. The choosing of the tags is based on: 1) the easiness of separating the 
four quasiisomers by fluorous HPLC; 2) the minimum fluorine contents of quasiisomers to avoid 
long retention times on the fluorous HPLC column; 3) the similar polarities of quasiisomers to 
make sure that they do not separate on regular silica gel. Lactone M-35 will be converted to the 
four final products 2a-2d by the reduction of the Δ9,10 alkene followed by demixing and 
detagging. M-35 can be assembled by the HWE reaction of ester 5-(R) and aldehyde M-36 
followed by the RCM reaction. Aldehyde M-36 can be prepared from silyl ether M-37 by TBS 
desilylation and oxidation. M-37 can be formed by the tagging and mixing of the two 
homoallylic alcohols M-38a and M-38b, which can be synthesized from 39-anti-F7 and 
39-syn-F9 by mixing, ozonolysis, splitting and (+)/(–)-Brown allylations. Silyl ethers 39-anti-F7 
and 39-syn-F9 can be made by the tagging reactions of 17-anti and 17-syn, which were already 
prepared in the single isomer synthesis. The synthesis of the four (13S) isomers 2e-2h followed 
the same route.  
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Scheme 2.19. Retrosynthesis and tagging strategy for FMS 
 
2.2.4  The FMS of eight stereoisomers of Sch725674.  
 
The FMS of the eight isomers of Sch725674 commenced with the tagging reactions of 
alcohols 17-anti (4.50 g) and 17-syn (4.50 g), which were already made in the single isomer 
synthesis. In the mixture synthesis stage, the product (fluorous mixture of quasidiastereomers) is 
usually purified by regular flash chromatography. During purification, it is helpful that the 
mixture components have similar polarities so they do not separate on the silica gel. To make 
sure that the tagging products of 17-syn and 17-anti have similar polarities, we did six 
small-scale silylations of 17-anti and 17-syn with three different silyl groups: TIPS, F7TIPS 
(diisopropyl(3,3,4,4,5,5,5-heptafluoropentyl)silyl), F9TIPS (diisopropyl(3,3,4,4,5,5,6,6,6-nonaflu- 
orohexyl)silyl). Tagging reagents F7TIPSOTf and F9TIPSOTf were made in situ by adding triflic 
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acid to diisopropyl(perfluoroalkylethyl)silane and stirring the mixture for 16 h (Scheme 
2.20).12,16  
SiH
Rf TfOH
16 h
SiOTf
Rf
Rf = C4F9: TIPSF9OTf
Rf = C3F7: TIPSF7OTf
  
 
Scheme 2.20. Preparation of the tagging reagents FTIPSOTf 
 
Alcohol 17-anti was tagged with F0TIPSOTf, F7TIPSOTf and F9TIPSOTf in the presence of 
2,6-lutidine in DCM to give products 39-anti-F0, 39-anti-F7 and 39-anti-F9 in 96%, 92% and 
82% yields, respectively. Under the same conditions, 17-syn was tagged to give 39-syn-F0, 
39-syn-F7 and 39-syn-F9 in 100%, 72% and 89% yields, respectively. The TLC data of the six 
products were compared. Products 39-anti-F0 and 39-syn-F0, which bore the null tag (TIPS), 
had higher Rf than the other four (Scheme 2.21). The four fluorous silyl ethers did not have much 
difference on TLC. However, co-spot experiments showed that 39-anti-F7 and 39-syn-F9 had 
the closest Rf, thus they were selected to continue the synthesis.  
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39-syn-F0: Tag = TIPS, 100%, Rf = 0.87
39-syn-F7: Tag = F7TIPS, 72%, Rf = 0.77
39-syn-F9: Tag = F9TIPS, 89%, Rf = 0.76  
 
Scheme 2.21. Small-scale tagging reactions of 17-anti and 17-syn and Rf on  
silica gel (20:1 Hex:EtOAc) 
 
Large-scale tagging reactions of 17-anti and 17-syn with F7TIPSOTf and F9TIPSOTf gave 
39-anti-F7 (8.50 g) and 39-syn-F9 (8.90 g) in 92% and 89% yields, respectively (Scheme 2.22). 
Equimolar amounts of 39-anti-F7 (3.00 g) and 39-syn-F9 (3.20 g) were mixed, and the mixture 
was subjected to ozonolysis followed by the reduction by Ph3P to afford aldehyde M-42 (5.80 g) 
in 93% yield after silica gel flash chromatography. Aldehyde M-42 showed only one spot on 
TLC (20:1 Hex:EtOAc).  
TBSO
OBn
OTIPSF7
TBSO
OBn
OH
2,6-lutidine, DCM
0 °C - rt, 10h, 92%
TIPSF7OTf
1) mix
2) O3, DCM, −78 °C
then Ph3P, 93%
TBSO
OBn
OH TIPSF9OTf
2,6-lutidine, DCM
0 °C - rt, 10h, 89%
TBSO
OBn
OTIPSF9
17-anti
17-syn
39-anti-F7
39-syn-F9
F7: (3S)
F9: (3R)
TBSO O
OBn
OTIPSF7,F9
M-42
3(4R)
 
Scheme 2.22. Preparation of aldehyde M-42 
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Aldehyde M-42 was split in half and subjected to Brown allylations. It was reported by 
Brown and coworkers that when a salt-free solution of Ipc2Ballyl was used, the allylation 
reactions of aldehydes gave more than 95% de.37 Addition of commercially available, salt-free 
(–)-Ipc2Ballyl solution (1 M in pentane) to the Et2O solution of M-42 at –100 °C provided 
(4S)-homoallylic alcohol M-38a in 85% yield after flash chromatography, as a mixture of two 
compounds (Scheme 2.23). (4R)-Homoallylic alcohol M-38b was prepared from the other half of 
M-42 with (+)-Ipc2Ballyl under the same conditions in 75% yield. Both M-38a and M-38b 
showed only one spot on TLC.  
 
F7: (3S)
F9: (3R)
1) (−)-Ipc2BAllyl, Et2O, −100 °C
2) NaOH, H2O2, 85%
TBSO
OBn
OTIPSF7,F9
OH
M-38aTBSO O
OBn
OTIPSF7,F9
TBSO
OBn
OTIPSF7,F9
OH
M-38b
1) (+)-Ipc2BAllyl, Et2O, −100 °C
2) NaOH, H2O2, 75%
M-42
F7: (3S)
F9: (3R)
(2R) 3
3
3(4R) F7: (3S)F9: (3R)
(2R)
 
 
Scheme 2.23. Brown allylations of aldehyde M-42  
 
To determine the diastereoselectivities of the Brown allylations, we analyzed alcohols 
M-38a and M-38b by fluorous HPLC. Two major peaks were observed in both HPLC traces of 
M-38a and M-38b (Figure 2.7). The co-injection of M-38a and M-38b also gave only two peaks. 
After the analytical HPLC experiments, 5.0 mg of each alcohol was demixed by preparative 
fluorous HPLC to produce four quasidiastereomers 38a[F7] (1.8 mg), 38a[F9] (2.3 mg), 38b[F7] 
 120
(2.0 mg) and 38b[F9] (1.9 mg), which were characterized by 1H NMR analysis. The NMR 
spectra of the four quasidiastereomers were different (Figure 2.8). No minor products were 
detected in any sample. For example, in the spectrum of 38a[F7], we did not observe any 
resonances of 38b[F7], which was the expected minor product. The small impurity peaks in the 
spectrum was from 38a[F9], which was the other quasidiastereomer in M-38a. This 
contamination was probably caused by incomplete demixing. These results suggested that: 1) 
both Brown allylations worked with excellent diastereoselectivities for both components of the 
starting mixture; 2) the two quasidiastereomers with a difference of one CF2 group could be well 
separated on the fluorous HPLC column.  
 
Conditions: PF-C8 column, 1 mL/min, 80:20 MeCN:H2O to 100% MeCN  
in 30 min, then isocratic MeCN for 30 min 
 
Figure 2.7. The analytical fluorous HPLC traces of M-38a (left) and M-38b (right) 
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Figure 2.8. 1H NMR spectra (δ 6.0–3.2 ppm, 500MHz, CDCl3) of quasidiastereomers of  
M-38a and M-38b after demixing  
 
The C5 configurations of allylation products M-38a and M-38b were next encoded by 
tagging with silyl groups. We used the null tag (TIPS) to protect M-38b and F7TIPS to protect 
M-38a. The use of TIPS minimizes the fluorine content of the tagged compounds. High fluorine 
content often causes a problem because compounds are too strongly retained in the fluorous 
HPLC column. Again, the tagged quasidiastereomers should have similar polarities. To find the 
best combination of tags and substrates, M-38a and M-38b were silylated with TIPS and F7TIPS 
on multi-milligram scale to give four products M-37c, M-37a, M-37b and M-37d in 49%, 70%, 
54% and 100% yields, respectively (Scheme 2.24). TLC data showed that M-37a and M-37b had 
smaller difference in Rf than M-37c and M-37d. Therefore, M-38a (1.80 g) and M-38b (1.60 g) 
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were treated with F7TIPSOTf and TIPSOTf in the presence of 2,6-lutidine to produce silyl ethers 
M-37a (2.50 g) and M-37b (1.80 g) in 97% and 92% yields after flash chromatography.  
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Scheme 2.24. Tagging reactions of M-38a and M-38b 
 
Fluorous mixtures M-37a (0.66 g) and M-37b (0.60 g) were next mixed in equimolar ratio 
to give M-37 as a mixture of four quasidiastereomers (Scheme 2.25). Mixture M-37 was treated 
with CH3COCl in MeOH to remove the TBS group.38 No reaction occurred at –10 °C, the same 
temperature used to desilylate the non-fluorous analog 21 in the single isomer synthesis (see 
Scheme 2.12). When the temperature was raised to 0 °C, two products were formed and isolated 
by flash chromatography: the less polar M-45 (34%) and the more polar M-46 (36%). The MS 
data of M-45 showed two components (45[F7F0] and 45[F9F0]) with masses of 732.4 and 782.4, 
indicating that M-45 was the TBS desilylation product from M-37b. The MS data of M-46 also 
showed two components (46[F7] and 46[F9]) with masses of 576.2 and 626.2, indicating that 
M-46 was the bis-desilylation product from M-37a with both TBS and F7TIPS (O5) groups fallen 
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off.  
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Scheme 2.25. Desilylation of M-37 by CH3COCl in MeOH 
 
In addition to desilylation, the F7TIPS/ F9TIPS groups that should be at O2 of M-45 and 
M-46 were suspected to transfer to O1. The desilylation reaction of M-37 was quenched with 
saturated aqueous NaHCO3, which might act as the base to initiate the silyl transfer (Scheme 
2.26). Three experiments were done to confirm the silyl transfer. First, treating alcohol M-45 
with Dess-Martin periodinane gave a ketone instead of an aldehyde, based on NMR analysis. 
Then, diol M-46 was treated with TBSCl in the presence of imidazole to protect the primary 
alcohol; however, no reaction occurred. At last, a small amount of M-45 was demixed by 
fluorous HPLC to give two alcohols 45[F7F0] and 45[F9F0]. Their 1H NMR spectra showed 
that the OH proton resonances were doublets instead of doublets of doublet, indicating that 
45[F7F0] and 45[F9F0] were secondary alcohols.  
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Scheme 2.26. The base-induced silyl transfer  
 
Due to the reactivity difference of the TIPS and F7TIPS groups at O5, we decided to 
desilylate M-37a and M-37b separately. Several desilylations of M-37a were tried as 
summarized in Scheme 2.27. The desilylation of M-37a with H2SiF6 and Et3N gave the desired 
primary alcohol M-47 and the undesired diol M-48 in 29% and 27% yields, respectively (entry 
1).49 The reaction of M-37a with BF3?Et2O in CHCl3 gave diol M-48 in 75% yield (entry 2).50 
No reaction took place when M-37a was treated with K2CO3 in MeOH (entry 3).51  
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Scheme 2.27. Desilylations of M-37a 
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To conserve M-37a and M-37b, we decided to try other TBS deprotection conditions on a 
single TBS ether. The needed compound 49 (560 mg) was prepared from aldehyde 19 by Brown 
allylation and the subsequent tagging reaction with F7TIPS group (Scheme 2.28).  
 
TBSO
OTIPS
OBn OH
TBSO
OTIPS
OBn
O
1) ()-Ipc2BAllyl, Et2O, 93 °C, 12 h
2) MeOH, then H2O2/NaOH, overnight
F7TIPSOTf, 2,6-lutidine
TBSO
OTIPS
OBn OTIPSF7
DCM, 10h, 0°C-rt
19 20a, 87%
49, 94%  
 
Scheme 2.28. Preparation of the single silyl ether 49  
 
Several desilylation reactions of 49 were tried as shown in Scheme 2.29. The desilylation of 
49 under acidic conditions such as HCl/EtOH,52 PPTS/MeOH53 or THF/H2O/HOAc54 afforded 
50 in only 20-30% yields (entry 1-3). The concomitant formation of diol 52 forced us to quench 
the reaction before the starting material 49 was completely consumed. The reaction of 49 with 
Lewis acid ZrCl4 gave fully desilylated product 53 in 46% yield in only 15 min (entry 4).55 The 
reaction of 49 with Zn(OTf)2 led to the decomposition of the starting material according to TLC 
analysis (entry 5). No reaction occurred when 49 was treated with CeCl3?7H2O and NaI in 
MeCN (entry 6). An interesting observation was that the desilylation of 49 with 1.0 equiv of 
TBAF in THF at –30 °C gave homoallylic alcohol 51 in 52% yield (entry 7).56,57 And when the 
mixture of 49 and TBAF (1.0 equiv) was stirred at 10 °C for 12 h, all three silyl groups were 
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removed to give triol 53 in 59% yield (entry 8). Since only 1.0 equiv of TBAF was added, the 
global desilylation was probably done by the base. None of these desilylations selectively gave 
the desired primary alcohol 50 in good yield.  
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Scheme 2.29. TBS desilylations of the single silyl ether 49  
 
The difference of desilylation products of entry 1-3 and entry 7 in Scheme 2.29 can be 
explained by the substituent effect of the silyl groups as a function of the reaction conditions. 
The desilylation under acidic conditions is accelerated by electron-donating substituents on the O 
atom of the silyloxy group. While under basic conditions, electron-withdrawing substituents on 
the Si atom accelerate the reaction (Figure 2.9). The F7TIPS group is supposed to be 
electron-poor because of its C3F7 group.58,59
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Figure 2.9. The reactivity difference of silyl groups under acidic/basic conditions 
 
Comparing the desilylation results in Scheme 2.29, we decided to use HCl/EtOH for the 
TBS deprotection of M-37a and M-37b since the reaction was fast and easy to perform. The 
desilylation of M-37a with 1.0 equiv of HCl in EtOH gave primary alcohol M-47 in 18% yield 
after flash chromatography (Scheme 2.30). The reaction was quenched with the buffer solution 
(pH = 7) to prevent the intramolecular silyl transfer. The low yield was due to the early 
quenching of the reaction before the formation of the diol. Approximately 58% of M-37a was 
recovered.  
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Scheme 2.30. Preparation of primary alcohol M-47  
 
Under the same conditions as desilylating M-37a, TBS ether M-37b was converted to the 
corresponding primary alcohol M-54 in 53% yield after flash chromatography (Scheme 2.31). 
Because the TIPS group (O5) of M-37b was not as labile as the F7TIPS group (O5) of M-37a, the 
diol was formed much more slowly. Thus we were able to run the reaction for a longer period of 
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time (7 h) to obtain M-54 in a higher yield than that of M-47. Approximately 30% of M-37b was 
recovered.  
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Scheme 2.31. Preparation of primary alcohol M-54  
 
The primary alcohols M-47 (106 mg) and M-54 (87 mg) were mixed in a ratio of 1/1 and 
subjected to Dess-Martin oxidation to afford aldehyde M-36 (160 mg) in 83% yield.60 To make 
the four triols with C13 being (R), M-36 was coupled with ester 5-(R) in the presence of LiCl 
and DBU in MeCN to afford α,β-unsaturated ester M-56 in 76% yield after flash 
chromatography (Scheme 2.32).  
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Scheme 2.32. Preparation of α,β-unsaturated ester M-56 
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The RCM reaction of ester M-56 with Grubbs 1st generation catalyst gave the cyclized 
product M-35 (93 mg) in 71% yield after flash chromatography (Scheme 2.33). The formation of 
the Δ9,10 double bond was confirmed by 1H NMR and MS analysis. However, unlike prior 
mixtures, lactone M-35 showed multiple spots on TLC.  
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Scheme 2.33. The RCM reaction of ester M-56  
 
Analysis of M-35 by fluorous HPLC gave four groups of peaks (Figure 2.10). It was 
suspected that each group of peaks represented a quasidiastereomer consisting of E/Z isomers 
(Δ9,10) and ring conformers. Since M-35 bears two double bonds, the rigid cyclic structure could 
possibly develop multiple conformers. However, after the reduction of Δ9,10 alkene of M-35, the 
ring tension would be relieved, thus less conformers of each quasidiastereomer would be formed. 
We expected that the reduction product of M-35 would have a less complicated HPLC trace.  
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Conditions: PF-C8 column, 1 mL/min, 80:20 MeCN:H2O to 100% MeCN  
in 30 min, then isocratic MeCN for 30 min 
 
Figure 2.10. The fluorous HPLC trace of lactone M-35 
 
A sample of lactone M-35 (5.0 mg) was demixed by preparative fluorous HPLC to give four 
quasidiastereomers 35[F7F0] (1.5 mg), 35[F9F0] (1.0 mg), 35[F7F7] (0.7 mg) and 35[F9F7] 
(1.0 mg). The 1H NMR resonances of H9 and H10 of the quasidiastereomers are listed in Table 
2.2. Although nearby minor products were also collected and combined with each of the four 
major product, the NMR spectra of the four saved fractions showed they were single compounds. 
This indicated that the minor products were probably conformers.  
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Table 2.2. Comparison of 1H NMR resonances for H9 and H10 of quasiisomers of M-35 a
 
O
C5H11
O
OBn
OTIPS
OTIPSF7
O
C5H11
O
OBn
OTIPS
OTIPSF9
O
C5H11
O
OBn
OTIPSF7
OTIPSF7
O
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O
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35[F7F0] 35[F9F0] 35[F7F7] 35[F9F7]
(13R)(13R)(13R)(13R)
(4R) (4R)(4R)(4R)
(5S) (5R)(5R) (5S)
(7R) (7S)(7S)(7R)
9
10
9
10
9
10
9
10
 
Quasiisomer Configuration δ (H9, ppm) J (H9, Hz) δ (H10, ppm) J (H10, Hz) 
35[F7F0] (4R,5S,7R,13R) 5.39 (ddd) 15.5, 9.0, 4.0 5.20 (ddd) 15.0, 9.5, 4.5
35[F9F0] (4R,5R,7R,13R) 5.57 (m) — 5.35 (m) — 
35[F7F7] (4R,5S,7S,13R) 5.36 (m) — 5.05 (ddd) 14.0, 9.0, 3.5
35[F9F7] (4R,5R,7S,13R) 5.40 (ddd) 15.5, 8.0, 5.0 5.18 (ddd) 14.5, 8.5, 3.5
a. NMR spectra were taken on a 500 MHz spectrometer with samples dissolved in CDCl3. 
 
The hydrogenation of M-35 with Pd/BaSO4 (1.0 equiv) in EtOH gave no product over 24 h 
according to MS analysis. To find the best conditions of this reaction, we decided to explore the 
reduction of a single lactone first.61 The single lactone 60 was prepared from primary alcohol 50, 
which was already made (Scheme 2.34). Dess-Martin oxidation of 50 afforded aldehyde 58 in 
83% yield. Masamune-Roush coupling of aldehyde 58 with ester 5-(S) in the presence of DBU 
and LiCl gave ester 59 in 76% yield. The RCM reaction of 59 with Grubbs 1st generation 
catalyst gave lactone 60 (72 mg) in 77% yield after flash chromatography. The Δ9,10 alkene of 60 
had only (E) configuration according to 1H NMR analysis. It was possible that the minor (Z) 
product was removed during purification by chromatography. The resonances of H9 and H10 of 
60 are listed in Scheme 2.34.  
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Scheme 2.34. Preparation of the single lactone 60 
 
Reductions of 60 by diimide and hydrogenations with palladium catalysts are summarized 
in Scheme 2.35. The diimide reduction of 60 with CuSO4 and NH2NH2 in EtOH gave 62 in 42% 
yield, in which the electron-poor Δ2,3 alkene was reduced (entry 1).10c The other diimide 
reduction of 60 with TsNHNH2 and NaOAc gave many new spots on TLC, indicating the 
possible decomposition of the starting material (entry 2).62 We next performed the 
Pd/BaSO4-catalyzed hydrogenation of 60 in MeOD-d4. 1H NMR analysis of the reaction mixture 
showed that no reaction occurred in 3 h (entry 3). This result further confirmed that the 
Rosenmond catalyst (Pd/BaSO4) did not work for this reduction. The hydrogenation of 60 with 
1.0 equiv of Pd/SrCO3, a similar catalyst to Pd/BaSO4, gave the desired product 61 in a yield of 
55% in only 1.5 h.63 No side product was formed, and approximately 30% of the starting 
material was recovered (entry 4). To confirm the chemoselectivity of Pd/SrCO3, we repeated the 
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reaction in entry 4 by running it for 20 h. The starting material 60 was completely consumed to 
give 61 and the over-reduced product 63 in yields of 23% and 40%, respectively (entry 5). Even 
though 63 was the major product after 20 h, Pd/SrCO3 still seemed to be selective to the Δ9,10 
alkene and could be used for the reduction of M-35.  
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O
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60
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OBn
OTIPSF7
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C5H11
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63
CuSO4, NH2NH2, EtOH, rt-70 °C, 20 h 62, 42%
TsNHNH2, NaOAc, DME, H2O, reflux, 4 h decomposition
Pd/SrCO3 (2 wt%, 1 equiv), H2, EtOH, 1.5 h 61, 55%
Pd/SrCO3 (2 wt%, 1 equiv), H2, EtOH, 20 h 61, 23%; 63, 40%
Pd/BaSO4 (5 wt%, 1 equiv), H2, MeOD-d4, 3 h no reaction
Condition YieldEntry
1
2
3
4
5  
 
Scheme 2.35. Reductions of the single lactone 60 
 
The hydrogenation of M-35 (15.0 mg) with Pd/SrCO3 (1.0 equiv) in EtOH was conducted 
with monitoring by fluorous HPLC (Scheme 2.36). Approximately 24 h after the reaction started, 
the several peaks of M-35 were completely converted to only four new peaks, indicating the 
formation of the products. The crude product M-64 (16.0 mg) was demixed by preparative 
fluorous HPLC to afford four quasidiastereomers 64[F7F0] (3.3 mg), 64[F9F0] (2.4 mg), 
64[F7F7] (2.9 mg) and 64[F9F7] (3.5 mg). The total yield of the reaction was 81% and the 
recovery of the demixing was 76%. As we expected, the HPLC trace of the reduction reaction 
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mixture (24 h) looked much simpler than that of M-35 (Figure 2.11). This result suggested that 
M-35 was indeed a mixture of isomers and conformers.  
F7F0: (5S,7R)
F9F0: (5R,7R)
F7F7: (5S,7S)
F9F7: (5R,7S)
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OTIPSF7,F9
M-35
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Scheme 2.36. The hydrogenation of M-35 and the demixing of M-64  
 
 
    Conditions: PF-C8 column, 1 mL/min, 80:20 MeCN:H2O to 100% MeCN  
    in 30 min, then isocratic MeCN for 30 min 
 
Figure 2.11. The fluorous HPLC trace of M-64  
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The four quasidiastereomers 64[F7F0], 64[F9F0], 64[F7F7] and 64[F9F7] were then 
individually deprotected with BF3?Et2O and EtSH in DCM at 35 ºC to give four final products 2a 
(0.9 mg), 2b (0.5 mg), 2c (0.7 mg) and 2d (1.0 mg) in 74%, 53%, 59% and 94% yields, 
respectively (Table 2.3). Product 2d is the same compound as the single isomer which was 
already made (see Section 2.2.2). Macrolactones 2a-2d were first purified by silica gel flash 
chromatography then by preparative HPLC with a Symmetry C-18 column (7.8 × 150 mm) 
under gradient conditions. The HPLC purification was done to remove nonpolar impurities such 
as grease.  
To make the other four triols with C13 being (S), aldehyde M-36 was then coupled with 
ester 5-(S) in the presence of LiCl and DBU in MeCN to afford α,β-unsaturated ester M-65 in 
79% yield after flash chromatography (Scheme 2.37). The RCM reaction of ester M-65 with 
Grubbs 1st generation catalyst gave the cyclized product M-66 in 86% yield after flash 
chromatography. The hydrogenation of M-66 (25.0 mg) with Pd/SrCO3 (1.0 equiv) in EtOH gave 
four quasidiastereomers 67[F7F0] (5.4 mg), 67[F9F0] (4.5 mg), 67[F7F7] (5.0 mg) and 
67[F9F7] (4.4 mg) after demixing by preparative fluorous HPLC. The total yield of the 
hydrogenation was 77%. 
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Scheme 2.37. The preparation and demixing of M-67 
 
The four quasidiastereomers 67[F7F0], 67[F9F0], 67[F7F7] and 67[F9F7] were 
individually deprotected with BF3?Et2O and EtSH in DCM at 35 ºC followed by purification by 
preparative HPLC with a Symmetry C-18 column (7.8 × 150 mm) under gradient conditions to 
give four products 2e (1.4 mg), 2f (0.6 mg), 2g (0.9 mg) and 2h (1.1 mg) in 70%, 38%, 57% and 
83% yields, respectively (Table 2.3).  
The structures of the eight triols 2a-2h were confirmed by 1H NMR, 13C NMR, COSY and 
HMQC experiments. The 1H and 13C NMR spectra of 2a-2h are all different. The resonances 
were assigned also based on 2D NMR experiments (COSY and HMQC). The comparison of 
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resonances of the eight synthetic isomers with those of Sch725674 are shown in Table 2.3. The 
1H NMR data of the synthetic samples show that the olefin protons (H2 and H3), the methine 
protons (H4, H5, H7 and H13) and one methylene proton (H6) have all different chemical shifts. 
Large differences of δ are observed at H4 (4.48, 4.16, 4.55, 4.27, 4.46, 4.03, 4.47 and 4.26 ppm; 
Δδmax = 0.39 ppm), H7 (3.99, 3.78, 3.38, 3.78, 3.67, 3.47, 3.64 and 3.92 ppm; Δδmax = 0.61 ppm) 
and one H6 (1.83, 1.63, 2.02, 1.73, 2.02, 1.77, 1.71 and 1.70 ppm; Δδmax = 0.39 ppm). The 
upfield proton resonances are not distinctive because of overlapping. In the 13C NMR spectra, the 
differences of δ are normally less than 3 ppm (for example, δ (C4) are 76.0, 77.6, 75.0, 75.4, 75.7, 
77.8, 74.7, 75.8 ppm, Δδmax = 3.1 ppm), except that a large difference of δ (C6) of 2b (42.0 ppm) 
and 2f (35.9 ppm) was observed (Δδ = 6.1 ppm).  
 
Table 2.3. Comparison of the NMR data of the natural product and 2a-2h  
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Table 2.3. Comparison of the NMR data of the natural product and 2a-2h (continued)  
 
δ ppm (multiplicity, J Hz) 
 
H a Sch725674 2a 2b 2c 2d 2e 2f 2g 2h 
2 
6.07 (dd, 
15.8, 1.6) 
6.08 (dd, 
15.5, 1.5)
6.11(dd, 
15.5, 1.0) 
6.14 (dd, 
15.5, 1.5)
6.12 (dd, 
16.0, 1.5)
6.06 (dd, 
15.6, 2.1)
6.09 (dd, 
16.2, 1.8) 
6.09 (dd, 
15.6, 1.8)
6.11 (dd, 
15.6, 1.2)
3 
6.86 (dd, 
15.8, 6.0) 
6.87 (dd, 
16.0, 6.0)
6.91 (dd, 
16.0, 6.5) 
6.95 (dd, 
16.0, 4.5)
7.07 (dd, 
16.0, 5.5)
7.01 (dd, 
16.2, 3.6)
6.96 (dd, 
15.6, 6.0) 
6.93 (dd, 
15.6, 4.2)
7.04 (dd, 
15.6, 5.4)
4 
4.48 (ddd, 
6.0, 3.0, 
1.6) 
4.48 (ddd, 
6.0, 3.0, 
1.5) 
4.16 (td, 
6.5, 1.0) 
4.55 (dddd, 
4.3, 2.6, 
1.8, 0.9) 
4.27 (td, 
5.0, 1.0)
4.46 (dt, 
3.6, 2.1) 
4.03 (ddd, 
7.8, 6.0, 
1.8) 
4.47 (ddd, 
4.8, 3.0, 
1.8) 
4.26 
(ddd, 6.6, 
5.4, 1.2)
5 
3.84 (ddd, 
6.0, 4.7, 
3.0) 
3.85 (ddd, 
6.0, 4.5, 
3.5) 
3.82 (ddd, 
8.7, 5.7, 
3.7) 
3.89 (dt, 
9.0, 2.5) 
3.90 (td, 
6.0, 3.0)
3.95 (ddd, 
8.4, 4.2, 
2.4) 
3.55 (td, 
8.4, 2.4) 
3.89 (ddd, 
7.2, 4.2, 
3.0) 
3.77 (dt, 
7.2, 4.2)
6 
1.82 (ddd, 
14.7, 6.5, 
6.0), 1.65 
(m) 
1.83 (ddd, 
14.6, 6.2, 
6.2), 1.65 
(m) 
1.63 (ddd, 
14.0, 9.0, 
3.5), 1.43 
(m) 
2.02 (ddd, 
14.5, 
9.0, 2.0), 
1.29 (m) 
1.73 (m),
1.68 (m)
2.02 (ddd, 
13.8, 7.8, 
4.2), 1.53 
(ddd, 13.8, 
7.8, 4.8) 
1.77 (ddd, 
15.0, 9.0, 
3.0), 1.56 
(ddd, 14.4, 
9.6, 1.8) 
1.71 (ddd, 
14.4, 6.6, 
4.2), 1.36 
(ddd, 14.4, 
9.0, 4.8) 
1.70 
(t, 5.1) 
7 
3.98 
(quint, 6.5) 
3.99 
(quint, 
6.5) 
3.78 (m) 
3.38 (ddt, 
11.6, 7.7, 
2.8) 
3.78 (tt, 
8.0, 3.5)
3.67 (tt, 
7.8, 4.2) 
3.47 (ddt, 
9.0, 7.2, 
3.0) 
3.64 (dq, 
10.2, 5.4)
3.92 
(quint, 
6.0) 
13 
4.94 
(dddd, 9.8, 
7.5, 5.0, 
2.2) 
4.95 
(dddd, 9.5, 
7.5, 4.5, 
2.0) 
5.02 (m) 
4.94 (tt, 
8.4, 5.6) 
4.97 
(dddd, 
16.5, 9.0, 
5.5, 3.5)
4.95 (ddt, 
13.2, 5.4, 
2.4) 
4.92 (m) 
5.00 (ddt, 
13.8, 4.8, 
3.0) 
4.95 (ddt, 
12.6, 7.2, 
2.4) 
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Table 2.3. Comparison of the NMR data of the natural product and 2a-2h (continued)  
 
C a Sch725674 2a 2b 2c 2d 2e 2f 2g 2h 
1 168.4 168.5 168.3 169.1 167.8 168.1 168.1 168.1 168.1 
2 123.1 123.1 124.3 121.8 123.3 122.4 123.1 123.4 123.5 
3 149.3 149.3 148.4 150.0 149.8 150.1 149.3 148.7 148.7 
4 76.0 76.0 77.6 75.0 75.4 75.7 77.8 74.7 75.8 
5 72.9 72.9 73.4 72.1 73.9 72.1 74.7 72.4 74.4 
6 38.3 38.3 42.0 40.5 38.3 39.5 35.9 39.2 37.9 
7 69.5 69.5 67.7 68.8 69.0 68.8 68.5 68.9 69.2 
8 36.8 36.8 37.0 35.9 35.8 35.0 35.1 36.4 36.9 
9 25.8 25.8 25.4 24.6 24.6 23.8 24.3 24.3 25.4 
10 29.5 29.5 30.1 27.3 27.9 28.7 30.5 30.3 29.7 
11 27.0 27.0 26.4 26.5 26.6 26.6 27.7 26.0 26.6 
12 34.1 34.1 34.5 33.9 33.7 33.0 33.4 34.4 34.2 
13 77.6 77.6 77.5 75.6 75.9 76.1 75.9 77.4 77.6 
14 36.5 36.5 36.0 36.2 35.6 34.7 35.6 35.7 36.3 
15 26.4 26.4 26.5 24.8 25.2 24.9 26.5 26.6 26.4 
16 32.9 33.0 32.9 33.1 33.1 32.8 33.1 32.9 33.0 
17 23.8 23.8 23.8 23.8 23.8 23.5 23.9 23.8 23.8 
18 14.5 14.5 14.6 14.1 14.5 14.5 14.5 14.5 14.5 
 
a.  NMR spectra were taken on a 500 or 600 MHz spectrometer with samples dissolved in MeOD-d4.  
 
The 1H and 13C resonances of 2a are identical to those of Sch725674 in terms of δ and J 
values, thus we expect 2a to be either Sch725674 itself or its enantiomer. The confirmation of 
the absolute configurations of Sch725674 requires other data such as the optical rotation of the 
natural sample, for which we do not have. However, based on the “13R law” for 14-membered 
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macrolactones, 2a is very likely to be the natural product since the configuration of C13 is (R).  
 
2.3  CONCLUSIONS 
 
Fluorous mixture synthesis (FMS) was applied to the synthesis of eight isomers of 
14-membered macrolactone Sch725674. A single diastereomer of Sch725674 was prepared first 
by traditional solution phase synthesis. In the FMS, stereoisomeric starting materials were tagged 
with different fluorous TIPS groups. The tagged quasidiastereomers were mixed and the mixture 
underwent a series of steps to make the fluorous tagged macrolactones, which were separated by 
fluorous HPLC followed by individual deprotections to provide the eight final products. The 
single isomer synthesis took 18 steps and the FMS of eight compounds only took 32 steps, with 
the longest linear sequence of 15 steps. The NMR data of the eight synthetic macrolactones were 
compared with those of Sch725674. Together with the 13R rule, the data show that the absolute 
configuration of Sch725674 is (4R,5S,7R,13R).  
 
 
2.4  EXPERIMENTAL 
 
2.4.1  General Information. 
All reactions were performed under an atmosphere of argon unless the reaction solvent 
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contained water. Reaction solvents were freshly dried either by distillation or by passing through 
an activated alumina column. DCM, THF, Et2O, toluene were dried by activated alumina 
according to Pangborn, A.; Giardello, M. A.; Grubbs, R, H.; Rosen, R. K.; Timmers, F.; J. 
Organometallics, 1996, 15, 1518. Products were analyzed by 1H NMR, 13C NMR, 19F NMR, 
FT-IR, high and low resolution mass spectroscopy, HPLC and TLC.  
1H and 13C NMR spectra were taken on Bruker models Avance DPX 300 (300 MHz), Avance 
300 (300 MHz), Avance DRX 500 (500 MHz) or Avance 600 (600 MHz) NMR spectrometers. 
Chemical shifts are reported in parts per million (ppm) downfield relative to TMS using the 
residue solvent proton resonance of CDCl3 (7.26 ppm for 1H NMR and 77.0 ppm for 13C NMR) 
or MeOD-d4 (3.31 ppm for 1H NMR and 49.2 ppm for 13C NMR) as internal standards. In 
reporting spectral data the format (δ) chemical shift (multiplicity, J values in Hz, integration) 
was used with the following abbreviations: s = singlet, d = doublet, t = triplet, q = quartet, quint 
= quintuplet, m = multiplet. Infrared spectra were taken on a Mattson Genesis Series FTIR using 
thin film on NaCl plate. Peaks are reported in wavenumbers (cm–1). High resolution mass spectra 
were reported in units of m/z, and were obtained on a V/G 70/70 double focusing machine, an 
Applied Biosystems 4700 instrument, or a Bruker Daltonics 12 Tesla FT-MS. HPLC analysis 
was performed on a Waters 600E Controller system with a Waters 2487 dual λ absorbance 
detector using a FluoroFlashTM PF-C8 HPLC column (5 μm, 10 Å, 4.6 × 150 mm). LC-MS 
spectra were obtained on an Agilent HP 1100 series LC-MSD using ESI mode. Solvent from the 
demixing was removed by the ThermoSavant SC210A SpeedVac Plus.  
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All chemical names (except fluorous mixtures) were generated by ChemDraw Ultra 10.0. In 
the numbering of the following text, “M” is used to denote a mixture of fluorous tagged 
quasiisomers. The letter “F” followed by a number (0, 7 or 9) is an abbreviation of the FTIPS 
group with a certain fluorine content (the regular TIPS group is often displayed as F0TIPS). A 
single component in the mixture is designated as the combination of a number and abbreviations 
of flourous tags. For example, “35[F9F7]” represents a quasiisomer in mixture M-35 that bears 
F9TIPS and F7TIPS groups.  
 
2.4.2  General Experimental Procedures.  
 
General conditions for analytical fluorous HPLC:  
A solution of the fluorous sample in 80:20 CH3CN:H2O was injected into the Waters HPLC 
system (Waters 600 Controller and Waters 2487 dual λ Absorbance Detector) with a 
FluoroFlashTM PF-C8 column (5 μm, 10 Å, 4.6 × 150 mm). The flow rate was 1.0 mL/min. The 
UV wavelengths for detection were 220 nm and 254 nm. The two frequently used elution 
conditions were:  
Condition 1: The gradient elution started at 80% CH3CN-20% H2O, and changed to 100% 
CH3CN in 30 min. The elution lasted for another 60 min with 100% CH3CN.  
Condition 2: The isocratic elution stays at 100% CH3CN (for a quick test).  
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General conditions for preparative fluorous HPLC (demixing):  
A solution of the fluorous mixture in 80:20 CH3CN:H2O was injected into the Waters 
HPLC system (Waters 600 controller and Waters 2487 dual ? absorbance detector) with a 
FluoroFlash
TM
 PF-C8 column (20 ? 250 mm). The gradient elution started at 80% CH3CN-20% 
H2O, and changed to 100% CH3CN in 30 min. The elution lasted for another 60 min with 100% 
CH3CN. The flow rate was 10.0 mL/min. The UV wavelengths for detection were 220 nm and 
254 nm. Fractions containing fluorous compounds were collected in culture tubes (16 ? 150 mm) 
and the solvent was removed by a ThermoSavant SC210A SpeedVac
 
Plus.  
 
General conditions for preparative reverse phase HPLC: 
A solution of the crude final triol 2 (purified by flash column first) in 20:80 CH3CN:H2O 
was injected to the Waters HPLC system (Waters 600 Controller and Waters 2487 dual ? 
Absorbance Detector) with the Waters SymmetryPrep
TM
 C18 column (7 μm, 7.8 ? 150 mm). The 
gradient elution started at 20% CH3CN-80% H2O, and changed to 100% CH3CN in 30 min. The 
elution lasted for another 30 min with 100% CH3CN. The flow rate was 4.0 mL/min. The UV 
wavelengths for detection were 220 nm and 254 nm. The fractions containing the product were 
collected in culture tubes (16 ? 150 mm) and the solvent was removed by a ThermoSavant 
SC210A SpeedVac
 
Plus.  
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2.4.3  Specific Experimental Procedures and Compound Data:  
(Compounds 30, 31, 49, 50, 53, 58-63 were model compounds or side products. Compounds 
39-anti-F0, 39-syn-F0, 39-syn-F7 and 39-syn-F9 were prepared for TLC experiment only. 
These compounds were only characterized by 
1
H NMR. Compounds 38a[F7], 38a[F9], 38b[F7] 
and 38b[F9] were quasidiastereomers after demixing, and they were only characterized by 1H 
NMR and HRMS.)   
O
O O
 
(R)-2,2-Dimethyl-1,3-dioxolane-4-carbaldehyde (13):27,28 
A 1 L three-necked flask equipped with a mechanical stirrer was filled with dry DCM (250 
mL) followed by addition of 1,2:5,6-di-O-isopropylidene-D-mannitol 12 (25.0 g, 194 mmol) and 
saturated aqueous NaHCO3 (10.4 mL). NaIO4 (40.8 g, 191 mmol) was added portionwise to 
make sure that the temperature of the suspension did not exceed 35 °C. The mixture was stirred 
at 23 °C for 2 h and then quenched with MgSO4 (12.5 g, 104 mmol). The mixture was stirred for 
another 20 min. The slurry was vacuum-filtered, and the filter cake was removed, and transferred 
back into the three-necked flask. DCM (100 mL) was added, and the resulting slurry was stirred 
for 10 min. The slurry was vacuum-filtered again and the filtrate was combined with the previous 
one. The solution was concentrated to yield aldehyde 13 (25.3 g, approximately 100%, 
containing very little DCM) as a colorless oil. The product polymerized on storage so it was 
subjected to allylation immediately: MS (EI) m/z [M
+?] 115; HRMS (EI) m/z [M+?] calcd for 
C5H7O3: 115.0395, found 115.0394.  
 
O
O
OH  
(R/S)-1-((R)-2,2-dimethyl-1,3-dioxolan-4-yl)but-3-en-1-ol (14):30
A 1 L round bottom flask was filled with dry diethyl ether (200 mL) followed by addition of 
aldehyde 13 (25.3 g, 194 mmol). At –78 °C, allylMgBr (1M in Et2O, 253 mL, 253 mmol) was 
added dropwise. The reaction was slowly warmed to 23 °C and stirred for 4 h. The reaction was 
quenched by addition of a saturated NH4Cl aqueous solution. The layers were separated and the 
aqueous layer was extracted with diethyl ether (2x). The combined organic fractions were dried 
over MgSO4. The solution was concentrated and the crude product was purified by silica gel 
flash chromatography eluting with hexane/EtOAc (4:1) to yield a mixture of two unseparable 
diastereomers 14 (23.2 g, 70 %, with a diastereomeric ratio of 1.4/1.0 anti/syn based on 1H NMR) 
as a yellow oil: 1H NMR (see appendix); MS (EI) m/z [M+?] 157; HRMS (EI) m/z [M+?] calcd for 
C8H13O3: 157.0865, found 157.0862.  
 
O
O
OBn  
(R)-4-((R/S)-1-(Benzyloxy)but-3-enyl)-2,2-dimethyl-1,3-dioxolane (15): 31,32
A 1 L round bottom flask was filled with dry THF (300 mL) followed by addition of 
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homoallylic alcohol 14 (23.0 g, 134 mmol, 1.0:0.70 mixture of diastereomers). At room 
temperature benzyl bromide (75.1 g, 307 mmol), tetrabutylammonium iodide (1.06 g, 2.00 mmol) 
and NaH (60 w% in mineral oil, 17.5 g, 174 mmol) were added. The mixture was refluxed for 12 
h. The reaction was quenched by addition of EtOAc (100 mL) and was extracted with diethyl 
ether (2x). The combined organic fractions were dried over MgSO4. The solution was 
concentrated and the crude mixture was purified by silica gel flash chromatography eluting with 
hexane/EtOAc (15:1) to yield 15 (35.0 g, 76 %, 1.0:0.61 mixture of (2R,3S) and (2R,3R) isomers 
based on 1H NMR) as a colorless oil: 1H NMR (see appendix). Separation of a small sample of 
15 (70.0 mg) by silica gel flash chromatography with hexane/EtOAc (20:1) afforded 15-anti 
(40.0 mg, less polar) and 15-syn (26.0 mg, more polar) as two diastereomers.  
 
O
O
OBn  
(R)-4-((S)-1-(Benzyloxy)but-3-enyl)-2,2-dimethyl-1,3-dioxolane (15-anti):  
[α]D25 +26.6 (c 0.20, CHCl3); 1H NMR (300 MHz, CDCl3) δ 7.40–7.25 (m, 5H), 5.90 (ddt, J = 
17.4, 10.2, 7.2 Hz, 1H), 5.15 (dd, J = 17.1, 1.5 Hz, 1H), 5.10 (dd, J = 10.2, 1.2 Hz, 1H), 4.66 (d, 
J = 11.4, 1H), 4.59 (d, J = 11.4 Hz, 1H), 4.11 (q, J = 6.3 Hz, 1H), 4.04 (dd, J = 7.8, 6.3 Hz, 1H), 
3.90 (dd, J = 7.8, 6.0 Hz, 1H), 3.57 (q, J = 5.7 Hz, 1H), 2.50–2.30 (m, 2H), 1.42 (s, 3H), 1.35 (s, 
3H); 13C NMR (75 MHz, CDCl3) δ 138.4, 134.2, 128.3, 127.8, 127.7, 117.5, 109.1, 78.9, 77.2, 
72.5, 66.4, 35.6, 26.6, 25.4; IR (thin film) 3055, 2987, 1641, 1496, 1373, 1265, 1073 cm–1; MS 
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(EI) m/z [M+?] 262; HRMS (EI) m/z [M+?] calcd for C16H22O3: 262.1569, found 262.1578.  
 
O
O
OBn  
(R)-4-((R)-1-(Benzyloxy)but-3-enyl)-2,2-dimethyl-1,3-dioxolane (15-syn):  
[α]D25 +13.0 (c 0.39, CHCl3); 1H NMR (300 MHz, CDCl3) δ 7.40–7.26 (m, 5H), 5.88 (ddt, J = 
17.1, 10.2, 6.9 Hz, 1H), 5.11 (dd, J = 17.1, 1.8 Hz, 1H), 5.07 (dd, J = 9.3, 1.2 Hz, 1H), 4.73 (d, J 
= 11.7, 1H), 4.65 (d, J = 12.0 Hz, 1H), 4.22 (q, J = 6.6 Hz, 1H), 3.99 (dd, J = 8.4, 6.6 Hz, 1H), 
3.71 (dd, J = 8.1, 7.5 Hz, 1H), 3.51 (td, J = 6.9, 4.5 Hz, 1H), 2.38–2.19 (m, 2H), 1.44 (s, 3H), 
1.37 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 138.6, 134.6, 128.3, 127.8, 127.6, 117.2, 109.3, 79.3, 
77.9, 72.5, 65.8, 35.3, 26.5, 25.4; IR (thin film) 3031, 2934, 1641, 1496, 1373, 1265, 1212, 1071 
cm–1; MS (EI) m/z [M+?] 262; HRMS (EI) m/z [M+?] calcd for C16H22O3: 262.1569, found 
262.1568.  
 
OH
HO
OBn  
(2R,3R/S)-3-(Benzyloxy)hex-5-ene-1,2-diol (8):33
To a solution of 15 (34.0 g, 130 mmol, 1.0:0.61 mixture of (2R,3S) and (2R,3R) isomers) in 
DCM (400 mL) at 23 °C was added FeCl3?6H2O (123 mg, 454 mmol). The resulting 
yellow-to-amber suspension was stirred for 2 h and the reaction was quenched by the addition of 
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saturated aqueous NaHCO3 (150 mL). The aqueous layer was extracted three times with DCM, 
and the combined organics were washed with brine, dried over MgSO4, and concentrated under 
reduced pressure. The resulting oil was redissolved in a minimum amount of DCM and passed 
through a short silica gel plug to remove any remaining iron species. The solution was 
concentrated and the crude mixture was purified by silica gel flash chromatography eluting with 
hexane/EtOAc (2:1) to yield a mixture of two unseparable diastereomers 8 (18.0 g, 63%, 
1.0:0.44 mixture of (2R,3S) and (2R,3R) isomers based on 1H NMR) as a colorless oil: 1H NMR 
(see appendix).  
 
OH
HO
OBn  
(2R,3S)-3-(Benzyloxy)hex-5-ene-1,2-diol (8-anti):  
The same procedure as 8 was followed by employing 15-anti (40.0 mg, 0.152 mmol), 
FeCl3.6H2O (144 mg, 0.534 mmol). The title compound 8-anti was prepared as a colorless oil 
(33.0 mg, 97%): [α]D25 +20.4 (c 0.22, CHCl3); 1H NMR (300 MHz, CDCl3) δ 7.40–7.28 (m, 5H), 
5.88 (ddt, J = 17.1, 10.2, 7.2 Hz, 1H), 5.16 (dd, J = 17.7, 1.5 Hz, 1H), 5.12 (dd, J = 9.3, 0.9 Hz, 
1H), 4.68 (d, J = 11.4, 1H), 4.52 (d, J = 11.4 Hz, 1H), 3.83–3.69 (m, 3H), 3.65 (q, J = 5.5 Hz, 
1H), 2.53–2.32 (m, 2H), 2.47 (d, J = 6.0 Hz, 1H), 2.15 (br, dd, J = 7.2, 4.5 Hz, 1H); 13C NMR 
(75 MHz, CDCl3) δ 138.0, 134.1, 128.5, 128.0, 127.9, 117.8, 80.6, 72.5, 72.3, 63.2, 35.1; IR (thin 
film) 3579, 3054, 2986, 1422, 1265, 1076, 896 cm–1; MS (EI) m/z [M+?] 222; HRMS (EI) m/z 
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[M+?] calcd for C13H18O3: 222.1256, found 222.1261.  
 
OH
HO
OBn  
(2R,3R)-3-(Benzyloxy)hex-5-ene-1,2-diol (8-syn):  
The same procedure as 8 was followed by employing 15-syn (26.0 mg, 0.0991 mmol), 
FeCl3.6H2O (93.7 mg, 0.347 mmol). The title compound 8-syn was prepared as a colorless oil 
(22.0 mg, 100%): [α]D25 –40.0 (c 0.15, CHCl3); 1H NMR (300 MHz, CDCl3) δ 7.40–7.25 (m, 
5H), 5.87 (ddt, J = 17.1, 10.2, 7.2 Hz, 1H), 5.17 (dd, J = 17.4, 1.5 Hz, 1H), 5.12 (dd, J = 10.2, 
1.2 Hz, 1H), 4.73 (d, J = 11.4, 1H), 4.47 (d, J = 11.4 Hz, 1H), 3.87–3.60 (m, 3H), 3.56 (q, J = 
5.4 Hz, 1H), 2.58 (br, s, 1H), 2.57–2.35 (m, 2H), 2.11 (br, s, 1H); 13C NMR (75 MHz, CDCl3) δ 
137.8, 133.8, 128.6, 128.0, 128.0, 118.0, 79.0, 72.5, 72.1, 63.8, 34.6; IR (thin film) 3426, 3054, 
2986, 1641, 1422, 1265, 1071, 896 cm–1; MS (ESI) m/z [M + Na]+ 245; HRMS (ESI) m/z [M + 
Na]+ calcd for C13H18NaO3: 245.1154, found 245.1158.  
 
OH
TBSO
OBn  
(2R,3R/S)-3-(Benzyloxy)-1-(tert-butyldimethylsilyloxy)hex-5-en-2-ol (17):  
To a solution of 8 (17.0 g, 76.5 mmol, 1.0:0.44 mixture of (2R,3S) and (2R,3R) isomers) in 
DCM (400 mL) at 23 °C was added imidazole (10.4 g, 153 mmol). The suspension was stirred 
until the imidazole was completely dissolved. The solution was cooled to 0 °C and TBSCl (12.7 
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g, 84.1 mmol) was added. The solution was slowly warmed to 23 °C and was stirred for 30 min. 
The reaction was quenched by addition of H2O (100 mL) and was extracted with DCM (2x). The 
combined organic fractions were dried over MgSO4. The solution was concentrated and the 
crude product was purified by silica gel flash chromatography eluting with hexane/EtOAc (10:1) 
to yield 17 (23.0 g, 89%, 1.0:0.84 mixture of (2R,3S) and (2R,3R) isomers based on 1H NMR) as 
a colorless oil: 1H NMR (see appendix). The first separation of 17 (10.6 g) by silica gel flash 
chromatography with pentane/Et2O (10:1) afforded diastereomers 17-anti (2.48 g, less polar) and 
17-syn (3.35 g, more polar), and unseparated mixture (4.77 g, combined with the rest of 17). The 
second separation of 17 (17.1 g) afforded 17-anti (4.50 g), 17-syn (4.50 g), and unseparated 
mixture (8.10 g). The characterizations of the two diastereomers of 17 are shown below.  
 
OH
TBSO
OBn  
(2R,3S)-3-(Benzyloxy)-1-(tert-butyldimethylsilyloxy)hex-5-en-2-ol (17-anti):  
[α]D25 +34.2 (c 0.42, CHCl3); 1H NMR (300 MHz, CDCl3) δ 7.27–7.19 (m, 5H), 5.92 (ddt, J = 
17.1, 10.2, 7.0 Hz, 1H), 5.17 (dd, J = 17.1, 2.0 Hz, 1H), 5.11 (dd, J = 10.2, 2.0 Hz, 1H), 4.65 (d, 
J = 11.4, 1H), 4.53 (d, J = 11.4 Hz, 1H), 3.77 (quint, J = 6.6 Hz, 1H), 3.68 (m, 2H), 3.53 (q, J = 
6.1 Hz, 1H), 2.56–2.38 (m, 3H), 0.83 (s, 9H), 0.00 (s, 6H); 13C NMR (75 MHz, CDCl3) δ 134.8, 
128.4, 127.8, 127.6, 117.2, 78.8, 72.5, 72.2, 63.7, 34.7, 25.9, –5.4; IR (thin film) 3564, 3471, 
3068, 3032, 2953, 2858, 1641, 1496, 1256, 1096, 838 cm–1; MS (ESI) m/z [M + Na]+ 359; 
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HRMS (ESI) m/z [M + Na]+ calcd for C19H32NaO3Si: 359.2018, found 359.2041.  
 
OH
TBSO
OBn  
(2R,3R)-3-(Benzyloxy)-1-(tert-butyldimethylsilyloxy)hex-5-en-2-ol (17-syn):  
[α]D25 –31.0 (c 0.19, CHCl3); 1H NMR (300 MHz, CDCl3) δ 7.36–7.27 (m, 5H), 5.87 (ddt, J = 
17.2, 10.1, 7.0 Hz, 1H), 5.15 (dd, J = 17.1, 2.0 Hz, 1H), 5.10 (dd, J = 10.3, 1.7 Hz, 1H), 4.69 (d, 
J = 11.4, 1H), 4.55 (d, J = 11.4 Hz, 1H), 3.75–3.60 (m, 5H), 2.55–2.40 (m, 2H), 0.90 (s, 9H), 
0.07 (s, 6H); 13C NMR (75 MHz, CDCl3) δ 134.7, 128.4, 127.9, 127.7, 117.3, 78.1, 72.7, 72.5, 
63.8, 35.0, 25.9, –5.4; IR (thin film) 3447, 3054, 2954, 2931, 2858, 1641, 1468, 1265, 1110, 839 
cm–1; MS (ESI) m/z [M + Na]+ 359; HRMS (ESI) m/z [M + Na]+ calcd for C19H32NaO3Si: 
359.2018, found 359.2044.  
 
OTIPS
TBSO
OBn  
(R)-6-((R)-1-(Benzyloxy)but-3-enyl)-8,8-diisopropyl-2,2,3,3,9-pentamethyl-4,7-dioxa-3,8-di-
siladecane (7):  
A 500 mL round bottom flask was filled with DCM (200 mL), followed by 17-syn (3.20 g, 
9.51 mmol). The solution was cooled to 0 °C and 2,6-lutidine (5.17 mL, 44.6 mmol) was added. 
TIPSOTf (7.99 mL, 29.7 mmol) was added, and stirring was continued for 3 hours. The reaction 
was quenched with H2O (100 mL). The layers were separated and the aqueous layer was 
 152
extracted with DCM (2x). The combined organic layers were dried over MgSO4, the resulting 
solution was concentrated and the crude product was purified by silica gel flash chromatography 
eluting with hexanes/EtOAc (30:1) to yield 7 (4.54 g, 96%) as a colorless oil: [α]D25 +18.2 (c 
0.33, CHCl3); 1H NMR (300 MHz, CDCl3) δ 7.33–7.24 (m, 5H), 5.88 (ddt, J = 17.1, 10.2, 6.9 
Hz, 1H), 5.09 (dd, J = 17.1, 1.8 Hz, 1H), 5.03 (dd, J = 10.2, 1.2 Hz, 1H), 4.60 (s, 2H), 4.00 (ddd, 
J = 7.2, 4.2, 3.3 Hz, 1H), 3.87 (dd, J = 10.5, 3.3 Hz, 1H), 3.59 (dd, J = 10.2, 6.6 Hz, 1H), 3.53 
(ddd, J = 9.1, 4.0, 3.4 Hz, 1H), 2.52 (dddt, J = 14.4, 6.9, 3.0, 1.5, 1H), 2.17 (dddt, J = 16.2, 9.0, 
7.2, 0.9, 1H), 1.11–1.02 (m, 3H), 1.06 (s, 18H), 0.90 (s, 9H), 0.050 (s, 3H), 0.047 (s, 3H); 13C 
NMR (75 MHz, CDCl3) δ 138.9, 136.5, 128.2, 127.7, 127.5, 116.3, 81.0, 74.5, 72.5, 64.6, 34.1, 
26.0, 18.4, 18.2, 12.6, –5.38, –5.41; IR (thin film) 3053, 2945, 2865, 1641, 1496, 1465, 1264, 
1095, 838 cm–1; MS (ESI) m/z [M + Na]+ 515; HRMS (ESI) m/z [M + Na]+ calcd for 
C28H52NaO3Si2: 515.3353, found 515.3330.  
 
OTIPS
TBSO O
OBn  
(3R,4R)-3-(Benzyloxy)-5-(tert-butyldimethylsilyloxy)-4-(triisopropylsilyloxy)pentanal (6): 34
Ozone was bubbled through a solution of the alkene 7 (4.00 g, 8.12 mmol) in DCM (150 
mL) at –78 °C. After the solution turned blue (about 20 min), the vessel was removed from the 
ozone atmosphere and the mixture was bubbled with argon for 20 min. Ph3P (2.77 g, 10.6 mmol) 
was added. The reaction mixture was slowly warmed up to 23 °C and stirred for 12 h. The 
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solvent was removed under reduced pressure. The crude product was purified by silica gel flash 
chromatography eluting with hexanes/EtOAc (20:1) to yield aldehyde 6 (2.2 g, 55%) as a 
colorless oil: [α]D25 +33.0 (c 0.10, CHCl3); 1H NMR (300 MHz, CDCl3) δ 9.77 (br, dd, J = 2.4, 
1.2 Hz, 1H), 7.50–7.26 (m, 5H), 4.62 (s, 2H), 4.11 (ddd, J = 8.1, 4.2, 4.2 Hz, 1H), 4.04 (dt, J = 
5.4, 3.3 Hz, 1H), 3.87 (dd, J = 10.5, 3.3 Hz, 1H), 3.63 (dd, J = 10.5, 6.0 Hz, 1H), 2.82 (ddd, J = 
16.8, 3.3, 1.2 Hz, 1H), 2.63 (ddd, J = 16.8, 8.7, 2.1 Hz, 1H), 1.14–0.98 (m, 3H), 1.05 (s, 18H), 
0.91 (s, 9H), 0.06 (s, 6H); 13C NMR (75 MHz, CDCl3) δ 201.3, 138.1, 128.3, 127.8, 127.7, 75.5, 
73.5, 72.4, 64.2, 44.5, 25.9, 18.3, 18.1, 12.5, –5.5; IR (thin film) 3054, 2944, 2866, 1723, 1641, 
1464, 1265, 1095, 838 cm–1; MS (ESI) m/z [M + Na]+ 517.3; HRMS (ESI) m/z [M + K]+ calcd 
for C27H50KO4Si2: 533.2885, found 533.2843.  
 
OTIPS
TBSO
OBn OH  
(4S,6R,7R)-6-(Benzyloxy)-8-(tert-butyldimethylsilyloxy)-7-(triisopropylsilyloxy)oct-1-en-4- 
ol (20a): 37
(–)-Methoxydiisopinocampheylborane (10.0 g, 31.6 mmol) was dissolved in dry diethyl 
ether (30 mL) in a 2-neck 100 mL flask previously heated under vacuum and flushed with argon. 
The solution was cooled to 0 °C before allylMgBr (1M in Et2O, 26.7 mL, 26.7 mmol) was added 
slowly via syringe. After 10 min, the cooling bath was removed and stirring of the mixture was 
continued for 3 h at 23 °C. Aldehyde 6 (1.90 g, 3.84 mmol) in Et2O (40 mL) was added slowly 
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via syringe. After 12 h at −78 °C, the reaction was quenched by addition of methanol (1 mL). 
The solution was warmed to 23 °C overnight before 3 N NaOH (4 mL) and 30% wt. H2O2 (8 mL) 
were added at 0 °C. After 10 min at 0 °C, the mixture was refluxed for 3 h. After cooling to 0 °C, 
a saturated Na2SO3 aqueous solution was added and the aqueous layer was extracted with diethyl 
ether (2x). The combined organic fractions were dried over MgSO4. The solution was 
concentrated and the crude mixture was purified by silica gel flash chromatography eluting with 
hexanes/EtOAc (30:1) to yield homoallylic alcohol 20a (1.18 g, 57 %) as a colorless oil: [α]D25 
+24.8 (c 0.65, CHCl3); 1H NMR (300 MHz, CDCl3) δ 7.37–7.25 (m, 5H), 5.82 (m, 1H), 5.10 (d, 
J = 15.9 Hz, 1H), 5.09 (d, J = 11.1 Hz, 1H), 4.65 (d, J = 11.7 Hz, 1H), 4.58 (d, J = 11.4 Hz, 1H), 
4.06 (ddd, J = 6.9, 4.2, 3.0 Hz, 1H), 3.87 (dd, J = 10.5, 3.0 Hz, 1H), 3.84–3.72 (m, 2H), 3.63 (dd, 
J = 10.5, 6.6 Hz, 1H), 2.49 (d, J = 4.5 Hz, 1H), 2.22 (t, J = 6.9 Hz, 2H), 1.67 (m, 2H), 1.15–1.06 
(m, 6H), 1.11 (s, 18H), 1.09 (s, 18H), 0.91 (s, 9H), 0.05 (s, 6H); 13C NMR (75 MHz, CDCl3) δ 
138.5, 135.1, 128.4, 127.9, 127.7, 117.5, 78.4, 74.6, 72.4, 68.1, 64.8, 42.3, 36.5, 26.0, 18.4, 18.2, 
18.1, 12.6, –5.38, –5.43; IR (thin film) 3427, 3054, 2946, 2866, 1641, 1465, 1265, 1091, 838 
cm–1; MS (ESI) m/z [M + Na]+ 559; HRMS (ESI) m/z [M + Na]+ calcd for C30H56NaO4Si2: 
559.3615, found 559.3617.  
 
OTIPS
TBSO
OBn OTIPS  
(6R,7R,9S)-9-Allyl-7-(benzyloxy)-11,11-diisopropyl-2,2,3,3,12-pentamethyl-6-(triisopropyl- 
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silyloxy)-4,10-dioxa-3,11-disilatridecane (21):  
The same procedure as 7 was followed by employing 20a (1.18 g, 2.20 mmol), 2,6-lutidine 
(0.764 mL, 6.59 mmol), TIPSOTf (1.18 mL, 4.40 mmol) and DCM (60 mL). The title compound 
21 was prepared as a colorless oil (1.10 g, 71%): [α]D25 +46.2 (c 0.26, CHCl3); 1H NMR (300 
MHz, CDCl3) δ 7.37–7.25 (m, 5H), 5.86 (m, 1H), 5.05 (d, J = 13.8 Hz, 1H), 5.04 (d, J = 12.3 Hz, 
1H), 4.67 (d, J = 11.7 Hz, 1H), 4.57 (d, J = 11.4 Hz, 1H), 4.17–4.06 (m, 2H), 3.89 (dd, J = 10.2, 
3.3 Hz, 1H), 3.84 (dt, J = 10.2, 3.3 Hz, 1H), 3.59 (dd, J = 9.9, 6.6 Hz, 1H), 2.41–2.30 (m, 2H), 
1.78 (ddd, J = 14.4, 7.8, 3.0 Hz, 1H), 1.67 (ddd, J = 14.4, 9.9, 4.5 Hz, 1H), 1.25–0.97 (m, 6H), 
1.11 (s, 18H), 1.09 (s, 18H), 0.91 (s, 9H), 0.05 (s, 6H); 13C NMR (75 MHz, CDCl3) δ 139.1, 
134.9, 128.2, 127.5, 127.3, 117.0, 77.8, 74.8, 71.5, 69.6, 64.8, 42.9, 36.7, 26.0, 18.4, 18.3, 18.3, 
18.2, 13.0, 12.9, –5.40, –5.43; IR (thin film) 3071, 3031, 2943, 2866, 1640, 1464, 1254, 1093, 
1000, 838 cm–1; MS (ESI) m/z [M + Na]+ 715.5; HRMS (ESI) m/z [M + Na]+ calcd for 
C39H76NaO4Si3: 715.4949, found 715.5006.  
 
OTIPS
HO
OBn OTIPS  
(2R,3R,5S)-3-(Benzyloxy)-2,5-bis(triisopropylsilyloxy)oct-7-en-1-ol (22): 38
A 250 mL round bottom flask was filled with MeOH (100 mL) and 21 (1.10 g, 1.59 mmol). 
The solution was cooled to –10 °C and acetyl chloride (1.11 g, 14.1 mmol) was added. The 
reaction was stirred for 1 h. The reaction was quenched by slowly adding saturated aqueous 
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NaHCO3 until pH was 7. The layers were separated and the aqueous layer was extracted with 
DCM (3x). The combined organic layers were dried over MgSO4. The resulting solution was 
concentrated and the crude product was purified by silica gel flash chromatography eluting with 
hexanes/EtOAc (30:1) to yield 22 (0.80 g, 87%) as a yellow oil: [α]D25 +46.6 (c 0.09, CHCl3); 1H 
NMR (300 MHz, CDCl3) δ 7.36–7.27 (m, 5H), 5.83 (ddt, J = 17.7, 9.6, 7.2 Hz, 1H), 5.10–4.99 
(m, 2H), 4.67 (d, J = 11.1 Hz, 1H), 4.55 (d, J = 11.4 Hz, 1H), 4.21 (dt, J = 6.9, 4.5 Hz, 1H), 4.12 
(tt, J = 7.2, 4.5 Hz, 1H), 3.92 (dt, J = 9.3, 3.9 Hz, 1H), 3.78 (ddd, J = 11.1, 7.2, 3.3 Hz, 1H), 
3.66 (ddd, J = 10.8, 8.4, 4.5 Hz, 1H), 2.56 (dd, J = 8.4, 3.3 Hz, 1H), 2.45–2.26 (m, 2H), 1.80 
(ddd, J = 14.4, 7.2, 3.0 Hz, 1H), 1.78 (ddd, J = 14.4, 9.0, 4.5 Hz, 1H), 1.12–1.04 (s, 36H), 
1.04–0.82 (m, 6H); 13C NMR (75 MHz, CDCl3) δ 138.1, 134.7, 128.4, 127.7, 127.7, 117.1, 79.4, 
72.1, 69.9, 69.4, 63.8, 42.8, 35.9, 18.4, 18.3, 18.1, 18.1, 13.0, 12.5; IR (thin film) 3454, 3054, 
2945, 2867, 1640, 1464, 1265, 1111, 1066, 884 cm–1; MS (ESI) m/z [M + Na]+ 601.3; HRMS 
(ESI) m/z [M + K]+ calcd for C33H60KO4Si2: 615.3667, found 615.3690.  
 
OTIPS
O
OBn OTIPS  
(2S,3R,5S)-3-(Benzyloxy)-2,5-bis(triisopropylsilyloxy)oct-7-enal (4):  
Alcohol 22 (750 mg, 1.30 mmol) was dissolved in dry DCM (100 mL) in a 250 mL round 
bottom flask. PCC (838 mg, 3.89 mmol) was added to the solution. The mixture was stirred for 
12 h. The solution was concentrated and the crude product was purified by silica gel flash 
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chromatography eluting with hexanes/EtOAc (30:1) to yield aldehyde 4 (590 mg, 79%) as a 
colorless oil: 1H NMR (300 MHz, CDCl3) δ 9.77 (d, J = 1.8 Hz, 1H), 7.37–7.23 (m, 5H), 5.78 
(ddt, J = 17.7, 9.3, 7.2 Hz, 1H), 5.03 (dd, J = 12.3, 0.6 Hz, 1H), 5.02 (dd, J = 15.3, 0.6 Hz, 1H), 
4.69 (d, J = 11.4 Hz, 1H), 4.57 (d, J = 11.4 Hz, 1H), 4.35 (dd, J = 4.5, 1.5 Hz, 1H), 4.09 (tt, J = 
7.8, 3.9 Hz, 1H), 4.01 (ddd, J = 10.2, 4.5, 2.4 Hz, 1H), 2.42–2.23 (m, 2H), 1.84 (ddd, J = 14.4, 
8.4, 2.7 Hz, 1H), 1.68 (ddd, J = 14.1, 10.5, 3.9 Hz, 1H), 1.17–0.92 (m, 6H), 1.05 (s, 36H); 13C 
NMR (75 MHz, CDCl3) δ 203.1, 138.3, 134.4, 128.3, 127.6, 127.6, 117.3, 78.5, 77.7, 72.1, 69.0, 
42.8, 37.7, 18.3, 18.3, 18.0, 17.9, 12.9, 12.2; IR (thin film) 3054, 2926, 2865, 1731, 1423, 1265, 
1107, 896 cm–1.  
 
OTIPS
BnO
TIPSO
C5H11
O
O
 
(4R,5R,7S,E)-((R)-Dec-1-en-5-yl)-5-(benzyloxy)-4,7-bis(triisopropylsilyloxy)deca-2,9-dieno-
ate (28): 40,41
DBU (42.2 mg, 0.277 mmol) was added to a stirred suspension of LiCl (14.1 mg, 0.333 
mmol) and phosphonate 5-(R) (102 mg, 0.333 mmol) in anhydrous acetonitrile (8 mL). After the 
solution became clear, aldehyde 4 (160 mg, 0.277 mmol) was added. The reaction mixture was 
allowed to stir for 24 h, and then it was concentrated under reduced pressure. Purification of the 
residue by silica gel flash chromatography eluting with hexanes/EtOAc (30:1) gave 28 (152 mg, 
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73%) as a colorless oil: [α]D25 +40.5 (c 0.19, CHCl3); 1H NMR (300 MHz, CDCl3) δ 7.36–7.24 
(m, 5H), 7.02 (dd, J = 15.6, 4.5 Hz, 1H), 6.01 (dd, J = 15.6, 1.5 Hz, 1H), 5.87–5.70 (m, 2H), 
5.07–4.90 (m, 4H), 4.99 (m, 1H), 4.67 (td, J = 4.5, 1.5 Hz, 1H), 4.66 (d, J = 11.7 Hz, 1H), 4.59 
(d, J = 11.7 Hz, 1H), 4.07 (tt, J = 6.9, 4.8 Hz, 1H), 3.81 (ddd, J = 9.6, 4.5, 2.7 Hz, 1H), 
2.35–2.28 (m, 2H), 2.11–2.00 (m, 2H), 1.78–1.60 (m, 3H), 1.60–1.45 (3H), 1.37–1.18 (m, 6H), 
1.12–0.95 (m, 6H), 1.05 (s, 36H), 0.86 (t, J = 6.6 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 166.0, 
147.5, 138.5, 138.0, 134.7, 128.3, 127.6, 127.6, 122.3, 117.0, 114.8, 79.5, 73.7, 72.1, 71.7, 69.3, 
42.6, 36.8, 34.1, 33.4, 31.7, 29.6, 24.9, 22.5, 18.3, 18.3, 18.1, 18.0, 14.0, 12.9, 12.3; IR (thin film) 
3054, 2944, 2867, 1711, 1641, 1463, 1265, 1098, 884 cm–1; MS (ESI) m/z [M + Na]+ 779.3; 
HRMS (ESI) m/z [M + H]+ calcd for C45H81O5Si2: 757.5623, found 757.5640.  
 
O
O
OTIPS
OBn
OTIPS
C5H11
 
(3E,5R,6R,8S,10E,14R)-6-(Benzyloxy)-14-pentyl-5,8-bis(triisopropylsilyloxy)oxacyclotetra-
deca-3,10-dien-2-one (3): 44,45
Ester 28 (150 mg, 0.198 mmol) was dissolved in dry and degassed DCM (250 mL) in a 500 
mL round bottom flask. Under vigorous stirring, a solution of Grubbs 1st generation catalyst 
[(PCy3)2Cl2Ru=CHPh] (160 mg, 0.198 mmol) in dichloromethane (15 mL) was added dropwise 
via syringe over 25 min. After being stirred for 12 h at 23 °C under an atmosphere of argon, the 
 159
reaction mixture was concentrated under reduced pressure to afford a brown oil, which was 
subjected to silica gel flash chromatography eluting with hexanes/EtOAc (30:1) to yield an 
inseparable 6:1 mixture of the E/Z isomers (as judged by 1H NMR) 3 (112 mg, 75%) as a 
yellow/brown oil: [α]D25 +15.3 (c 0.78, CHCl3); 1H NMR (500 MHz, CDCl3) (the E-isomer) δ 
7.37–7.27 (m, 5H), 6.80 (dd, J = 16.0, 5.0 Hz, 1H), 6.00 (dd, J = 16.0, 1.5 Hz, 1H), 5.43 (ddd, J 
= 14.8, 7.9, 4.7 Hz, 1H), 5.27 (ddd, J = 14.6, 8.3, 4.5 Hz, 1H), (for the Z-isomer: 5.50 (ddd, J = 
9.7, 6.5, 2.8 Hz, 1H), 5.36 (m, 1H)), 4.94 (m, 1H), 4.64 (d, J = 12.0 Hz, 1H), 4.60 (d, J = 12.0 
Hz, 1H), 4.60 (m, 1H), 3.95 (m, 1H), 3.77 (quint, J = 4.5 Hz, 1H), 2.38–2.25 (m, 2H), 2.12 (m, 
1H), 2.04 (m, 1H), 1.87 (ddd, J = 19.0, 10.0, 4.2 Hz, 1H), 1.80 (m, 1H), 1.72–1.62 (m, 2H), 1.55 
(m, 1H), 1.49 (ddd, J = 15.3, 7.9, 4.2 Hz, 1H), 1.39–1.21 (m, 6H), 1.10–0.95 (m, 42H), 0.88 (t, J 
= 6.9 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 167.0, 147.3, 138.7, 134.5, 128.3, 127.6, 127.5, 
125.9, 123.4, 79.0, 75.4, 72.4, 71.6, 68.2, 42.5, 36.3, 34.1, 32.8, 31.7, 28.7, 25.1, 22.5, 18.3, 18.0, 
14.0, 12.7, 12.2; IR (thin film) 3054, 2944, 2867, 1712, 1423, 1265, 1108, 895 cm–1; MS (ESI) 
m/z [M + Na]+ 751.3; HRMS (MALDI) m/z [M + Na]+ calcd for C43H76NaO5Si2: 751.5129, 
found 751.5131.  
 
O
O
OTIPS
OBn
OTIPS
C5H11
 
(5R,6R,8S,14R)-6-(Benzyloxy)-14-pentyl-5,8-bis(triisopropylsilyloxy)oxacyclotetradecan-2- 
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one (30): 10c
NH2NH2?H2O (50.0 μL, 1.00 mol) was added to a suspension of 3 (3.0 mg, 0.00412 mmol) 
and CuSO4 (34.0 mg, 0.213 mmol) in ethanol (2 mL). After being stirred at room temperature for 
15 min, the reaction mixture was warmed to 70 °C. After being stirred at 70 °C for 20 h, the 
reaction was cooled to room temperature. H2O (1.5 mL) was added, and the reaction mixture was 
extracted with ether (3x). The organic layers were combined, washed with brine. The combined 
organic layers were dried over MgSO4. The resulting solution was concentrated and the crude 
product was purified by silica gel flash chromatography eluting with hexanes/EtOAc (30:1) to 
yield 30 (3.4 mg, 100%) as a colorless oil: 1H NMR (300 MHz, CDCl3) δ 7.33–7.26 (m, 5H), 
4.90 (m, 1H), 4.69 (d, J = 12.0 Hz, 1H), 4.52 (d, J = 12.0 Hz, 1H), 3.95 (dt, J = 8.7, 3.0 Hz, 1H), 
3.88 (t, J = 6.0 Hz, 1H), 3.59 (ddd, J = 8.1, 5.1, 3.0 Hz, 1H), 2.28 (m, 1H), 2.05 (m, 1H), 1.95 (dt, 
J = 13.5, 5.7 Hz, 1H), 1.79 (dt, J = 13.2, 6.6 Hz, 1H), 1.61–1.39 (m, 7H), 1.39–1.17 (m, 13H), 
1.13–0.97 (m, 42H), 0.87 (t, J = 6.6 Hz, 3H).  
 
O
O
OTIPS
OH
OTIPS
C5H11
 
(5R,6R,8S,14R)-6-Hydroxy-14-pentyl-5,8-bis(triisopropylsilyloxy)oxacyclotetradecan-2-one 
(31):  
Following the same procedure as 32, lactone 3 (3.0 mg, 0.00411 mmol), Pd/C (5 wt.%) (1.0 
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mg catalyst, 0.000470 mmol Pd), ethanol (3 mL) were mixed and the mixture was stirred at 23 
°C for 20 h. The title compound 31 was prepared as a colorless oil (2.0 mg, 76%): 1H NMR (300 
MHz, CDCl3) δ 4.98 (m, 1H), 4.09 (m, 1H), 3.89 (d, J = 9.9 Hz, 1H), 3.78 (dd, J = 9.6, 4.5 Hz, 
1H), 2.58 (ddd, J = 16.8, 12.6, 4.2 Hz, 1H), 2.44 (dt, J = 16.8, 3.9 Hz, 1H), 2.13 (m, 2H), 1.93 (m, 
1H), 1.80 (m, 1H), 1.70–1.21 (m, 18H), 1.21–0.95 (m, 42H), 0.87 (t, J = 6.6 Hz, 3H).  
 
O
O
OTIPS
OBn
OTIPS
C5H11
 
(5R,6R,8S,14R,E)-6-(Benzyloxy)-14-pentyl-5,8-bis(triisopropylsilyloxy)oxacyclotetradec-3- 
en-2-one (32): 44
A mixture of 3 (10.5 mg, 0.0144 mmol), ethanol (40 mL), and Pd/BaSO4 (5 wt.%) (22.0 mg 
catalyst, 0.0104 mmol Pd) was placed under a hydrogen atmosphere and stirred at 23 °C for 48 h. 
The reaction mixture was then filtered and the filtrate was concentrated under reduced pressure 
to afford a light yellow oil, which was subjected to silica gel flash chromatography eluting with 
hexanes/EtOAc (30:1) to yield 32 (8.2 mg, 78%) as a colorless oil: [α]D25 +13.3 (c 0.08, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 7.32–7.26 (m, 5H), 6.86 (dd, J = 16.0, 5.5 Hz, 1H), 6.08 (dd, J = 
16.0, 1.5 Hz, 1H), 5.01 (m, 1H), 4.67 (d, J = 11.5 Hz, 1H), 4.63 (d, J = 11.0 Hz, 1H), 4.62 (t, J = 
6.0 Hz, 1H), 3.89 (m, 1H), 3.80 (quint, J = 4.5 Hz, 1H), 1.73 (m, 2H), 1.71–1.61 (m, 3H), 1.57 
(m, 1H), 1.52–1.45 (m, 2H), 1.42 (m, 2H), 1.38–1.15 (m, 10H), 1.10–0.98 (m, 42H), 0.88 (t, J = 
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7.0 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 167.2, 147.5, 138.8, 128.2, 127.5, 127.4, 123.6, 79.2, 
75.7, 72.5, 72.3, 69.6, 37.5, 37.4, 34.2, 32.4, 31.7, 30.6, 25.2, 25.0, 24.2, 22.5, 18.3, 18.3, 18.0, 
18.0, 14.0, 12.8, 12.2; IR (thin film) 3055, 2986, 2930, 2866, 1712, 1643, 1422, 1265, 896 cm–1; 
MS (ESI) m/z [M + Na]+ 753.5.  
 
O
O
OH
OH
OH
C5H11
 
(5R,6R,8S,14R,E)-5,6,8-Trihydroxy-14-pentyloxacyclotetradec-3-en-2-one (2d): 48
Lactone 32 (5.0 mg, 0.00685 mmol) was dissolved in dry DCM (3 mL) in a 50 mL round 
bottom flask. Ethane thiol (18.0 μL, 0.234 mmol) was added, and mixture was cooled to –78 °C. 
Under an atmosphere of argon, BF3?Et2O (6.0 μL, 0.0465 mmol) was added via syringe. The 
reaction mixture was stirred for 20 min and then slowly warmed to 23 °C. A condenser was set 
up on the top of the flask and the mixture was heated to 32 °C. After 24 h, the reaction was 
quenched by adding saturated aqueous NaHCO3 (0.5 mL). The layers were separated and the 
aqueous layer was extracted with DCM (3x). The combined organic layers were dried over 
MgSO4. The resulting solution was concentrated and the crude product was purified by silica gel 
flash chromatography eluting with DCM/MeOH (20:1) to yield 2d (1.9 mg, 85%), which was 
further purified by preparative reverse phase HPLC to afford a white solid (1.3 mg, 68% 
recovery): [α]D25 +12.4 (c 0.056, MeOH); 1H NMR (500 MHz, MeOD-d4) δ 7.07 (dd, J = 16.0, 
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5.5 Hz, 1H), 6.12 (dd, J = 16.0, 1.5 Hz, 1H), 4.97 (dddd, J = 16.5, 9.0, 5.5, 3.5 Hz, 1H), 4.27 (td, 
J = 5.0, 1.0 Hz, 1H), 3.90 (td, J = 6.0, 3.0 Hz, 1H), 3.78 (tt, J = 8.0, 3.5 Hz, 1H), 1.75–1.71 (m, 
2H), 1.71–1.60 (m, 2H), 1.59–1.51 (m, 2H), 1.48–1.18 (m, 14H), 0.91 (t, J = 7.0 Hz, 3H); 13C 
NMR (75 MHz, MeOD-d4) δ 167.6, 149.6, 123.1, 75.7, 75.2, 73.7, 68.8, 38.1, 35.6, 35.4, 33.5, 
32.9, 27.7, 26.4, 25.0, 24.4, 23.6, 14.3; IR (thin film) 3583, 3385, 3020, 2925, 1712, 1431, 1215, 
1020 cm–1; MS (ESI) m/z [M + Na]+ 351.2; HRMS (MALDI) m/z [M + Na]+ calcd for 
C18H32NaO5: 351.2147, found 351.2143.  
 
OH
 
(S)-Dec-1-en-5-ol (9-(S)):  
A solution of 5-(S) (32.0 mg, 0.0958 mmol) in MeOH (1 mL) was added K2CO3 (26.5 mg, 
0.192 mmol). The mixture was stirred at 23 °C for 5 h before it was concentrated under reduced 
pressure. Purification of the residue by silica gel flash chromatography eluting with 
hexanes/EtOAc (4:1) gave 9-(S) (14.0 mg, 94%) as a colorless oil: 1H NMR (300 MHz, CDCl3) 
δ 5.85 (ddt, J = 17.1, 10.2, 6.6 Hz, 1H), 5.06 (dd, J = 17.4, 1.8 Hz, 1H), 4.97 (d, J = 10.2 Hz, 
1H), 3.62 (m, 1H), 2.19 (m, 2H), 1.65–1.54 (m, 2H), 1.54–1.39 (m, 2H), 1.39–1.20 (m, 6H), 0.89 
(t, J = 6.6 Hz, 3H).  
 
OH
 
(R)-Dec-1-en-5-ol (9-(R)):  
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The same procedure as 9-(S) was followed by employing 5-(R) (30.0 mg, 0.0898 mmol), 
K2CO3 (24.8 mg, 0.180 mmol) and MeOH (1 mL). The title compound 9-(R) was prepared as a 
colorless oil (11.0 mg, 79%): 1H NMR (300 MHz, CDCl3) δ 5.85 (ddt, J = 17.1, 10.2, 6.6 Hz, 
1H), 5.05 (dd, J = 17.1, 1.8 Hz, 1H), 4.97 (d, J = 9.9 Hz, 1H), 3.62 (m, 1H), 2.19 (m, 2H), 
1.66–1.52 (m, 2H), 1.52–1.39 (m, 2H), 1.39–1.20 (m, 6H), 0.89 (t, J = 6.6 Hz, 3H).  
 
O O
MeO
Ph
F3C
 
(S)-((S)-Dec-1-en-5-yl) 3,3,3-trifluoro-2-methoxy-2-phenylpropanoate (27-(S)): 39
Alcohol 9-(S) (5.0 mg, 0.03201 mmol) was dissolved in DCM (10 mL) in a 50 mL round 
bottom flask. Pyridine (25.3 mg, 0.320 mmol), (R)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoyl 
chloride (81.0 mg, 0.320 mmol) and DMAP (2.0 mg, 0.0160 mmol) were added to the solution. 
The mixture was stirred for 12 h and 19F NMR was done to determine the ee: 19F NMR δ –71.97 
(major diastereomer), –71.92 (minor diastereomer), major:minor = 1.00:0.01 (98% ee).  
 
O O
MeO
Ph
F3C
 
(S)-((R)-dec-1-en-5-yl) 3,3,3-trifluoro-2-methoxy-2-phenylpropanoate (27-(R)):  
Following the same procedure as 27-(S), alcohol 9-(R) (5.0 mg, 0.03201 mmol) and the 
same amount of all other reagents were stirred for 12 h and 19F NMR of the mixture was done: 
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19F NMR δ –71.92 (major diastereomer), –71.97 (minor diastereomer), major:minor = 1.00:0.00 
(> 99% ee).  
 
TBSO O
BnO
Si
CF2CF2CF3
 
(R)-6-((S)-1-(Benzyloxy)but-3-enyl)-11,11,12,12,13,13,13-heptafluoro-8,8-diisopropyl-2,2,3,3
-tetramethyl-4,7-dioxa-3,8-disilatridecane (39-anti-F7): 12,16
Trifluoromethanesulfonic acid (neat, 1.54 mL, 17.4 mmol) was added to 
(3,3,4,4,5,5,5-heptafluoropentyl)diisopropylsilane (neat, 7.52 g, 24.1 mmol) at 0 °C quickly via 
syringe. The reaction mixture was slowly warmed to 23 °C and stirred for 16 h. Alcohol 17-anti 
(4.50 g, 13.4 mmol) and 2,6-lutidine (3.90 mL, 33.5 mmol) in DCM (150 mL) were added at 0 
°C via syringe. The solution was slowly warmed to room temperature and stirred for 24 h before 
the reaction was quenched with H2O (100 mL). The reaction mixture was extracted with DCM 
(3x) and the combined organic extracts were washed with brine, and dried over MgSO4. The 
crude product was purified by column chromgatography (hexane/EtOAc = 30:1) to afford the 
title compound 39-anti-F7 (8.50 g, 98%) as a colorless oil: [α]D25 –9.6 (c 0.80, CHCl3); 1H NMR 
(300 MHz, CDCl3) δ 7.32–7.26 (m, 5H), 5.86 (ddt, J = 16.8, 9.5, 6.1 Hz, 1H), 5.10 (d, J = 16.9 
Hz, 1H), 5.04 (d, J = 11.6 Hz, 1H), 4.60 (d, J = 11.5 Hz, 1H), 4.55 (d, J = 11.5 Hz, 1H), 3.94 (td, 
J = 5.7, 2.4 Hz, 1H), 3.74–3.51 (m, 3H), 2.35 (m, 2H), 2.13 (m, 2H), 1.16–0.93 (m, 14H), 0.88 (s, 
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9H), 0.83 (m, 2H), 0.03 (s, 6H); 13C NMR (75 MHz, CDCl3) δ 138.6, 135.7, 128.2, 127.8, 127.5, 
116.7, 80.3, 75.6, 72.3, 64.8, 34.6, 25.9, 18.8, 17.7–17.6 (m), 12.8, 12.6, 0.7, –5.5, –5.6; IR (thin 
film) 3054, 2950, 2866, 1465, 1353, 1265, 1229, 1181, 1111, 838 cm–1; MS (ESI): m/z [M + 
Na]+ 669.2; HRMS (ESI) m/z [M + Na]+ calcd for C30H49F7NaO3Si2: 669.3006, found 669.2941.  
 
TBSO O
BnO
Si
CF2CF2CF2CF3
 
(R)-6-((R)-1-(Benzyloxy)but-3-enyl)-11,11,12,12,13,13,14,14,14-nonafluoro-8,8-diisopropyl- 
2,2,3,3-tetramethyl-4,7-dioxa-3,8-disilatetradecane (39-syn-F9):  
Trifluoromethanesulfonic acid (neat, 1.54 mL, 17.4 mmol) was added to 
diisopropyl(3,3,4,4,5,5,6,6,6-nonafluorohexyl)silane (neat, 8.73 g, 24.1 mmol) at 0 °C quickly 
via syringe. The reaction mixture was slowly warmed to room temperature and stirred for 16 h. 
Alcohol 17-syn (4.50 g, 13.4 mmol) and 2,6-lutidine (3.90 mL, 33.5 mmol) in DCM (150 mL) 
were added at 0 °C via syringe. The solution was slowly warmed to room temperature and stirred 
for 24 h before the reaction was quenched with H2O (100 mL). The reaction mixture was 
extracted with DCM (3x) and the combined organic extracts were washed with brine, and dried 
over MgSO4. The crude product was purified by column chromgatography (hexane/EtOAc = 
30:1) to afford the title compound 39-syn-F9 (8.90 g, 95%) as a colorless oil: [α]D25 +8.8 (c 0.16, 
CHCl3); 1H NMR (300 MHz, CDCl3) δ 7.32–7.26 (m, 5H), 5.85 (ddt, J = 17.1, 9.9, 6.9 Hz, 1H), 
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5.10 (d, J = 17.1 Hz, 1H), 5.04 (d, J = 10.2 Hz, 1H), 4.60 (d, J = 11.7 Hz, 1H), 4.54 (d, J = 11.7 
Hz, 1H), 3.87 (m, 1H), 3.82 (dd, J = 10.2, 3.0 Hz, 1H), 3.55 (dd, J = 10.2, 6.6 Hz, 1H), 3.47 (dt, 
J = 8.7, 4.2 Hz, 1H), 2.45 (m, 1H), 2.25–2.00 (m, 3H), 1.09–0.98 (m, 14H), 0.88 (s, 9H), 0.85 (m, 
2H), 0.04 (s, 3H), 0.03 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 138.5, 135.7, 128.2, 127.7, 127.5, 
116.5, 80.4, 75.0, 72.5, 64.5, 34.1, 25.9, 18.7, 17.6–17.5 (m), 12.9, 12.7, 0.6, –5.6; IR (thin film) 
3054, 2951, 2866, 1464, 1423, 1265, 1235, 1132, 1085, 886, 840 cm–1; HRMS (MALDI) m/z [M 
+ Na]+ calcd for C31H49F9NaO3Si2: 719.2974, found 719.3015.  
 
TBSO O
BnO
Si
 
(R)-6-((S)-1-(Benzyloxy)but-3-enyl)-8,8-diisopropyl-2,2,3,3,9-pentamethyl-4,7-dioxa-3,8-di- 
siladecane (39-anti-F0):  
The same procedure as 7 was followed by employing 17-anti (10.0 mg, 0.0298 mmol), 
2,6-lutidine (10.3 μL, 0.0891 mmol), TIPSOTf (15.9 μL, 0.0595 mmol) and DCM (0.8 mL). The 
title compound 39-anti-F0 was prepared as a colorless oil (14.0 mg, 96%): 1H NMR (300 MHz, 
CDCl3) δ 7.35–7.26 (m, 5H), 5.91 (ddt, J = 17.1, 10.2, 6.9 Hz, 1H), 5.09 (dd, J = 17.1, 1.8 Hz, 
1H), 5.02 (d, J = 10.2 Hz, 1H), 4.67 (d, J = 11.7 Hz, 1H), 4.53 (d, J = 11.7 Hz, 1H), 4.01 (td, J = 
5.7, 2.4 Hz, 1H), 3.71–3.60 (m, 3H), 2.38 (m, 2H), 1.18–1.00 (m, 21H), 0.88 (s, 9H), 0.03 (s, 
6H).  
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 TBSO O
BnO
Si
 
(R)-6-((R)-1-(Benzyloxy)but-3-enyl)-8,8-diisopropyl-2,2,3,3,9-pentamethyl-4,7-dioxa-3,8-di-
siladecane (39-syn-F0):  
The same procedure as 7 was followed by employing 17-syn (10.0 mg, 0.0298 mmol), 
2,6-lutidine (10.3 μL, 0.0891 mmol), TIPSOTf (15.9 μL, 0.0595 mmol) and DCM (0.8 mL). The 
title compound 39-syn-F0 was prepared as a colorless oil (15.0 mg, 100%): 1H NMR (300 MHz, 
CDCl3) δ 7.33–7.26 (m, 5H), 5.87 (ddt, J = 17.1, 10.2, 7.1 Hz, 1H), 5.08 (dd, J = 17.1, 1.8 Hz, 
1H), 5.02 (d, J = 10.2 Hz, 1H), 4.59 (s, 2H), 4.00 (m, 1H), 3.86 (dd, J = 10.5, 3.3 Hz, 1H), 3.69
－3.50 (m, 1H), 3.59 (dd, J = 10.2, 6.6 Hz, 1H), 2.50 (m, 1H), 2.19 (m, 1H), 1.17–1.02 (m, 21H), 
0.89 (s, 9H), 0.04 (s, 6H).  
 
TBSO O
BnO
Si
CF2CF2CF3
 
(R)-6-((R)-1-(Benzyloxy)but-3-enyl)-11,11,12,12,13,13,13-heptafluoro-8,8-diisopropyl-2,2,3,3
-tetramethyl-4,7-dioxa-3,8-disilatridecane (39-syn-F7):  
The same procedure as 39-anti-F7 was followed by employing 17-syn (5.0 mg, 0.0149 
mmol), 2,6-lutidine (4.3 μL, 0.0372 mmol), trifluoromethanesulfonic acid (1.7 μL, 0.0193 
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mmol), (3,3,4,4,5,5,5-heptafluoropentyl)diisopropylsilane (8.4 mg, 0.0268 mmol) and DCM (0.2 
mL). The title compound 39-syn-F7 was prepared as a colorless oil (7.0 mg, 72%): 1H NMR 
(300 MHz, CDCl3) δ 7.33–7.26 (m, 5H), 5.85 (ddt, J = 17.1, 10.2, 7.1 Hz, 1H), 5.08 (d, J = 17.1 
Hz, 1H), 5.04 (d, J = 10.2 Hz, 1H), 4.60 (d, J = 11.7 Hz, 1H), 4.54 (d, J = 11.7 Hz, 1H), 3.87 (m, 
1H), 3.82 (dd, J = 10.2, 3.0 Hz, 1H), 3.55 (dd, J = 10.2, 6.6 Hz, 1H), 3.47 (dt, J = 8.4, 4.2 Hz, 
1H), 2.45 (m, 1H), 2.25–1.97 (m, 3H), 1.10–0.92 (m, 14H), 0.89 (s, 9H), 0.85 (m, 2H), 0.04 (s, 
3H), 0.04 (s, 3H).  
 
TBSO O
BnO
Si
CF2CF2CF2CF3
 
(R)-6-((S)-1-(Benzyloxy)but-3-enyl)-11,11,12,12,13,13,14,14,14-nonafluoro-8,8-diisopropyl- 
2,2,3,3-tetramethyl-4,7-dioxa-3,8-disilatetradecane (39-anti-F9):  
The same procedure as 39-syn-F9 was followed by employing 17-anti (6.0 mg, 0.0179 
mmol), 2,6-lutidine (5.2 μL, 0.0447 mmol), trifluoromethanesulfonic acid (2.1 μL, 0.0232 
mmol), diisopropyl(3,3,4,4,5,5,6,6,6-nonafluorohexyl)silane (11.6 mg, 0.0321 mmol) and DCM 
(0.2 mL). The title compound 39-anti-F9 was prepared as a colorless oil (10.0 mg, 82%): 1H 
NMR (300 MHz, CDCl3) δ 7.32–7.26 (m, 5H), 5.86 (ddt, J = 17.1, 10.2, 7.2 Hz, 1H), 5.10 (d, J 
= 17.4 Hz, 1H), 5.04 (d, J = 10.5 Hz, 1H), 4.59 (d, J = 11.7 Hz, 1H), 4.53 (d, J = 11.7 Hz, 1H), 
3.93 (td, J = 5.7, 3.0 Hz, 1H), 3.67 (dd, J = 10.5, 5.7 Hz, 1H), 3.58 (dd, J = 10.5, 6.0 Hz, 1H), 
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3.55 (m, 1H), 2.36 (m, 2H), 2.10 (m, 2H), 1.11–0.92 (m, 14H), 0.88 (s, 9H), 0.83 (m, 2H), 0.03 
(s, 6H).  
 
F7: (3S)
F9: (3R)
TBSO O
OBn
OTIPSF7,F9
3(4R)
 
(3R/S,4R)-3-(Benzyloxy)-4-((perfluoroalkylethyl)diisopropylsilyloxy)-5-(tert-butyldimethyl-
silyloxy)pentanal (M-42):  
The same procedure as 6 was followed by employing 39-anti-F7 (3.00 g, 4.64 mmol), 
39-syn-F9 (3.20 g, 4.59 mmol), DCM (200 mL), and Ph3P (4.80 g, 18.5 mmol). The title 
compound M-42 was prepared as a colorless oil (5.80 g, 93%) with an isomeric ratio of 1.0/0.56 
(42[F7]/42[F9], based on F-HPLC): 1H NMR (see Appendix); MS (ESI) m/z [M + Na + MeOH]+ 
703.3 (42[F7]), 753.3 (42[F9]); HRMS (MALDI) for 42[F7] m/z [M + K]+ calcd for 
C29H47F7KO4Si2: 687.2538, found 687.2567; 42[F9] m/z [M + K]+ calcd for C30H47F9KO4Si2: 
737.2506, found 737.2501; analytical fluorous HPLC (condition 1) tR = 18.1 min (42[F7]), 23.4 
min (42[F9]).  
 
TBSO
OBn
OTIPSF7,F9
OH
(2R) 3 F7: (3S)
F9: (3R)
 
(2R,3R/S,5S)-1-(tert-Butyldimethylsilyloxy)-2-((perfluoroalkylethyl)diisopropylsilyloxy)-3- 
(benzyloxy)oct-7-en-5-ol (M-38a):  
A 500 mL round bottom flask was filled with a mixture of aldehyde M-42 (2.00 g, 2.97 
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mmol) followed by dry Et2O (180 mL). The solution was cooled to –100 °C before 
(–)-allyldiisopinocampheylborane (1M in pentane, 8.00 mL, 8.00 mmol) was added slowly via 
syringe. The temperature of the cooling bath was maintained at −100 °C for 15 h, before the 
reaction was quenched by addition of methanol (2 mL). The solution was warmed to 23 °C 
overnight before 3 N NaOH (8 mL) and 30% wt. H2O2 (16 mL) were added at 0 °C. After 10 min 
at 0 °C, the mixture was refluxed for 3 h. After cooling to 0 °C, a saturated Na2SO3 aqueous 
solution was added and the aqueous layer was extracted with diethyl ether (2x). The combined 
organic fractions were dried over MgSO4. The solution was concentrated and the crude mixture 
was purified by silica gel flash chromatography eluting with pentane/Et2O (40:1 to 35:1) to yield 
a mixture of two homoallylic alcohols M-38a (1.80 g, 85%) as a colorless oil with an isomeric 
ratio of 1.0/0.99 (38a[F7]/38a[F9], based on F-HPLC): analytical fluorous HPLC (condition 1) 
tR = 21.8 min (38a[F7]), 26.6 min (38a[F9]). A small amount of fluorous mixture M-38a (5.0 mg) 
was subjected to preparative fluorous HPLC with the standard demixing conditions to afford 
quasidiastereomers 38a[F7] (1.8 mg) and 38a[F9] (2.3 mg).  
 
TBSO O
BnO
HO
Si
C3F7
 
(2R,3S,5S)-1-(tert-Butyldimethylsilyloxy)-2-((3,3,4,4,5,5,5-heptafluoropentyl)diisopropylsil-
yloxy)-3-(benzyloxy)oct-7-en-5-ol (38a[F7]):  
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1H NMR (500 MHz, CDCl3) δ 7.38–7.25 (m, 5H), 5.80 (ddt, J = 17.0, 10.0, 7.0 Hz, 1H), 5.08 (d, 
J = 17.0 Hz, 1H), 5.06 (d, J = 9.5 Hz, 1H), 4.69 (d, J = 11.0 Hz, 1H), 4.47 (d, J = 11.0 Hz, 1H), 
4.03 (td, J = 13.0, 1.5 Hz, 1H), 3.83－3.77 (m, 2H), 3.58 (dd, J = 10.0, 5.5 Hz, 1H), 3.53 (dd, J 
= 10.0, 7.5 Hz, 1H), 3.51 (d, J = 1.5 Hz, 1H), 2.24–2.08 (m, 4H), 1.73 (ddd, J = 15.0, 9.0, 9.0 
Hz, 1H), 1.64 (ddd, J = 15.0, 3.0, 3.0 Hz, 1H), 1.05 (s, 12H), 1.04 (m, 2H), 0.89 (m, 2H), 0.88 (s, 
9H), 0.05 (s, 3H), 0.04 (s, 3H); MS (ESI) m/z [M + Na]+ 713.3; HRMS (MALDI) m/z [M + Na]+ 
calcd for C32H53F7NaO4Si2: 713.3268, found 713.3307.  
 
TBSO O
BnO
HO
Si
C4F9
 
(2R,3R,5S)-1-(tert-Butyldimethylsilyloxy)-2-(diisopropyl(3,3,4,4,5,5,6,6,6-nonafluorohexyl)- 
silyloxy)-3-(benzyloxy)oct-7-en-5-ol (38a[F9]):  
1H NMR (500 MHz, CDCl3) δ 7.36–7.24 (m, 5H), 5.80 (ddt, J = 17.0, 9.5, 7.0 Hz, 1H), 5.10 (m, 
2H), 4.63 (d, J = 11.5 Hz, 1H), 4.58 (d, J = 11.5 Hz, 1H), 3.95 (ddd, J = 7.0, 4.5, 2.5 Hz, 1H), 
3.85 (dd, J = 10.5, 2.5 Hz, 1H), 3.78 (m, 1H), 3.75 (ddd, J = 17.5, 9.0, 4.0 Hz, 1H), 3.57 (dd, J = 
9.9, 7.3 Hz, 1H), 2.27–2.08 (m, 4H), 2.15 (d, J = 4.0 Hz, 1H), 1.67 (ddd, J = 14.0, 9.5, 3.5 Hz, 
1H), 1.58 (ddd, J = 11.5, 9.0, 2.5 Hz, 1H), 1.07–1.01 (m, 2H), 1.04 (s, 12H), 0.89 (s, 9H), 0.87 
(m, 2H), 0.05 (s, 3H), 0.04 (s, 3H); MS (ESI) m/z [M + Na]+ 763.3; HRMS (MALDI) m/z [M + 
Na]+ calcd for C33H53F9NaO4Si2: 763.3236, found 763.3241.  
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 TBSO
OBn
OTIPSF7,F9
OH
F7: (3S)
F9: (3R)3
(2R)
 
(2R,3R/S,5R)-1-(tert-Butyldimethylsilyloxy)-2-((perfluoroalkylethyl)diisopropylsilyloxy)-3- 
(benzyloxy)oct-7-en-5-ol (M-38b):  
A 500 mL round bottom flask was filled with a mixture of aldehyde M-42 (2.00 g, 2.97 
mmol) followed by dry Et2O (180 mL). The solution was cooled to –100 °C before 
(+)-allyldiisopinocampheylborane (1M in pentane, 8.00 mL, 8.00 mmol) was added slowly via 
syringe. The temperature of the cooling bath was maintained at −100 °C for 15 h, before the 
reaction was quenched by addition of methanol (2 mL). The solution was warmed to 23 °C 
overnight before 3 N NaOH (8 mL) and 30% wt. H2O2 (16 mL) were added at 0 °C. After 10 min 
at 0 °C, the mixture was refluxed for 3 h. After cooling to 0 °C, a saturated Na2SO3 aqueous 
solution was added and the aqueous layer was extracted with diethyl ether (2x). The combined 
organic fractions were dried over MgSO4. The solution was concentrated and the crude mixture 
was purified by silica gel flash chromatography eluting with pentane/Et2O (40:1 to 35:1) to yield 
a mixture of two homoallylic alcohols M-38b (1.60 g, 75 %) as a colorless oil with an isomeric 
ratio of 1.0/0.42 (38b[F7]/38b[F9], based on F-HPLC): analytical fluorous HPLC (condition 1) 
tR = 21.2 min (38b[F7]), 26.8 min (38b[F9]). A small amount of fluorous mixture M-38b (5.0 
mg) was subjected to preparative fluorous HPLC with the standard demixing conditions to afford 
quasidiastereomers 38b[F7] (2.0 mg) and 38b[F9] (1.9 mg).  
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 TBSO O
BnO
HO
Si
C3F7
 
(2R,3S,5R)-1-(tert-Butyldimethylsilyloxy)-2-((3,3,4,4,5,5,5-heptafluoropentyl)diisopropylsil-
yloxy)-3-(benzyloxy)oct-7-en-5-ol (38b[F7]):  
1H NMR (500 MHz, CDCl3) δ 7.37–7.25 (m, 5H), 5.79 (ddt, J = 18.0, 9.5, 7.0 Hz, 1H), 5.09 (m, 
2H), 4.67 (d, J = 11.5 Hz, 1H), 4.50 (d, J = 11.5 Hz, 1H), 4.02 (td, J = 6.0, 2.5 Hz, 1H), 3.85 (m, 
1H), 3.82 (dt, J = 9.5, 2.5 Hz, 1H), 3.57 (d, J = 6.5 Hz, 2H), 2.21–2.09 (m, 4H), 1.95 (d, J = 4.5 
Hz, 1H), 1.78 (ddd, J = 15.0, 9.5, 2.5 Hz, 1H), 1.49 (ddd, J = 14.8, 9.5, 3.0 Hz, 1H), 1.04 (s, 
12H), 1.03 (m, 2H), 0.91–0.88 (m, 2H), 0.89 (s, 9H), 0.05 (s, 6H); MS (ESI) m/z [M + Na]+ 
713.3; HRMS (ESI) m/z [M + Na]+ calcd for C32H53F7NaO4Si2: 713.3268, found 713.3278.  
 
TBSO O
BnO
HO
Si
C4F9
 
(2R,3R,5R)-1-(tert-Butyldimethylsilyloxy)-2-(diisopropyl(3,3,4,4,5,5,6,6,6-nonafluorohexyl)- 
silyloxy)-3-(benzyloxy)oct-7-en-5-ol (38b[F9]):  
1H NMR (500 MHz, CDCl3) δ 7.36–7.24 (m, 5H), 5.77 (ddt, J = 17.0, 10.5, 7.0 Hz, 1H), 5.08 (d, 
J = 17.0 Hz, 1H), 5.07 (d, J = 9.0 Hz, 1H), 4.68 (d, J = 11.5 Hz, 1H), 4.54 (d, J = 11.0 Hz, 1H), 
4.02 (ddd, J = 7.0, 4.5, 2.5 Hz, 1H), 3.86 (dd, J = 10.5, 2.5 Hz, 1H), 3.77 (m, 1H), 3.68 (ddd, J = 
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10.0, 4.0, 3.0 Hz, 1H), 3.55 (dd, J = 10.5, 7.0 Hz, 1H), 3.32 (d, J = 1.5 Hz, 1H), 2.24–2.05 (m, 
4H), 1.88 (ddd, J = 14.5, 3.0, 3.0 Hz, 1H), 1.48 (ddd, J = 15.0, 10.0, 10.0 Hz, 1H), 1.07－1.02 
(m, 2H), 1.03 (s, 12H), 0.90 (s, 9H), 0.88 (m, 2H), 0.06 (s, 3H), 0.05 (s, 3H); MS (ESI) m/z [M + 
Na]+ 763.3; HRMS (MALDI) m/z [M + Na]+ calcd for C33H53F9NaO4Si2: 763.3236, found 
763.3183.  
 
TBSO
OTIPSF7,F9
OBn OTIPSF7
(2R) 3 5 F7F7: (3S,5S)F9F7: (3R,5S)
 
(2R,3R/S,5S)-1-(tert-Butyldimethylsilyloxy)-2-((perfluoroalkylethyl)diisopropylsilyloxy)-3- 
(benzyloxy)-5-((3,3,4,4,5,5,5-heptafluoropentyl)diisopropylsilyloxy)oct-7-en (M-37a):  
The same procedure as 39-anti-F7 was followed by employing M-38a (1.80 g, 2.52 mmol), 
2,6-lutidine (0.88 mL, 7.55 mmol), trifluoromethanesulfonic acid (0.33 mL, 3.78 mmol), 
(3,3,4,4,5,5,5-heptafluoropentyl)diisopropylsilane (1.42 g, 4.53 mmol) and DCM (30 mL). The 
title compound M-37a was prepared as a colorless oil (2.50 g, 97%) with an isomeric ratio of 
1.0/1.1 (37a[F7F7]/37a[F9F7], based on F-HPLC): 1H NMR (see appendix); MS (ESI) m/z [M + 
Na]+ 1023.3 (37a[F7F7]), 1073.3 (37a[F9F7]); HRMS (MALDI) for 37a[F7F7] m/z [M + Na]+ 
calcd for C43H70F14NaO4Si3: 1023.4256, found 1023.4196; 37a[F9F7] m/z [M + Na]+ calcd for 
C44H70F16NaO4Si3: 1073.4224, found 1073.4252; analytical fluorous HPLC (condition 1) tR = 
47.7 min (37a[F7F7]), 54.1 min (37a[F7F7]).  
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TBSO
OTIPSF7,F9
OBn OTIPS
F7F0: (3S,5R)
F9F0: (3R,5R)
(2R) 3 5
 
(2R,3R/S,5R)-1-(tert-Butyldimethylsilyloxy)-2-((perfluoroalkylethyl)diisopropylsilyloxy)-3- 
(benzyloxy)-5-(triisopropylsilyloxy)oct-7-en (M-37b):  
The same procedure as 7 was followed by employing M-38b (1.60 g, 2.24 mmol), 
2,6-lutidine (0.72 g, 6.71 mmol), TIPSOTf (1.03 g, 3.54 mmol) and DCM (30 mL). The title 
compound M-37b was prepared as a colorless oil (1.80 g, 92%) with an isomeric ratio of 
1.0/0.54 (37b[F7F0]/37b[F9F0], based on F-HPLC): 1H NMR (see appendix); MS (ESI) m/z [M 
+ Na]+ 869.3 (37b[F7F0]), 919.3 (37b[F9F0]); HRMS (MALDI) for 37b[F7F0] m/z [M + Na]+ 
calcd for C41H73F7NaO4Si3: 869.4603, found 869.4623; 37b[F9F0] m/z [M + Na]+ calcd for 
C42H73F9NaO4Si3: 919.4571, found 919.6423; analytical fluorous HPLC (condition 1) tR = 39.1 
min (37b[F7F0]), 42.8 min (37b[F9F0]).  
 
TBSO
OBn
O
Si
O
Si
CF2CF2CF3
 
(6R,7R,9S)-9-Allyl-7-(benzyloxy)-14,14,15,15,16,16,16-heptafluoro-11,11-diisopropyl-2,2,3,3
-tetramethyl-6-(triisopropylsilyloxy)-4,10-dioxa-3,11-disilahexadecane (49):  
The same procedure as 39-anti-F7 was followed by employing 20a (500 mg, 0.931 mmol), 
2,6-lutidine (300 mg, 2.79 mmol), trifluoromethanesulfonic acid (210 mg, 1.40 mmol), 
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(3,3,4,4,5,5,5-heptafluoropentyl)diisopropylsilane (523 mg, 1.68 mmol) and DCM (200 mL). 
The title compound 49 was prepared as a colorless oil (560 mg, 71%): 1H NMR (300 MHz, 
CDCl3) δ 7.33–7.24 (m, 5H), 5.78 (ddt, J = 17.0, 10.0, 7.0 Hz, 1H), 5.04 (d, J = 11.7 Hz, 1H), 
5.03 (d, J = 15.3 Hz, 1H), 4.64 (d, J = 11.4 Hz, 1H), 4.52 (d, J = 11.7 Hz, 1H), 4.11–4.98 (m, 
2H), 3.85 (dd, J = 10.2, 3.3 Hz, 1H), 3.74 (dt, J = 10.8, 3.6 Hz, 1H), 3.55 (dd, J = 10.2, 6.6 Hz, 
1H), 2.30 (m, 2H), 2.10 (m, 2H), 1.76 (m, 1H), 1.64 (ddd, J = 14.4, 10.2, 4.2 Hz, 1H), 1.20–0.98 
(m, 35H), 0.89 (m, 11H), 0.03 (s, 3H), 0.02 (s, 6H).  
 
HO
OBn
O
Si
O
Si
CF2CF2CF3
 
(2R,3R,5S)-3-(Benzyloxy)-5-((3,3,4,4,5,5,5-heptafluoropentyl)diisopropylsilyloxy)-2-(triiso- 
propylsilyloxy)oct-7-en-1-ol (50):  
The same procedure as M-47 was followed by employing 49 (490 mg, 0.578 mmol), 
hydrochloric acid (1 M in H2O) (0.58 mL, 0.578 mmol) and EtOH (40 mL). The mixture was 
stirred for 4 h at 23 °C. The title compound 50 was prepared as a yellow oil (107 mg, 25%): 1H 
NMR (300 MHz, CDCl3) δ 7.34–7.26 (m, 5H), 5.78 (m, 1H), 5.06 (d, J = 11.4 Hz, 1H), 5.05 (d, 
J = 15.9 Hz, 1H), 4.67 (d, J = 11.1 Hz, 1H), 4.53 (d, J = 11.1 Hz, 1H), 4.20 (dt, J = 6.6, 4.5 Hz, 
1H), 4.08 (m, 1H), 3.85 (ddd, J = 9.9, 4.0, 3.0 Hz, 1H), 3.77 (ddd, J = 9.6, 6.9, 2.7 Hz, 1H), 3.68 
(ddd, J = 12.9, 8.1, 4.5 Hz, 1H), 2.46 (dd, J = 8.2, 3.0 Hz, 1H), 2.32 (m, 2H), 2.10 (m, 2H), 1.84 
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(ddd, J = 14.4, 8.1, 3.0 Hz, 1H), 1.74 (ddd, J = 14.4, 10.2, 4.8 Hz, 1H), 1.27–0.95 (m, 35H), 
0.86 (m, 2H).  
 
HO
OBn
OH
OH  
(2R,3R,5S)-3-(Benzyloxy)oct-7-ene-1,2,5-triol (53): 56,57
Silyl ether 50 (10.2 mg, 0.0120 mmol) was dissolved in THF (2 mL) in a 50 mL round 
bottom flask. The solution was cooled to –78 °C before TBAF (1 M in THF) (12.0 μL, 0.0120 
mmol) was added. The mixture was stirred for 4 h at –78 °C and then warmed to 10 °C over 12 h. 
The mixture was concentrated and the crude product was purified by silica gel flash 
chromatography eluting with hexanes/Et2O (1:1) to yield 53 (1.9 mg, 59%) as a colorless oil: 1H 
NMR (500 MHz, CDCl3) δ 7.37–7.25 (m, 5H), 5.80 (m, 1H), 5.15 (d, J = 10.0 Hz, 1H), 5.14 (d, 
J = 17.5 Hz, 1H), 4.73 (d, J = 11.5 Hz, 1H), 4.59 (d, J = 11.5 Hz, 1H), 3.87 (m, 1H), 3.79 (dt, J = 
12.0, 5.0 Hz, 1H), 3.75 (dt, J = 11.0, 5.0 Hz, 1H), 3.70 (m, 1H), 3.64 (dd, J = 11.5, 6.0 Hz, 1H), 
2.32–2.19 (m, 2H), 1.79 (ddd, J = 14.5, 7.0, 2.5 Hz, 1H), 1.73 (ddd, J = 15.0, 9.5, 5.0 Hz, 1H).  
 
HO
OTIPSF7,F9
OBn OTIPSF7
F7F7: (3S,5S)
F9F7: (3R,5S)
(2R) 3 5
 
(2R,3R/S,5S)-2-((Perfluoroalkylethyl)diisopropylsilyloxy)-3-(benzyloxy)-5-((3,3,4,4,5,5,5- 
heptafluoropentyl)diisopropylsilyloxy)oct-7-en-1-ol (M-47):52
A 250 mL round bottom flask was filled with EtOH (80 mL), followed by M-37a (1.05 g, 
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1.02 mmol). Hydrochloric acid (1 M in H2O) (1.02 mL, 1.02 mmol) was added. The reaction was 
stirred for 4.5 hours at 23 °C and was carefully monitored by TLC. The reaction was quenched 
by slowly adding buffer solution (pH = 7, 30 mL). The layers were separated and the aqueous 
layer was extracted with DCM (3x). The combined organic layers were dried over MgSO4. The 
resulting solution was concentrated and the crude product was purified by silica gel flash 
chromatography eluting with hexanes/EtOAc (20:1) to yield M-47 (165 mg, 18%) with an 
isomeric ratio of 1.0/1.2 (47[F7F7]/47[F9F7], based on 19F NMR; 1.0/1.2 based on F-HPLC) as 
a yellow oil: 1H NMR (see appendix); MS (ESI) m/z [M + Na]+ 909.2 (47[F7F7]), 959.2 
(47[F9F7]); HRMS (MALDI) for 47[F7F7] m/z [M + Na]+ calcd for C37H56F14NaO4Si2: 
909.3391, found 909.3353; 47[F9F7] m/z [M + Na]+ calcd for C38H56F16NaO4Si2: 959.3359, 
found 959.3391; analytical fluorous HPLC (condition 2) tR = 3.6 min (47[F7F7]), 4.4 min 
(47[F9F7]).  
 
(2R) 3 5HO
OTIPSF7,F9
OBn OTIPS
F7F0: (3S,5R)
F9F0: (3R,5R)
 
(2R,3R/S,5R)-2-((Perfluoroalkylethyl)diisopropylsilyloxy)-3-(benzyloxy)-5-(triisopropylsily-
loxy)oct-7-en-1-ol (M-54):  
The same procedure as M-47 was followed by employing M-37b (190 mg, 0.218 mmol), 
hydrochloric acid (1 M in H2O) (0.22 mL, 0.218 mmol), and EtOH (15 mL). The mixture was 
stirred for 7 h at 23 °C. The title compound M-54 was prepared as a yellow oil (88.0 mg, 53%), 
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with an isomeric ratio of 1.0/0.74 (54[F7F0]/54[F9F0], based on 19F NMR; 1.0/0.79 based on 
F-HPLC): 1H NMR (see appendix); MS (ESI) m/z [M + Na]+ 755.3 (54[F7F0]), 805.3 
(54[F9F0]); HRMS (MALDI) for 54[F7F0] m/z [M + Na]+ calcd for C35H59F7NaO4Si2: 
755.3738, found 755.3723; 54[F9F0] m/z [M + Na]+ calcd for C36H59F9NaO4Si2: 805.3706, 
found 805.3636; analytical fluorous HPLC (condition 2) tR = 2.5 min (54[F7F0]), 2.8 min 
(54[F9F0]).  
 
O
OTIPSF7,F9
OBn OTIPSF0,F7
F7F0: (3S,5R)
F9F0: (3R,5R)
F7F7: (3S,5S)
F9F7: (3R,5S)
(2S)
3 5
 
(2S,3R/S,5R/S)-3-(Benzyloxy)-2,5-bis((perfluoroalkylethyl)diisopropylsilyloxy)oct-7-enal 
(M-36):60
Alcohols M-47 (106 mg, 0.116 mmol) and M-54 (87.0 mg, 0.115 mmol) were dissolved in 
dry DCM (25 mL) in a 50 mL round bottom flask. Dess-Martin periodinane (196 mg, 0.462 
mmol) was added to the solution. The reaction was stirred for 2 h. The solution was filtered 
through a pad of silica gel and then concentrated under reduced pressure to yield M-36 (160 mg, 
83%) with an isomeric ratio of 1.0/0.85/1.3/1.4 (36[F7F0]/36[F9F0]/36[F7F7]/36[F9F7], based 
on F-HPLC) as a colorless oil: 1H NMR (see appendix); MS (ESI) m/z [M + Na]+ 753.3 
(36[F7F0]), 803.2 (36[F9F0]), 907.3 (36[F7F7]), 957.3 (36[F9F7]); HRMS (MALDI) for 
36[F7F0] m/z [M + Na]+ calcd for C35H57F7NaO4Si2: 753.3581, found 753.3495; 36[F9F0] m/z 
[M + Na]+ calcd for C36H57F9NaO4Si2: 803.3549, found 803.3471; 36[F7F7] m/z [M + Na]+ 
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calcd for C37H54F14NaO4Si2: 907.3235, found 907.3276; 36[F9F7] m/z [M + Na]+ calcd for 
C38H54F16NaO4Si2: 957.3203, found 957.3179; analytical fluorous HPLC (condition 2) tR = 3.8 
min (36[F7F0]), 4.6 min (36[F9F0]), 7.0 min (36[F7F7]), 9.2 min (36[F9F7]).  
 
OTIPSF7,F9
BnO
F0,F7TIPSO
C5H11
O
O
(4R)
(R)
5
7
F7F0: (5S,7R)
F9F0: (5R,7R)
F7F7: (5S,7S)
F9F7: (5R,7S)
 
(4R,5R/S,7R/S,E)-((R)-Dec-1-en-5-yl)-5-(benzyloxy)-4,7-bis((perfluoroalkylethyl)diisoprop-
ylsilyloxy)deca-2,9-dienoate (M-56):  
The same procedure as 28 was followed by employing LiCl (9.7 mg, 0.229 mmol), 
phosphonate 5-(R) (76.6 mg, 0.229 mmol), anhydrous acetonitrile (15 mL), DBU (29.1 mg, 
0.191 mmol) and aldehyde M-36 (159 mg, 0.191 mmol). The title compound M-56 was prepared 
as a colorless oil (146 mg, 76%), with an isomeric ratio of 1.0/0.46/1.1/0.71 
(56[F7F0]/56[F9F0]/56[F7F7]/56[F9F7], based on F-HPLC): 1H NMR (see appendix); HRMS 
(MALDI) for 56[F7F0] m/z [M + Na]+ calcd for C47H77F7NaO5Si2: 933.5095, found 933.5176; 
56[F9F0] m/z [M + Na]+ calcd for C48H77F9NaO5Si2: 983.5064, found 983.5159; 56[F7F7] m/z 
[M + Na]+ calcd for C49H74F14NaO5Si2: 1087.4749, found 1087.4863; 56[F9F7] m/z [M + Na]+ 
calcd for C50H74F16NaO5Si2: 1137.4717, found 1137.4756; analytical fluorous HPLC (condition 
2) tR = 3.7 min (56[F7F0]), 4.5 min (56[F9F0]), 6.5 min (56[F7F7]), 9.0 min (56[F9F7]).  
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O
C5H11
O
OBn
OTIPSF0,F7
OTIPSF7,F9
F7F0: (5S,7R)
F9F0: (5R,7R)
F7F7: (5S,7S)
F9F7: (5R,7S)
(13R) (4R)
 
(2E,4R,5R/S,7R/S,9E/Z,13R)-5-(Benzyloxy)-13-pentyl-4,7-bis((perfluoroalkylethyl)diiso- 
propylsilyloxy)oxacyclotetradeca-2,9-dien-1-one (M-35):  
The same procedure as 3 was followed by employing M-56 (135 mg, 0.133 mmol), Grubbs 
1st generation catalyst [(PCy3)2Cl2Ru=CHPh] (110 mg, 0.133 mmol) and anhydrous DCM (156 
mL, and another 10 mL to dissolve the catalyst). The title compound M-35 was prepared as a 
yellow/brown oil (112 mg, 75%) with an isomeric ratio of 1.0/0.32/0.65/0.57 
(35[F7F0]/35[F9F0]/35[F7F7]/35[F9F7], based on F-HPLC): 1H NMR (see appendix); MS 
(ESI) m/z [M + Na]+ 905.5 (35[F7F0]), 955.5 (35[F9F0]), 1059.5 (35[F7F7]), 1109.5 
(35[F9F7]); analytical fluorous HPLC (condition 1, listed as major peaks) tR = 32.7 min 
(35[F7F0]), 35.0 min (35[F9F0]), 44.5 min (35[F7F7]), 51.6 min (35[F9F7]).  
 
O
OBn
O
Si
O
Si
CF2CF2CF3
 
(2S,3R,5S)-3-(Benzyloxy)-5-((3,3,4,4,5,5,5-heptafluoropentyl)diisopropylsilyloxy)-2-(triiso- 
propylsilyloxy)oct-7-enal (58):  
The same procedure as M-36 was followed by employing 50 (106 mg, 0.145 mmol), 
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Dess-Martin periodinane (123 mg, 0.289 mmol) and dry DCM (15 mL). The title compound 58 
was prepared as a colorless oil (89.0 mg, 84%): 1H NMR (300 MHz, CDCl3) δ 9.77 (d, J = 1.8 
Hz, 1H), 7.34–7.26 (m, 5H), 5.78 (ddt, J = 16.2, 11.1, 7.2 Hz, 1H), 5.05 (d, J = 10.8 Hz, 1H), 
5.04 (d, J = 16.5 Hz, 1H), 4.70 (d, J = 11.4 Hz, 1H), 4.55 (d, J = 11.4 Hz, 1H), 4.35 (dd, J = 4.5, 
1.8 Hz, 1H), 4.06 (m, 1H), 3.94 (ddd, J = 10.5, 4.5, 2.4 Hz, 1H), 2.28 (m, 2H), 2.11 (m, 2H), 
1.85 (ddd, J = 14.1, 8.4, 2.4 Hz, 1H), 1.67 (ddd, J = 14.1, 10.5, 3.6 Hz, 1H), 1.15–0.92 (m, 35H), 
0.86 (m, 2H).  
 
OBn
O
Si
O
Si
CF2CF2CF3C5H11
O
O
 
(4R,5R,7S,E)-((S)-Dec-1-en-5-yl)-5-(benzyloxy)-7-((3,3,4,4,5,5,5-heptafluoropentyl)diisopr- 
opylsilyloxy)-4-(triisopropylsilyloxy)deca-2,9-dienoate (59):  
The same procedure as 28 was followed by employing LiCl (6.1 mg, 0.145 mmol), 
phosphonate 5-(S) (48.3 mg, 0.145 mmol), anhydrous acetonitrile (10 mL), DBU (18.3 mg, 
0.120 mmol) and aldehyde 58 (88.0 mg, 0.120 mmol). The title compound 59 was prepared as a 
colorless oil (98.0 mg, 89%): 1H NMR (500 MHz, CDCl3) δ 7.36–7.27 (m, 5H), 7.01 (dd, J = 
15.5, 4.5 Hz, 1H), 6.02 (dd, J = 15.5, 1.5 Hz, 1H), 5.78 (m, 2H), 5.00 (m, 4H), 4.69 (dd, J = 4.5, 
1.5 Hz, 1H), 4.67 (d, J = 11.5 Hz, 1H), 4.57 (d, J = 12.0 Hz, 1H), 4.04 (m, 1H), 3.77 (ddd, J = 
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10.0, 4.0, 2.0 Hz, 1H), 2.28 (t, J = 6.0 Hz, 2H), 2.15–2.02 (m, 4H), 1.82 (m, 1H), 1.74 (ddd, J = 
14.5, 8.0, 2.5 Hz, 1H), 1.66 (m, 2H), 1.50 (m, 1H), 1.33–1.24 (m, 7H), 1.15–0.95 (m, 35H), 0.87 
(t, J = 7.0 Hz, 3H), 0.83 (m, 2H).  
 
O
O
OBn
O
Si
F3CF2CF2C
O Si
 
(3E,5R,6R,8S,10E,14S)-6-(Benzyloxy)-8-((3,3,4,4,5,5,5-heptafluoropentyl)diisopropylsilylo- 
xy)-14-pentyl-5-(triisopropylsilyloxy)oxacyclotetradeca-3,10-dien-2-one (60):  
The same procedure as 3 was followed by employing 59 (97.0 mg, 0.107 mmol), Grubbs 1st 
generation catalyst [(PCy3)2Cl2Ru=CHPh] (87.6 mg, 0.107 mmol), anhydrous DCM (123 mL, 
and another 10 mL to dissolve the catalyst). The title compound 60 was prepared as a 
yellow/brown oil (72 mg, 77%): 1H NMR (500 MHz, CDCl3) δ 7.37–7.26 (m, 5H), 6.96 (dd, J = 
16.0, 3.0 Hz, 1H), 6.02 (dd, J = 16.0, 1.5 Hz, 1H), 5.41 (ddd, J = 15.5, 6.0, 6.0 Hz, 1H), 5.29 
(ddd, J = 15.5, 8.0, 6.0 Hz, 1H), 4.99 (m, 1H), 4.69 (t, J = 4.5 Hz, 1H), 4.68 (d, J = 12.0 Hz, 1H), 
4.54 (d, J = 12.0 Hz, 1H), 3.87 (m, 1H), 3.68 (dt, J = 10.5, 4.5 Hz, 1H), 2.42 (m, 1H), 2.32 (m, 
1H), 2.17–2.01 (m, 4H), 1.97 (ddd, J = 14.3, 10.1, 6.9 Hz, 1H), 1.85 (m, 1H), 1.69 (m, 2H), 1.55 
(m, 1H), 1.41 (dt, J = 13.7, 4.0 Hz, 1H), 1.37–1.25 (m, 6H), 1.10–0.92 (m, 35H), 0.88 (t, J = 6.5 
Hz, 3H), 0.78 (m, 2H).  
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(5R,6R,8S,14S,E)-6-(Benzyloxy)-8-((3,3,4,4,5,5,5-heptafluoropentyl)diisopropylsilyloxy)-14-
pentyl-5-(triisopropylsilyloxy)oxacyclotetradec-3-en-2-one (61):  
A magnetically stirred solution of 60 (8.0 mg, 0.00906 mmol) in ethanol (8 mL) containing 
Pd/SrCO3 (2 wt.%) (48.2 mg catalyst, 0.00906 mmol Pd) was placed under a hydrogen 
atmosphere at 23 °C for 1.5 h. The reaction was carefully monitored by TLC and was stopped 
before it was complete. The suspension was then filtered and the filtrate was concentrated under 
reduced pressure to afford a light yellow oil which was then subjected to silica gel flash 
chromatography eluting with hexanes/EtOAc (40:1) to yield the title compound 61 (4.4 mg, 55%) 
as a colorless oil: 1H NMR (500 MHz, CDCl3) δ 7.36–7.27 (m, 5H), 7.10 (dd, J = 16.0, 3.0 Hz, 
1H), 6.10 (dd, J = 16.0, 2.0 Hz, 1H), 4.99 (m, 1H), 4.72 (t, J = 2.0 Hz, 1H), 4.71 (d, J = 12.0 Hz, 
1H), 4.59 (d, J = 12.0 Hz, 1H), 3.91 (m, 1H), 3.70 (dt, J = 9.5, 5.0 Hz, 1H), 2.06 (m, 2H), 1.84 
(ddd, J = 14.8, 9.7, 5.0 Hz, 1H), 1.66 (m, 1H), 1.65–1.40 (m, 3H), 1.39–1.15 (m, 15H), 
1.15–0.90 (m, 35H), 0.88 (t, J = 6.5 Hz, 3H), 0.77 (m, 2H).  
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(5R,6R,8S,14S,E)-6-(Benzyloxy)-8-((3,3,4,4,5,5,5-heptafluoropentyl)diisopropylsilyloxy)-14-
pentyl-5-(triisopropylsilyloxy)oxacyclotetradec-10-en-2-one (62): 10c
Anhydrous hydrazine (18.1 mg, 0.566 mol) was added to a suspension of 60 (5.0 mg, 
0.00566 mmol) and CuSO4 (5.1 mg, 0.0566 mmol) in ethanol (0.5 mL). After being stirred at 
room temperature for 15 min, the reaction mixture was warmed to 70 °C. After being stirred at 
70 °C for 20 h, the reaction was cooled to room temperature. H2O (1.5 mL) was added, and the 
reaction mixture was extracted with ether (3x). The organic layers were combined, washed with 
brine. The combined organic layers were dried over MgSO4. The resulting solution was 
concentrated and the crude product was purified by silica gel flash chromatography eluting with 
hexanes/EtOAc (30:1) to yield 62 (2.1 mg, 42%) as a colorless oil: 1H NMR (300 MHz, CDCl3) 
δ 7.32–7.26 (m, 5H), 5.45 (ddd, J = 15.6, 6.8, 6.8 Hz, 1H), 5.34 (ddd, J = 15.3, 7.5, 7.5 Hz, 1H), 
4.97 (m, 1H), 4.62 (d, J = 11.7 Hz, 1H), 4.48 (d, J = 11.7 Hz, 1H), 4.16 (dt, J = 9.3, 3.1 Hz, 1H), 
4.01 (m, 1H), 3.72 (dt, J = 12.3, 3.1 Hz, 1H), 2.56–1.95 (m, 10H), 1.75 (m, 1H), 1.61 (m, 1H), 
1.50 (m, 2H), 1.35–1.20 (m, 8H), 1.09–0.92 (m, 35H), 0.86 (t, J = 6.3 Hz, 3H), 0.82 (m, 2H).  
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(5R,6R,8S,14S)-6-(Benzyloxy)-8-((3,3,4,4,5,5,5-heptafluoropentyl)diisopropylsilyloxy)-14- 
pentyl-5-(triisopropylsilyloxy)oxacyclotetradecan-2-one (63):  
Following the same procedure as 61, lactone 60 (8.7 mg, 0.00985 mmol), Pd/SrCO3 (2 wt.%) 
(52.4 mg catalyst, 0.00985 mmol Pd) and ethanol (8 mL) were mixed and the mixture was stirred 
at 23 °C for 24 h. The filtered and concentrated crude mixture was subjected to the preparative 
fluorous HPLC with the standard demixing conditions to afford the title compound 63 (3.5 mg, 
40%) and 61 (2.0 mg, 23%) as colorless oils: 1H NMR (63) (500 MHz, CDCl3) δ 7.35–7.28 (m, 
5H), 4.89 (m, 1H), 4.60 (d, J = 12.0 Hz, 1H), 4.56 (d, J = 12.0 Hz, 1H), 4.09 (dt, J = 9.5, 3.5 Hz, 
1H), 3.98 (quint, J = 6.0 Hz, 1H), 3.61 (ddd, J = 8.0, 5.0, 3.5 Hz, 1H), 2.55 (dt, J = 16.6, 5.9 Hz, 
1H), 2.37 (ddd, J = 16.0, 9.2, 6.9 Hz, 1H), 2.14–1.97 (m, 4H), 1.87 (ddd, J = 15.1, 9.2, 6.5 Hz, 
1H), 1.82 (dt, J = 14.0, 5.7 Hz, 1H), 1.69 (m, 1H), 1.57 (m, 2H), 1.50–1.39 (m, 5H), 1.39–1.20 
(m, 10H), 1.11–0.90 (m, 35H), 0.87 (t, J = 6.5 Hz, 3H), 0.82 (m, 2H).  
 
F7F0: (5S,7R)
F9F0: (5R,7R)
F7F7: (5S,7S)
F9F7: (5R,7S)
O
C5H11
O
OBn
OTIPSF0,F7
OTIPSF7,F9
(4R)(13R)
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(2E,4R,5R/S,7R/S,13R)-5-(Benzyloxy)-13-pentyl-4,7-bis((perfluoroalkylethyl)diisopropylsil-
yloxy)oxacyclotetradec-2-en-1-one (M-64): 63
A mixture of M-35 (15.0 mg, 0.0152 mmol), ethanol (6.5 mL) and Pd/SrCO3 (2 wt.%) (81.0 
mg catalyst, 0.0152 mmol Pd) was placed under a hydrogen atmosphere and stirred at 23 °C for 
24 h. The reaction was carefully monitored by analytical fluorous HPLC (condition 1): tR = 42.4 
min (64[F7F0]), 44.4 min (64[F9F0]), 54.9 min (64[F7F7]), 63.1 min (64[F9F7]). The reaction 
mixture was then filtered and the filtrate was concentrated under reduced pressure to afford a 
light yellow oil which was subjected to preparative fluorous HPLC with the standard demixing 
conditions. Demixing of the crude product (16.0 mg) afforded quasidiastereomers 64[F7F0] (3.3 
mg), 64[F9F0] (2.4 mg), 64[F7F7] (2.9 mg), 64[F9F7] (3.5 mg) as colorless oils. The yield of 
the reaction was 81% (based on the total weight of four products: 12.1 mg) and the recovery of 
the demixing was 76%. Characterizations of the four products are shown below.  
 
O
O
O
OBn
OTIPS
Si
C3F7
 
(4R,5S,7R,13R,E)-5-(Benzyloxy)-4-((3,3,4,4,5,5,5-heptafluoropentyl)diisopropylsilyloxy)-13-
pentyl-7-(triisopropylsilyloxy)oxacyclotetradec-2-en-1-one (64[F7F0]):  
1H NMR (500 MHz, CDCl3) δ 7.33–7.20 (m, 5H), 6.67 (dd, J = 16.0, 7.5 Hz, 1H), 5.76 (dd, J = 
16.0, 1.0 Hz, 1H), 4.87 (m, 1H), 4.62 (d, J = 12.0 Hz, 1H), 4.53 (d, J = 12.0 Hz, 1H), 4.49 (d, J 
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= 7.5 Hz, 1H), 3.90 (m, 1H), 3.40 (td, J = 4.0, 1.0 Hz, 1H), 2.26–2.02 (m, 2H), 1.81 (ddd, J = 
14.5, 7.0, 5.0 Hz, 1H), 1.65–1.55 (m, 3H), 1.50 (m, 1H), 1.41 (m, 1H), 1.38–1.20 (m, 12H), 
1.20–1.09 (m, 2H), 1.09–0.96 (m, 35H), 0.85 (t, J = 7.5 Hz, 3H), 0.83 (m, 2H); 13C NMR (75 
MHz, CDCl3) δ 165.7, 147.8, 137.9, 128.2, 127.7, 127.4, 122.2, 79.4, 75.7, 75.2, 71.5, 70.0, 37.2, 
36.4, 35.7, 35.4, 31.7, 27.8, 27.4, 25.2, 24.8, 24.1, 22.5, 18.2 (m), 17.5 (m), 13.9, 12.6 (m), 0.4.  
 
O
O
OBn
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O
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(4R,5R,7R,13R,E)-5-(Benzyloxy)-4-(diisopropyl(3,3,4,4,5,5,6,6,6-nonafluorohexyl)silyloxy)- 
13-pentyl-7-(triisopropylsilyloxy)oxacyclotetradec-2-en-1-one (64[F9F0]):  
1H NMR (500 MHz, CDCl3) δ 7.33–7.22 (m, 5H), 6.76 (dd, J = 16.0, 8.0 Hz, 1H), 6.00 (d, J = 
16.0, 1H), 5.08 (m, 1H), 4.75 (d, J = 12.0 Hz, 1H), 4.61 (d, J = 12.0 Hz, 1H), 4.26 (t, J = 8.0 Hz, 
1H), 3.78 (tt, J = 9.5, 5.0 Hz, 1H), 3.29 (td, J = 7.5, 3.0 Hz, 1H), 2.22–2.01 (m, 2H), 1.80–1.60 
(m, 2H), 1.50–1.40 (m, 2H), 1.40–1.15 (m, 16H), 1.15–0.94 (m, 35H), 0.85 (t, J = 6.0 Hz, 3H), 
0.83 (m, 2H); 13C NMR (75 MHz, CDCl3) δ 165.7, 146.6, 138.5, 128.2, 127.9, 127.5, 124.8, 81.2, 
77.3, 75.9, 74.0, 68.8, 38.0, 34.5, 33.1, 31.6, 31.5, 30.3, 25.3, 25.2, 24.3, 22.5, 21.4, 18.1 (m), 
17.5 (m), 13.9, 12.5 (m), 0.5.  
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(4R,5S,7S,13R,E)-5-(Benzyloxy)-4,7-bis((3,3,4,4,5,5,5-heptafluoropentyl)diisopropylsilyloxy)
-13-pentyloxacyclotetradec-2-en-1-one (64[F7F7]):  
1H NMR (500 MHz, CDCl3) δ 7.34–7.25 (m, 5H), 6.79 (dd, J = 16.0, 7.0 Hz, 1H), 5.87 (dd, J = 
16.0, 1.0 Hz, 1H), 4.89 (m, 1H), 4.66 (d, J = 7.0 Hz, 1H), 4.59 (d, J = 12.0 Hz, 1H), 4.36 (d, J = 
12.0 Hz, 1H), 3.65 (m, 1H), 2.97 (d, J = 7.5 Hz, 1H), 2.27–2.00 (m, 4H), 1.95 (dd, J = 14.9, 10.3 
Hz, 1H), 1.61 (m, 2H), 1.40 (m, 1H), 1.36–1.22 (m, 14H), 1.17 (m, 2H), 1.09–0.91 (m, 28H), 
0.87 (t, J = 6.5 Hz, 3H), 0.81 (m, 4H); 13C NMR (75 MHz, CDCl3) δ 165.7, 148.2, 137.6, 128.4, 
128.2, 127.9, 122.1, 80.7, 75.8, 72.4, 71.3, 69.4, 37.2, 35.1, 34.1, 32.1, 31.7, 28.2, 25.7, 25.3, 
25.0, 24.9, 22.5, 20.0, 17.5 (m), 13.9, 12.6 (m), 0.4, 0.3.  
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C4F9  
(4R,5R,7S,13R,E)-5-(Benzyloxy)-4-(diisopropyl(3,3,4,4,5,5,6,6,6-nonafluorohexyl)silyloxy)- 
7-((3,3,4,4,5,5,5-heptafluoropentyl)diisopropylsilyloxy)-13-pentyloxacyclotetradec-2-en-1- 
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one (64[F9F7]):  
1H NMR (500 MHz, CDCl3) δ 7.34–7.25 (m, 5H), 6.81 (dd, J = 16.0, 5.5 Hz, 1H), 6.04 (dd, J = 
16.0, 1.0 Hz, 1H), 5.03 (m, 1H), 4.67 (d, J = 11.5 Hz, 1H), 4.61 (d, J = 12.0 Hz, 1H), 4.47 (t, J = 
5.5 Hz, 1H), 3.82 (m, 1H), 3.65 (td, J = 5.5, 4.5 Hz, 1H), 2.18–1.95 (m, 4H), 1.80–1.60 (m, 2H), 
1.41 (m, 2H), 1.39–1.16 (m, 16H), 1.09–0.92 (m, 28H), 0.88 (t, J = 6.5 Hz, 3H), 0.82 (m, 4H). 
13C NMR (125 MHz, CDCl3) δ 166.4, 146.2, 138.4, 128.3, 127.6, 127.3, 124.1, 79.2, 75.6, 73.4, 
72.8, 69.8, 37.8, 37.0, 33.8, 31.9, 31.7, 31.3, 29.8, 25.3, 25.2, 24.5, 24.3, 22.5, 17.5 (m), 13.9, 
12.7 (m), 0.9, 0.2.  
 
O
O
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OH
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(4R,5S,7R,13R,E)-4,5,7-Trihydroxy-13-pentyloxacyclotetradec-2-en-1-one (2a):  
The same procedure as 2d was followed by employing 64[F7F0] (3.3 mg, 0.00373 mmol), 
ethane thiol (15.0 μL, 0.220 mmol), BF3?Et2O (5.0 μL, 0.0380 mmol) and dry DCM (3.7 mL). 
The title compound 2a was prepared and then purified by preparative reverse phase HPLC to 
afford a white solid (0.9 mg, 74 %): [α]D25 –22.2 (c 0.081, MeOH); 1H NMR (500 MHz, 
MeOD-d4) δ 6.87 (dd, J = 16.0, 6.0 Hz, 1H), 6.08 (dd, J = 15.5, 1.5 Hz, 1H), 4.95 (dddd, J = 9.5, 
7.5, 4.5, 2.0 Hz, 1H), 4.48 (ddd, J = 6.0, 3.0, 1.5 Hz, 1H), 3.99 (quint, J = 6.5 Hz, 1H), 3.85 (ddd, 
J = 6.0, 4.5, 3.5 Hz, 1H), 1.83 (ddd, J = 14.6, 6.2, 6.2 Hz, 1H), 1.71 (m, 1H), 1.68–1.51 (m, 4H), 
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1.45 (m, 1H), 1.40–1.27 (m, 10H), 1.25–1.12 (m, 3H), 0.90 (t, J = 7.0 Hz, 3H); 13C NMR (150 
MHz, MeOD-d4) δ 168.5, 149.3, 123.1, 77.6, 76.0, 72.9, 69.5, 38.3, 36.8, 36.5, 34.1, 33.0, 29.5, 
27.0, 26.4, 25.8, 23.8, 14.5; IR (thin film) 3685, 3610, 3020, 2930, 1711, 1521, 1424, 1216, 1035, 
929 cm–1; HRMS (MALDI) m/z [M + H]+ calcd for C18H33O5: 329.2328, found 329.2356.  
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(4R,5R,7R,13R,E)-4,5,7-Trihydroxy-13-pentyloxacyclotetradec-2-en-1-one (2b):  
The same procedure as 2d was followed by employing 64[F9F0] (2.4 mg, 0.00257 mmol), 
ethane thiol (15.0 μL, 0.220 mmol), BF3?Et2O (5.0 μL, 0.0380 mmol) and dry DCM (3.7 mL). 
The title compound 2b was prepared and then purified by preparative reverse phase HPLC to 
afford a white solid (0.5 mg, 53 %): [α]D25 +18.7 (c 0.075, MeOH); 1H NMR (500 MHz, 
MeOD-d4) δ 6.91 (dd, J = 16.0, 6.5 Hz, 1H), 6.11 (dd, J = 15.5, 1.0 Hz, 1H), 5.02 (m, 1H), 4.16 
(td, J = 6.5, 1.0 Hz, 1H), 3.82 (ddd, J = 8.7, 5.7, 3.7 Hz, 1H), 3.78 (m, 1H), 1.77 (m, 1H), 
1.67–1.59 (m, 1H), 1.63 (ddd, J = 14.0, 9.0, 3.5 Hz, 1H), 1.56 (m, 1H), 1.51–1.39 (m, 5H), 
1.38–1.26 (m, 6H), 1.26–1.15 (m, 2H), 1.11 (m, 1H), 0.90 (t, J = 6.5 Hz, 3H); 13C NMR (150 
MHz, MeOD-d4) δ 168.3, 148.4, 124.3, 77.6, 77.5, 73.4, 67.7, 42.0, 37.0, 36.0, 34.5, 32.9, 30.1, 
26.5, 26.4, 25.4, 23.8, 14.6; IR (thin film) 3684, 3620, 3020, 2930, 1712, 1525, 1425, 1217, 1029, 
929 cm–1; HRMS (MALDI) m/z [M + Na]+ calcd for C18H32NaO5: 351.2147, found 351.2143.  
 193
 O
O
OH
OH
OH
 
(4R,5S,7S,13R,E)-4,5,7-Trihydroxy-13-pentyloxacyclotetradec-2-en-1-one (2c):  
The same procedure as 2d was followed by employing 64[F7F7] (3.9 mg, 0.00375 mmol), 
ethane thiol (16.0 μL, 0.234 mmol), BF3?Et2O (5.5 μL, 0.0380 mmol) and dry DCM (3.0 mL). 
The title compound 2c was prepared and then purified by preparative reverse phase HPLC to 
afford a white solid (0.7 mg, 59%): [α]D25 –10.7 (c 0.056, MeOH); 1H NMR (700 MHz, 
MeOD-d4) δ 6.95 (dd, J = 16.0, 4.5 Hz, 1H), 6.14 (dd, J = 15.5, 1.5 Hz, 1H), 4.94 (tt, J = 8.4, 
5.6 Hz, 1H), 4.55 (dddd, J = 4.3, 2.6, 1.8, 0.9 Hz, 1H), 3.89 (dt, J = 9.0, 2.5 Hz, 1H), 3.38 (ddt, J 
= 11.6, 7.7, 2.8 Hz, 1H), 2.02 (ddd, J = 14.5, 9.0, 2.0 Hz, 1H), 1.68–1.61 (m, 3H), 1.57–1.45 (m, 
3H), 1.45–1.25 (m, 10H), 1.24–1.16 (m, 3H), 0.91 (t, J = 6.5 Hz, 3H); 13C NMR (150 MHz, 
MeOD-d4) δ 169.1, 150.0, 121.8, 75.6, 75.0, 72.1, 68.8, 40.5, 36.2, 35.9, 33.9, 33.0, 27.3, 26.5, 
24.8, 24.6, 23.8, 14.5; IR (thin film) 3684, 3381, 3020, 2931, 1708, 1521, 1424, 1216, 1065, 929 
cm–1; HRMS (MALDI) m/z [M + Na]+ calcd for C18H32NaO5: 351.2147, found 351.2143.  
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(4R,5R,7S,13R,E)-4,5,7-Trihydroxy-13-pentyloxacyclotetradec-2-en-1-one (2d):  
The same procedure as 2d in the single isomer synthesis was followed by employing 
64[F9F7] (3.5 mg, 0.00279 mmol), ethane thiol (15.0 μL, 0.220 mmol), BF3?Et2O (5.0 μL, 
0.0380 mmol) and dry DCM (3.2 mL). The title compound 2d was prepared and then purified by 
preparative reverse phase HPLC to afford a white solid (1.0 mg, 94%). Spectroscopy data are 
identical with 2d prepared in the single isomer synthesis.  
 
OTIPSF7,F9
BnO
F0,F7TIPSO
C5H11
O
O
(4R)
(S)
5
7
F7F0: (5S,7R)
F9F0: (5R,7R)
F7F7: (5S,7S)
F9F7: (5R,7S)
 
(4R,5R/S,7R/S,E)-((S)-Dec-1-en-5-yl)-5-(benzyloxy)-4,7-bis((perfluoroalkylethyl)diisoprop-y
lsilyloxy)deca-2,9-dienoate (M-65):  
The same procedure as 28 was followed by employing LiCl (12.8 mg, 0.303 mmol), 
phosphonate 5-(S) (101 mg, 0.303 mmol), anhydrous acetonitrile (20 mL), DBU (38.4 mg, 0.252 
mmol) and aldehyde M-36 (210 mg, 0.252 mmol). The title compound M-65 was prepared as a 
colorless oil (202 mg, 79%), with an isomeric ratio of 1.0/0.33/0.80/0.67 
(65[F7F0]/65[F9F0]/65[F7F7]/65[F9F7], based on F-HPLC): 1H NMR (see appendix); 
analytical fluorous HPLC (condition 1) tR = 32.4 min (65[F7F0]), 35.5 min (65[F9F0]), 40.5 min 
(65[F7F7]), 45.0 min (65[F9F7]).  
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O
C5H11
O
OBn
OTIPSF0,F7
OTIPSF7,F9
F7F0: (5S,7R)
F9F0: (5R,7R)
F7F7: (5S,7S)
F9F7: (5R,7S)
(13S) (4R)
 
(2E,4R,5R/S,7R/S,9E/Z,13S)-5-(Benzyloxy)-13-pentyl-4,7-bis((perfluoroalkylethyl)diiso- 
propylsilyloxy)oxacyclotetradeca-2,9-dien-1-one (M-66):  
The same procedure as 3 was followed by employing M-65 (200 mg, 0.197 mmol), Grubbs 
1st generation catalyst [(PCy3)2Cl2Ru=CHPh] (155 mg, 0.188 mmol) and anhydrous DCM (250 
mL, and another 15 mL to dissolve the catalyst). The title compound M-66 was prepared as a 
yellow/brown oil (167 mg, 86%) with an isomeric ratio of 1.0/0.34/0.78/0.58 
(66[F7F0]/66[F9F0]/66[F7F7]/66[F9F7], based on F-HPLC): 1H NMR (see appendix); 
analytical fluorous HPLC (condition 1, listed as major peaks) tR = 28.5 min (66[F7F0]), 33.3 min 
(66[F9F0]), 37.2 min (66[F7F7]), 41.5 min (66[F9F7]).  
 
F7F0: (5S,7R)
F9F0: (5R,7R)
F7F7: (5S,7S)
F9F7: (5R,7S)
O
C5H11
O
OBn
OTIPSF0,F7
OTIPSF7,F9
(4R)(13S)
 
(2E,4R,5R/S,7R/S,13S)-5-(Benzyloxy)-13-pentyl-4,7-bis((perfluoroalkylethyl)diisopropylsil-
yloxy)oxacyclotetradec-2-en-1-one (M-67): 63
A mixture of M-66 (25.0 mg, 0.0253 mmol), ethanol (8.0 mL) and Pd/SrCO3 (2 wt.%) (135 
mg catalyst, 0.0253 mmol Pd) was placed under a hydrogen atmosphere and stirred at 23 °C for 
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15 h. The reaction was carefully monitored by analytical fluorous HPLC (condition 1): tR = 29.5 
min (67[F7F0]), 34.0 min (67[F9F0]), 38.6 min (67[F7F7]), 43.8 min (67[F9F7]). The reaction 
mixture was then filtered and the filtrate was concentrated under reduced pressure to afford a 
light yellow oil which was subjected to preparative fluorous HPLC with the standard demixing 
conditions. Demixing of the crude product afforded quasidiastereomers 67[F7F0] (5.4 mg), 
67[F9F0] (4.5 mg), 67[F7F7] (5.0 mg), 67[F9F7] (4.4 mg) as colorless oils. The yield of the 
reaction was 77% (based on the total weight of four products: 19.3 mg). Characterizations of the 
four products are shown below.  
 
O
O
O
OBn
OTIPS
Si
C3F7
 
(4R,5S,7R,13S,E)-5-(Benzyloxy)-4-((3,3,4,4,5,5,5-heptafluoropentyl)diisopropylsilyloxy)-13-
pentyl-7-(triisopropylsilyloxy)oxacyclotetradec-2-en-1-one (67[F7F0]):  
1H NMR (500 MHz, CDCl3) δ 7.34–7.26 (m, 5H), 6.76 (dd, J = 15.5, 3.0 Hz, 1H), 6.03 (dd, J = 
15.5, 2.0 Hz, 1H), 4.96 (dtd, J = 7.5, 6.0, 4.0 Hz, 1H), 4.68 (m, 1H), 4.61 (d, J = 12.0 Hz, 1H), 
4.53 (d, J = 12.0 Hz, 1H), 3.75 (tt, J = 7.0, 3.5 Hz, 1H), 3.53 (ddd, J = 7.0, 4.0, 1.5 Hz, 1H), 
2.15–1.96 (m, 2H), 1.71–1.60 (m, 2H), 1.67 (ddd, J = 13.5, 9.0, 4.0 Hz, 1H), 1.54–1.45 (m, 3H), 
1.37–1.15 (m, 14H), 1.09–0.98 (m, 35H), 0.87 (t, J = 6.5 Hz, 3H), 0.76 (m, 2H); 13C NMR (75 
MHz, CDCl3) δ 165.4, 147.2, 138.2, 128.3, 127.8, 127.6, 122.0, 78.1, 74.7, 74.5, 71.2, 69.0, 36.8, 
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34.6, 33.0, 31.7, 30.9, 29.7, 27.5, 25.3, 23.6, 22.5, 21.7, 18.2 (m), 17.6 (m), 14.0, 12.7 (m), 0.8.  
 
O
O
OBn
OTIPS
O
Si
C4F9
 
(4R,5R,7R,13S,E)-5-(Benzyloxy)-4-(diisopropyl(3,3,4,4,5,5,6,6,6-nonafluorohexyl)silyloxy)- 
13-pentyl-7-(triisopropylsilyloxy)oxacyclotetradec-2-en-1-one (67[F9F0]):  
1H NMR (500 MHz, CDCl3) δ 7.31–7.22 (m, 5H), 7.12 (dd, J = 16.0, 4.5 Hz, 1H), 6.11 (dd, J = 
16.0, 2.0 Hz, 1H), 4.91 (quint, J = 5.5 Hz, 1H), 4.65 (d, J = 12.0 Hz, 1H), 4.63 (d, J = 12.0 Hz, 
1H), 4.37 (ddd, J = 8.0, 4.5, 2.0 Hz, 1H), 3.69 (m, 1H), 3.26 (dt, J = 7.0, 3.0 Hz, 1H), 2.20–2.05 
(m, 2H), 1.82 (ddd, J = 15.0, 8.0, 4.0 Hz, 1H), 1.68–1.59 (m, 3H), 1.58–1.41 (m, 3H), 1.40–1.17 
(m, 12H), 1.17–1.10 (m, 1H), 1.09–0.96 (m, 35H), 0.87 (t, J = 7.0 Hz, 3H), 0.85 (m, 2H); 13C 
NMR (75 MHz, CDCl3) δ 165.5, 148.0, 138.4, 128.2, 127.8, 127.5, 122.4, 81.4, 75.6, 75.5, 73.1, 
69.2, 38.2, 35.2, 34.8, 31.7, 31.4, 29.7, 28.3, 25.4, 25.0, 22.5, 22.0, 18.4 (m), 17.6 (m), 14.0, 12.6 
(m), 0.2.  
 
O
O
OBn
O
Si
C3F7
O Si
C3F7  
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(4R,5S,7S,13S,E)-5-(Benzyloxy)-4,7-bis((3,3,4,4,5,5,5-heptafluoropentyl)diisopropylsilyloxy)
-13-pentyloxacyclotetradec-2-en-1-one (67[F7F7]):  
1H NMR (500 MHz, CDCl3) δ 7.38–7.25 (m, 5H), 6.73 (dd, J = 16.0, 3.0 Hz, 1H), 6.05 (dd, J = 
16.0, 2.0 Hz, 1H), 5.05 (m, 1H), 4.82 (m, 1H), 4.66 (d, J = 12.0 Hz, 1H), 4.33 (d, J = 12.0 Hz, 
1H), 3.73 (m, 1H), 3.14 (d, J = 9.5 Hz, 1H), 2.16–1.97 (m, 4H), 1.74–1.58 (m, 4H), 1.53–1.47 
(m, 2H), 1.46–1.38 (m, 2H), 1.38–1.23 (m, 8H), 1.22–1.12 (m, 4H), 1.10–0.96 (m, 28H), 
0.96–0.90 (m, 2H), 0.88 (t, J = 7.0 Hz, 3H), 0.78 (m, 2H); 13C NMR (75 MHz, CDCl3) δ 165.6, 
147.9, 137.5, 128.4, 128.3, 128.0, 122.7, 79.1, 75.7, 71.9, 71.5, 68.9, 33.9, 33.6, 33.3, 32.2, 31.7, 
30.7, 25.3, 25.3, 25.2, 24.2, 22.5, 20.3, 17.5 (m), 14.0, 12.6 (m), 0.6, 0.2.  
 
O
O
OBn
O
Si
C3F7
O Si
C4F9  
(4R,5R,7S,13S,E)-5-(Benzyloxy)-4-(diisopropyl(3,3,4,4,5,5,6,6,6-nonafluorohexyl)silyloxy)- 
7-((3,3,4,4,5,5,5-heptafluoropentyl)diisopropylsilyloxy)-13-pentyloxacyclotetradec-2-en-1- 
one (67[F9F7]):  
1H NMR (500 MHz, CDCl3) δ 7.38–7.21 (m, 5H), 7.05 (dd, J = 16.0, 3.5 Hz, 1H), 6.07 (dd, J = 
15.5, 2.0 Hz, 1H), 4.96 (qd, J = 7.0, 2.0 Hz, 1H), 4.68 (d, J = 12.0 Hz, 1H), 4.65 (d, J = 12.0 Hz, 
1H), 4.52 (ddd, J = 6.5, 4.5, 3.0 Hz, 1H), 3.89 (m, 1H), 3.55 (td, J = 7.0, 4.0 Hz, 1H), 2.14–1.97 
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(m, 4H), 1.85 (ddd, J = 15.0, 7.5, 5.5 Hz, 1H), 1.70–1.56 (m, 2H), 1.62 (dt, J = 15.5, 4.0 Hz, 1H), 
1.53–1.39 (m, 4H), 1.38–1.22 (m, 10H), 1.20–1.12 (m, 2H), 1.07–1.02 (m, 4H), 1.02–0.91 (m, 
24H), 0.88 (t, J = 7.0 Hz, 3H), 0.85–0.75 (m, 4H); 13C NMR (75 MHz, CDCl3) δ 165.6, 147.5, 
138.4, 128.2, 127.4, 127.1, 122.7, 79.1, 75.8, 73.3, 72.6, 69.9, 37.0, 36.3, 34.7, 32.0, 31.7, 29.7, 
29.1, 25.3, 25.2, 25.1, 23.5, 22.5, 17.5 (m), 14.0, 12.7 (m), 0.4, 0.2.  
 
O
O
OH
OH
OH
 
(4R,5S,7R,13S,E)-4,5,7-Trihydroxy-13-pentyloxacyclotetradec-2-en-1-one (2e):  
The same procedure as 2d was followed by employing 67[F7F0] (5.4 mg, 0.00610 mmol), 
ethane thiol (50.0 μL, 0.733 mmol), BF3?Et2O (7.0 μL, 0.0532 mmol) and dry DCM (1.5 mL). 
The title compound 2e was prepared and then purified by preparative reverse phase HPLC to 
afford a white solid (1.4 mg, 70 %): [α]D25 +4.4 (c 0.14, MeOH); 1H NMR (600 MHz, MeOD-d4) 
δ 7.01 (dd, J = 16.2, 3.6 Hz, 1H), 6.06 (dd, J = 15.6, 2.1 Hz, 1H), 4.95 (ddt, J = 13.2, 5.4, 2.4 Hz, 
1H), 4.46 (dt, J = 3.6, 2.1 Hz, 1H), 3.95 (ddd, J = 8.4, 4.2, 2.4 Hz, 1H), 3.67 (tt, J = 7.8, 4.2 Hz, 
1H), 2.02 (ddd, J = 13.8, 7.8, 4.2 Hz, 1H), 1.72–1.64 (m, 2H), 1.64–1.57 (m, 2H), 1.57–1.50 (m, 
2H), 1.53 (ddd, J = 13.8, 7.8, 4.8 Hz, 1H), 1.40–1.21 (m, 12H), 0.91 (t, J = 6.9 Hz, 3H); 13C 
NMR (150 MHz, MeOD-d4) δ 168.1, 150.1, 122.4, 76.1, 75.7, 72.1, 68.8, 39.5, 35.0, 34.7, 33.0, 
32.8, 28.7, 26.6, 24.9, 23.8, 23.5, 14.5; IR (thin film) 3684, 3610, 3412, 3020, 2931, 1708, 1521, 
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1424, 1216, 1044, 929 cm–1; HRMS (MALDI) m/z [M + Na]+ calcd for C18H32NaO5: 351.2147, 
found 351.2143.  
 
O
O
OH
OH
OH
 
(4R,5R,7R,13S,E)-4,5,7-Trihydroxy-13-pentyloxacyclotetradec-2-en-1-one (2f):  
The same procedure as 2d was followed by employing 67[F9F0] (4.5 mg, 0.00481 mmol), 
ethane thiol (50.0 μL, 0.733 mmol), BF3?Et2O (7.0 μL, 0.0532 mmol) and dry DCM (1.5 mL). 
The title compound 2f was prepared and then purified by preparative reverse phase HPLC to 
afford a white solid (0.6 mg, 38 %): [α]D25 –4.0 (c 0.075, MeOH); 1H NMR (600 MHz, 
MeOD-d4) δ 6.96 (dd, J = 15.6, 6.0 Hz, 1H), 6.09 (dd, J = 16.2, 1.8 Hz, 1H), 4.92 (m, 1H), 4.03 
(ddd, J = 7.8, 6.0, 1.8 Hz, 1H), 3.55 (td, J = 8.4, 2.4 Hz, 1H), 3.47 (ddt, J = 9.0, 7.2, 3.0 Hz, 1H), 
1.77 (ddd, J = 15.0, 9.0, 3.0 Hz, 1H), 1.72–1.59 (m, 3H), 1.57–1.46 (m, 4H), 1.56 (ddd, J = 14.4, 
9.6, 1.8 Hz, 1H), 1.39–1.28 (m, 8H), 1.28–1.20 (m, 3H), 0.91 (t, J = 6.9 Hz, 3H); 13C NMR (150 
MHz, MeOD-d4) δ 168.1, 149.3, 123.1, 77.8, 75.9, 74.7, 68.5, 35.9, 35.6, 35.1, 33.4, 33.1, 30.5, 
27.7, 26.5, 24.3, 23.9, 14.5; IR (thin film) 3684, 3611, 3020, 2927, 1712, 1521, 1425, 1216, 1024, 
929 cm–1; HRMS (MALDI) m/z [M + Na]+ calcd for C18H32NaO5: 351.2147, found 351.2143.  
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(4R,5S,7S,13S,E)-4,5,7-Trihydroxy-13-pentyloxacyclotetradec-2-en-1-one (2g):  
The same procedure as 2d was followed by employing 67[F7F7] (5.0 mg, 0.00481 mmol), 
ethane thiol (50.0 μL, 0.733 mmol), BF3?Et2O (7.0 μL, 0.0532 mmol) and dry DCM (1.5 mL). 
The title compound 2g was prepared and then purified by preparative reverse phase HPLC to 
afford a white solid (0.9 mg, 57 %): [α]D25 –7.1 (c 0.11, MeOH); 1H NMR (600 MHz, MeOD-d4) 
δ 6.93 (dd, J = 15.6, 4.2 Hz, 1H), 6.09 (dd, J = 15.6, 1.8 Hz, 1H), 5.00 (ddt, J = 13.8, 4.8, 3.0 Hz, 
1H), 4.47 (ddd, J = 4.8, 3.0, 1.8 Hz, 1H), 3.89 (ddd, J = 7.2, 4.2, 3.0 Hz, 1H), 3.64 (dq, J = 10.2, 
5.4 Hz, 1H), 1.78–1.74 (m, 1H), 1.71 (ddd, J = 14.4, 6.6, 4.2 Hz, 1H), 1.62 (m, 1H), 1.55 (m, 
1H), 1.49–1.39 (m, 5H), 1.39–1.27 (m, 7H), 1.36 (ddd, J = 14.4, 9.0, 4.8 Hz, 1H), 1.25–1.15 (m, 
2H), 1.15–1.06 (m, 1H), 0.90 (t, J = 6.9 Hz, 3H); 13C NMR (150 MHz, MeOD-d4) δ 168.1, 
148.7, 123.4, 77.4, 74.7, 72.4, 68.9, 39.2, 36.4, 35.7, 34.4, 32.9, 30.3, 26.6, 26.0, 24.3, 23.8, 14.5; 
IR (thin film) 3684, 3612, 3412, 3020, 2930, 1709, 1521, 1424, 1216, 1032, 929 cm–1; HRMS 
(MALDI) m/z [M + Na]+ calcd for C18H32NaO5: 351.2147, found 351.2143.   
 
O
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(4R,5R,7S,13S,E)-4,5,7-Trihydroxy-13-pentyloxacyclotetradec-2-en-1-one (2h):  
The same procedure as 2d was followed by employing 67[F9F7] (4.4 mg, 0.00404 mmol), 
ethane thiol (50.0 μL, 0.733 mmol), BF3?Et2O (7.0 μL, 0.0532 mmol) and dry DCM (1.5 mL). 
The title compound 2h was prepared and then purified by preparative reverse phase HPLC to 
afford a white solid (1.1 mg, 83 %): [α]D25 +10.3 (c 0.088, MeOH); 1H NMR (600 MHz, 
MeOD-d4) δ 7.04 (dd, J = 15.6, 5.4 Hz, 1H), 6.11 (dd, J = 15.6, 1.2 Hz, 1H), 4.95 (ddt, J = 12.6, 
7.2, 2.4 Hz, 1H), 4.26 (ddd, J = 6.6, 5.4, 1.2 Hz, 1H), 3.92 (quint, J = 6.0 Hz, 1H), 3.77 (dt, J = 
7.2, 4.2 Hz, 1H), 1.77–1.67 (m, 1H), 1.70 (t, J = 5.1 Hz, 2H), 1.62 (tt, J = 14.4, 7.8 Hz, 1H), 
1.58–1.49 (m, 2H), 1.49–1.38 (m, 3H), 1.38–1.24 (m, 8H), 1.23–1.13 (m, 3H), 0.90 (t, J = 6.6 
Hz, 3H); 13C NMR (150 MHz, MeOD-d4) δ 168.1, 148.7, 123.5, 77.6, 75.8, 74.4, 69.2, 37.9, 
36.9, 36.3, 34.2, 33.0, 29.7, 26.6, 26.4, 25.4, 23.8, 14.5; IR (thin film) 3684, 3613, 3412, 3020, 
2930, 1712, 1521, 1424, 1216, 1029, 929 cm–1; HRMS (MALDI) m/z [M + Na]+ calcd for 
C18H32NaO5: 351.2147, found 351.2143.  
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APPENDIX 
 
 
(CHAPTER 2) 
 
1) 1H NMR spectra of compound 14 and all fluorous mixtures 
 
2) 1H, 13C NMR, COSY and HMQC spectra of triols 2a-2h 
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7.299
7.304
7.310
7.320
7.323
7.330
7.334
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222
8
7
6
5
4
3
2
1
0
ppm 0.068
0.774
0.792
0.804
0.853
0.865
0.877
0.884
0.911
0.918
0.941
0.950
0.966
0.981
1.000
1.011
1.021
1.027
1.036
1.059
1.249
1.282
1.363
1.377
1.396
1.411
1.438
1.515
1.531
1.597
1.655
1.675
1.728
1.826
1.843
1.863
1.888
1.907
1.930
1.950
1.962
2.048
2.064
2.072
2.247
2.272
4.607
7.260
7.289
7.301
7.311
7.320
7.331
7.337
7.349
9.09
35.56
13.67
2.92
1.93
1.36
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2.06
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 2b, COSY, MeOD, 500MHz
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 2c, COSY, 700MHz, MeOD
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 2d, COSY, MeOD, 500MHz
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 2f, 500MHz, HMQC, MeOD
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